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ABSTRACT
The modem pharmaceutical organisation is driven by the need to discover, develop 
and market innovative pharmaceutical products. Key to this mission is the process of 
drug discovery that involves allocating vast resources to (i) identify appropriate target 
diseases, (ii) discover and confirm appropriate solutions, (iii) clinically develop and 
legally approve the solution, for (iv) manufacture and supply of the product
Historically the drug discovery process was led by curiosity and pure research, but 
today it is akin to a factory system that conducts mass volume, applied and market 
focused research This change in focus has also been companied by numerous 
advancements in science, technology and market expectations As will be shown and 
verified in this thesis, there is relatively little in the way of existing literature and 
studies that focus on drug discovery strategies, and what does exist is fragmented 
across a number of disciplines including technology management, chemistry, 
automation, marketing, knowledge management and strategy
With this background, the aim of this thesis is to make a contribution that includes 
understanding and defining the concept of drug discovery as a strategy, and exploring 
how such strategies change through time. Within management and organisational 
literature, there is a body of knowledge that seeks to understand how and why 
organisations develop different strategies and organisational forms. This thesis adopts 
this evolutionary and classification paradigm to examine, define and classify the 
different strategies that exist to discover drugs In particular, four requirements of 
evolution (existence in populations, the process of variation, the process of heredity,
14
and the process of selection) are identified and translated into a strategic management 
and drug discovery context to create four testable hypotheses. These are:
1. There are similar drug discovery strategies employed by different 
organisations to form populations whose (the population’s) size follows a 
concave pattern of growth and decline
2. Within a drug discovery population, there are strategies that differ to each 
other in terms of their characteristics and their fitness
3. Those characteristics of drug discovery strategies credited with successful 
drug discovery performance are likely to appear in future strategic 
configurations, while those characteristics that are not, are likely to be absent
4 With a change in the environmental conditions those drug discovery strategies 
that remain, are the ones whose strategic characteristics are favoured by the 
environment.
To address these hypotheses a business historical study is conducted using data that 
investigates how the pharmaceutical industry has evolved in terms o f  technology, 
knowledge, human capital and the surrounding environment. The result is an 
evolutionary classification that has been constructed using the cladistic method This 
classification provides a system of information, evidence and assumptions that is the 
basis for testing the four hypotheses. The classification also provides a framework 
that integrates and presents the key contributions to knowledge made by this thesis 
These include:
. The creation o f a definition for drug discovery strategy
• The identification o f the factors that influence the change of drug discovery
strategies
15
The creation o f  an evolutionary classification that identifies and arranges different 
types of drug discovery strategy, and reveals the characteristics of the fittest
The validation of evolution as a process for understanding change in drug 
discovery strategies
16
1. INTRODUCTION
During the next century we shall surely obtain a fu ll  understanding o f the body 
(through the human genome project), and then discover how to cure the disease and 
save the patient (Mann, 1999, p. 197)
1.1. Background
With the virtual elimination o f viral diseases such as smallpox; the ability to routinely 
produce images of fractures and tumours, and the commonplace transplantation of 
human organs, it seems that given enough time and money, almost any medical 
problem can be solved with science and technology. For pharmaceutical 
organisations such challenges motivate their business strategy and shape their 
competitive landscape in terms o f  profits, costs, and above all ethics. With significant 
technological advances in the drug discovery process (such as genomic based 
technologies that use genetic instructions that characterise organisms) and the 
development of the biotechnology industry, pharmaceutical organisations are facing 
increased pressure to produce more and better drugs, at a faster rate and with greater 
economic benefits to the business.
As with other industrial sectors, the pharmaceutical sector is a highly competitive 
and global industry. Yet, unlike most other sectors the pharmaceutical industry 
focuses on and allocates the majority of its resources to the process of innovation 
(drug discovery), whilst processes such as manufacturing, marketing, and logistics are 
very much secondary. In addition, the organisational characteristics that accompany 
the innovation process are relatively extreme in terms of time scales (new product 
development typically takes between eight and twelve years), search space (there are 
1 O'80 possible drugs, but only a possible 100 that may generate a profit), and
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investment (the average cost to research, develop, and bring to market a prescription 
drug in the US has reached $802 million)1.
Today, the success of the drug discovery process relies heavily on the successful 
application o f scientific knowledge and technology, yet back in the early 1900s there 
was a limited understanding of human biology and chemistry. During this period the 
majority o f drug discoveries were unplanned and emerged from a process of scientific 
enquiry that was motivated by the curiosity and academic freedom of individual 
scientists. Since then, science, technology and market forces have created 
organizational systems that have shifted the process of drug discovery towards a more 
targeted, rational and planned business system
Accompanying this development in the drug discovery process has been the 
increasing popularity of research into the formation and change of organisational 
strategy (Mintzberg, 1996, Mintzberg et al., 1998, Whittington 1993, Quinn, 1989) 
which has led to the identification and classification o f various strategy types based 
on factors such as the degree of planning involved versus the emergent nature of 
change At one end o f this spectrum, fit strategies are those that are rational and 
planned, and involve a careful and detailed analysis o f the strengths and weaknesses 
of the organisation, and the opportunities and threats o f the surrounding environment 
At the other end, fit strategies are those that are flexible and adaptive and can respond 
appropriately to unpredictable and uncertain environmental changes. It is important 
to note, that the terms “fit” and “fittest” refer to a condition where the configuration of 
an organisational strategy matches that of the environment and the frequency o f its
1 This figure was calculated by the Tufts centre for the study of drug development (Tufts, 2002)
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characteristics appearing in future strategies is high. These terms are discussed in 
detail in chapter 5.
This thesis examines these different strategic types and using an evolutionary and 
classification approach (cladistics) relates them to the area of drug discovery. At this 
point, it is important to note that evolutionary theory does not just apply to biological 
organisms. If an entity (technological, social, or economical) evolves, then systems 
and strategy research provides a framework to understand the evolutionary processes. 
Pharmaceutical organisations are complex adaptive systems that evolve. They do not 
exist in equilibrium or chaos, but rather as a periodic order of evolutionary progress 
based on four requirements: existence in populations, variation, heredity, and 
selection. As this thesis will explain, these requirements are developed into four 
hypotheses that are represented and evaluated using a cladistic classification of 
different drug discovery strategy configurations along with the defining 
characteristics and capabilities.
1.2. Research Questions
From this background, a number of research questions are developed and proposed 
(see Chapter 3). These are as follows:
1. How does the discipline of strategic management relate to the process o f  drug 
discovery and what is the definition of a drug discovery strategy?
2. What are the factors (internal and external) that influence and define different 
drug discovery strategies?
3. How can an evolutionary and classification approach be used to study drug 
discovery strategies?
4 What are the characteristics of the fittest drug discovery strategies?
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1.3. Structure o f  this thesis
The current chapter (Chapter 1) provides an introduction to the thesis. It provides an 
overview of the challenges that pharmaceutical organisations face and introduces the 
research questions. This chapter also outlines the structure of the thesis as follows.
Chapter 2 introduces and justifies the research methodology and approach used to 
conduct this study. It provides an outline of the various research activities and each 
stage of the research. Furthermore, it introduces the rationale and forethought on 
using an evolutionary and classification approach.
Chapter 3 discusses and confirms the research questions that this thesis seeks to 
address. It considers and reviews existing drug discovery management and strategy 
literature and positions the thesis within this existing body of work
The aim of chapter 4 is to address the first and second research questions. It reviews 
the literature on strategic management in terms o f the origins o f strategy, the strategic 
levels, the strategic types, and the strategic classifications It shows and justifies that 
the factors that influence the changes in drug discovery strategy are technology, 
knowledge, organisation, and environment. The chapter concludes by providing a 
definition of drug discovery strategy within the scope of this thesis.
Chapter 5 reviews the concepts of evolution and fitness There are two reasons for 
this review. The first is to provide the background for addressing the third research 
question i.e identifying the requirements that evolving systems should meet for 
evolution to explain their change. These are existence in populations, variation, 
heredity, and selection. Chapter 5 develops the four requirements into four 
hypotheses for the evolution o f drug discovery strategies as shown in Table 1-1. 
These hypotheses are examined and validated in chapters 7 and 8 by using the
20
classification methodology cladistics as explained and justified in chapter 6. The 
second aim of this chapter is to provide the background for addressing the fourth 
research question by providing a definition of the term fitness.
Table 1-1 Hypotheses
Requirement Hypothesis
Existence in 
populations
There are similar drug discovery strategies employed by different 
pharmaceutical organisations to form populations whose (the 
population’s) size follows a concave pattern o f growth and decline.
Variation Within a drug discovery population, there are strategies that differ to 
each other in terms o f their characteristics and their fitness.
Heredity Those characteristics o f drug discovery strategies credited with 
successful drug discovery performance are likely to appear in future 
strategic configurations, while those characteristics that are not are 
likely to be absent.
Selection With a change in the environmental conditions those drug discovery 
strategies that remain are the ones whose strategic characteristics are 
favoured by the environment.
Chapter 6 explains and justifies the cladistic classification methodology used to test 
the four hypotheses. The chapter begins by substantiating the need for a classification 
and concludes by justifying the use of cladistics. The chapter then explains in detail 
the methodology of constructing cladistic classifications. Finally, it concludes by 
explaining specifically how cladistics is used for this research It argues that two 
cladistic classifications will be constructed The unit of analysis o f  both will be drug 
discovery strategies as defined in chapter 4. The first (a population cladogram) will 
use historical secondary data to identify and classify types or forms drug discovery 
strategies The second (an organisation cladogram) will use data collected from the 
pharmaceutical industry to identify and classify drug discovery strategies found in 
individual organisations. Chapter 6 also justifies the benefits of this approach.
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Chapter 7 presents the construction o f the population cladogram. It explains how the 
classification data was collected (the sources that were used) and processed (the 
techniques, and the criteria employed), and then presents the classification. The 
chapter concludes by discussing how the population cladogram advances the research 
towards validating the hypotheses and hence addressing the third research question. It 
presents its limitations and verifies the need for the organisation cladogram
Chapter 8 describes the construction of the organisation cladogram. Similar to 
chapter 7, it describes how the classification data was collected and processed and 
then presents the classification The chapter concludes by discussing how the 
organisation cladogram validates the four hypotheses and explains and compares the 
insights and information provided by the two types of cladogram
Chapter 9 is the conclusion chapter of this thesis. It summarises the progress and 
contribution made by the thesis and its constituent chapters towards the research 
questions listed in chapter 1 and confirmed in chapter 3. It also provides a discussion 
of the limitations of this work and suggestions for future work.
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2. RESEARCH METHODOLOGY
2.1. Introduction
The scholarship and definition o f a research project can benefit greatly from a 
carefully selected and well-defined research process. The aim of this chapter is to 
evaluate, justify and describe the research process of this work It begins by
addressing the question What is research?. Then it provides an account of the various 
types of research and concludes with a description and rationalisation o f  the 
methodology used. Finally, an explanation of how the research was organised and 
conducted is provided
2.2. What is research ?
Despite the wider recognition of the importance of research, there is not a widely 
accepted definition of the term. From the many different definitions of research 
offered in the literature, there appears to be agreement on the following (Hussey and 
Hussey, 1997):
• It is a process of enquiry and investigation
• It is systematic and methodological
. It seeks to refine and advance knowledge
Phillips and Pugh (2000) distinguish between intelligence gathering and research 
The former is concerned with answering the what questions. These questions are 
descriptive in nature, and require rigorous definition of the terms, unbiased collection 
of information, meticulous statistical treatment and careful summarising to obtain a 
balanced description of the situation The latter is concerned with the why and  when
questions that go beyond description and require analysis They require explanations, 
comparisons, predictions, generalisations and theories. Although the why and when 
questions are similar to the what questions in that they require intelligence gathering, 
the information in the why and when questions is used for the purpose of developing 
understanding. All research questions require some form of generalisation and to be 
useful, explanations should be applicable in all situations (Phillips and Pugh, 2000).
2.3. Method and Methodology
To help enhance the quality of this research process and outputs a recognised 
methodology is used. Hussey and Hussey (1997) define methodology as the overall 
approach to the research process, including the theoretical underpinning to the 
collection and analysis o f the data. They further distinguish method from 
methodology as the means by which data can be collected and/or analysed. 
Therefore, methodology is concerned with the following main issues:
• Why was the data collected? (e g. to understand and define different drug
discovery strategies)
• What data was collected? (e g data about how drug discovery strategies have
evolved over time)
• Where was it collected from? (e g historical databases, company annual reports
etc.)
• When was it collected? (e g during the last century)
• How was it collected? (e g. by collecting annual reports, searching historical
databases)
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• How was it analysed? (eg. using the evolutionary classification technique 
cladistics)
The methodology used when conducting research depends on the type of research 
that is being employed Sekaran (2000) defines research as the process o f  finding 
solutions to a problem after a thorough study and analysis o f  the situation factors 
From this statement, there are four possible aims of research:
• to gain familiarity with a phenomenon or to gain insight,
• to describe things,
• to determine associations between variables, and/or
• to test hypotheses.
The aims of this research involve three of the above Firstly, it seeks to gain 
familiarity with a phenomenon i.e. understand and define drug discovery strategies in 
terms of evolutionary change. Secondly, it aims to  determine associations between 
variables as it identifies relationships between strategic management and drug 
discovery. Finally, it aims to test four hypotheses that emerge (see chapter 6) from 
research question 3 ‘How can an evolutionary and classification approach be used to 
study drug discovery strategies?' The testing of these hypotheses also advances the 
research towards meeting the other two aims
Since research design is closely linked to a researcher’s objectives, there are several 
types or approaches to research. The following section introduces some of the most 
common types, while positioning this types against this research.
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2.3.1. Applied versus Basic Research
A common aspiration of research is to solve real problems that lead to benefits for 
industry, society, government or other stakeholders. In this research, an organisation 
may seek to improve the competitiveness o f its drug discovery process by better 
understanding its current process and designing a new one. Such research is called 
applied research, as the output and research environment is pragmatic. The theory, 
methods and ideas that are used to examine the problem are usually the basis of the 
novelty.
If the research has no application in the short or medium term, but instead aims to 
generate a body of knowledge about how certain problems occur in organisations, 
then this type of research is called basic research Basic research is considered more 
academic as its main aim is contribution to knowledge. This contribution is usually 
for the general good as opposed to the application to a specific problem of an 
organisation.
Table 2-1 summarises the differences between the two research types 
Table 2-1 Basic and Applied Research
Basic research Applied research
Purpose:
• Expand knowledge of 
processes of business and 
management
• Results in universal principles 
relating to the process and its 
relationship to outcomes
• Findings of significance and 
value to society in general
Context:
• Undertaken by people based in 
universities
• Choice of topic and objectives 
determined by the researcher
• Flexible time-scales
Purpose:
• Improve understanding of particular 
business or management problem
• Results in solution to problem
• New knowledge limited to problem
• Findings of practical relevance and 
value to managcr(s) in organisation(s)
Context:
• Undertaken by people based in a 
variety of settings including 
organisations and universities
• Objectives negotiated with originator
• Tight time-scales__________________
Source: Saunders ct al. (2000). pg. 3
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The purpose of this research is to examine the change of drug discovery strategies in 
the pharmaceutical industry. This purpose is not directly linked to an industry need, 
but it does expand the knowledge of business and management in this sector. 
Furthermore, the results and findings of this research are not concentrated on one 
particular organisation. Rather, they focus on the strategic change of one business 
process (drug discovery) in one particular sector (pharmaceutical). Finally, this 
research is conducted by a university-based researcher as part of a four year 
programme research that has had relatively flexible time scales Therefore, the 
current research falls under the category of basic research
2.3.2. Empirical versus Theoretical Research
Empirical research is based on the results o f  observation, whilst theoretical research 
is concerned with the theory o f  a subject. Theoretical research begins by developing a 
theory using a priori knowledge; the theory is then tested using a variety of methods 
including data collection and case studies Empirical research gathers the data 
(empirical evidence) and then processes this evidence using numerical tools. The 
observations identified and the resulting theories are formed primarily from this 
statistical process. Hence, the data employed is used to construct the empirical 
research, instead o f supporting the research, as is the case with the theoretical 
approach
Although it is obvious that these two approaches are different, they are both regarded 
as valuable ways of building knowledge. However, it is not always easy to 
distinguish them apart. Most research projects, including the one presented in this 
thesis, involve both theoretical and empirical approaches. Before any empirical 
investigation can be conducted, a researcher should have a degree of understanding
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about the entity/subject under investigation and therefore holds some form of 
theoretical position. Without studying the subject, the empiricist is not able to 
properly understand the problems and hence is limited in the collection of empirical 
evidence. Likewise, the theorist, without the evidence presented by existing studies, 
is unlikely to have ideas or arguments to build on. Theoretical research, therefore, 
does not occur in a vacuum. It is the result of rationalising the findings of previous 
empirical studies and presenting different views from the interpretations previously 
made.
This thesis presents a combination of the theoretical and empirical approach. The 
theoretical part of the research uses the existing literature to understand the subject 
matter (drug discovery strategy), develop hypotheses, and design the research 
(Chapters 4, 5, and 6). This theoretical aspect of the research addresses research 
questions 1 and 2 (Chapter 4), while the empirical aspect, assesses the viability of the 
hypotheses (research question 3) by developing two cladistic classifications (Chapters 
7 and 8). It also identifies the characteristics of the fittest strategies (Research 
question 4).
2.3.3. Positivistic versus Phenomenological Research
There are two main research paradigms or philosophies, these are the positivistic and 
the phenomenological (Hussey and Hussey, 1997) the main features and differences 
of which are shown in Table 2-2.
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Tabic 2-2 Positivistic versus Phenomenological Research
Positivistic Research Phenomenological Research
Tends to produce quantitative data 
Data is highly specific and precise 
Research concentrates on description 
and explanation.
Well-defined, narrow studies 
Uses large samples
Concerned with hypothesis testing 
Research concentrates on generalisation 
and abstraction.
Generalises from sample to population
Reliability is high 
Validity is low
Statistical and mathematical techniques 
for quantitative processing of data arc 
central.
Researchers are detached, i.e., they 
maintain a distance between themselves 
and the objective of research; take on 
the role of external observer
Tends to produce qualitative data 
Research concentrates on understanding and 
interpretation
Narrow as well as total studies (holistic 
view )
Uses small samples 
Concerned with generating theories 
Researchers concentrate on the specific and 
concrete ("local theory"), but also attempt 
generalisations.
Generalises from one setting to another
Reliability is low
Validity is high
Data is rich and subjective
Both distance and commitment; researchers 
arc actors who also want to experience what 
they are studying from the inside.
Source: Gummcsson (1991), pg. 153
Although there are several distinct differences between the two paradigms, they are 
seen as a continuum where at the one end there is the positivistic approach and at the 
other end the phenomenological. In reality, a combination of the two paradigms is 
also considered appropriate.
2.3.3.1 The Positivistic Paradigm
The positivistic paradigm is based on statistical approaches used in the natural 
sciences (e g physics chemistry and biology) for analysing data collected using 
descriptive and comparative studies and experiments. The use of these approaches in 
the natural sciences has been very successful and is the main reason why social 
scientists adopted this approach at the beginning of the nineteenth century. It was 
assumed that only knowledge obtained by means o f measurement and objective
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identification could be considered valid The main principle of analysis is the cause 
and effect o f the variables under study.
The positivistic paradigm seeks facts or causes of social phenomena without taking 
into account the subjective state of the researcher who conducts the study. It is based 
on the idea that studies of human behaviour should be conducted in the same way as 
the studies conducted in the natural sciences (Hussey and Hussey, 1997).
The process that is usually being followed when conducting positivistic research is 
to study the literature and establish an appropriate theory and construct hypotheses. 
The hypotheses are then tested using statistical analysis Such an approach requires 
the data to be highly specific and precise. Therefore, the type of data required should 
be quantitative and considerably rigorous to ensure accuracy of the measurement.
Within the positivistic paradigm, there are three different types of methodologies:
. Cross-sectional studies: this is a methodology designed to obtain data on variables 
in different contexts, but at the same time. Different organisations or groups of 
people are selected and a study is conducted to identify how factors differ. 
Statistical analysis is then performed to identify how the variables of the study 
differ. This methodology is useful when a snapshot of reality is required e g. in 
the investigations of economic characteristics of large numbers o f people.
. Experimental studies, this is a methodology conducted in a systematic way in a 
laboratory or in a natural setting. Its aim is to change the independent variable 
and to identify what is the effect of this change on the dependent variable. This 
allows the causal relationships between the independent and the dependent 
variables to be defined
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• Longitudinal studies, the study of a variable or a group of subjects over time. Its 
aim is to explore the dynamics of the problem under investigation by examining 
the same situation or group of people several times over the period that the 
problem occurs. This period can be many years and permits the examination of 
the change processes within a social, economic and political context.
2.3.32. The Phenomenological Paradigm
Criticism o f the positivistic paradigm resulted in the development of the 
phenomenological paradigm. Table 2-3 includes a list of the most common criticisms 
of the positivistic approach
Tabic 2-3 Criticisms of the positivistic paradigm (From Hussey and Hussey, 1997, p. S3)
• It is impossible to treat people as being separate from their social contexts and they 
cannot be understood without examining the perceptions they have of their own 
activities.
. A highly structured research design imposes certain constraints on the results and may 
ignore more relevant and interesting findings.
• Researchers are not objective, but part of what they observe. They bring their own 
interests and values to the research.
• Capturing complex phenomena in a single measure is, at best, misleading. For example,
is it possible to assign a numerical value to a person’s intelligence?_________________
The phenomenological approach uses a more personal and interpretative process to 
"understand reality" The concept of reality is interpreted by the researcher who 
observes and experiences the situation. Without this interacting role between the 
researcher and the situation, rich insights into the complex research areas are often 
lost. Therefore by interpreting and understanding a problem from different 
viewpoints, an enhanced understanding is achieved. In other words, by translating the 
realities and having empathy with reality allows knowledge to be accumulated
Phenomenology is the science of phenomena A phenomenon is a fact or occurrence
that appears or is perceived, especially one whose cause is in question. Therefore, the
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phenomenological paradigm is concerned with understanding human behaviour from 
the participant’s own frame of reference, which in the case o f this research is 
evolutionary and classification based. Social reality is within us and consequently the 
study of the reality has an effect on the reality (Hussey and Hussey, 1997). 
Phenomenologists believe that social reality is dependent on the mind and therefore, 
what is being researched cannot be unaffected by the process of research
As opposed to the positivistic paradigm the process of conducting a 
phenomenological study seeks to construct a theory that explains the phenomena or 
the pattern that emerges in the data. The type of data that is being collected is usually 
qualitative as the emphasis is on the quality and the depth
There are various methodologies used to conduct phenomenological research The 
ones, most relevant to this thesis, are:
. Case studies this is an empirical inquiry that investigates a contemporary 
phenomenon within its real life context, especially when the boundaries between 
phenomenon and context are not clearly evident (Yin, 1994 p. 13). Case studies 
are often used in areas where there are few theories or a deficient body of 
knowledge
. Grounded theory, this is when a theory is derived from data that has been 
systematically gathered and analysed through the research process With this 
method, data collection, analysis and eventual theory stand in close relationship to 
each other. Research begins with an area of study and allows the theory to 
emerge (Strauss and Corbin, 1998).
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2 .3 .3  3. M ix ing  th e  m e th o d o lo g ies
The research presented in this thesis (and like most management research projects) is 
a combination o f both phenomenological and positivistic approaches This research 
seeks to define and map the evolution of different drug discovery strategies, while 
understanding the factors that influence and shape different strategies. The research 
extends from the beginning of the nineteenth century to current time A pure 
positivistic approach would require accurate and comprehensive collection and 
analysis of empirical data for this period, while a pure phenomenological approach 
would require the careful examination of one or more cases. Although not 
impossible, neither of the two options is difficult to realise with the appropriate level 
of resource (time and money). However, a careful combination of the two approaches 
can provide the research with better reliability and credibility. Such a research 
process is described by Hendry (1992) and has been labelled business strategy and 
business history. This methodology determines the role that history can play in social 
science theory building and is in accord with and complementary to the aims and 
objectives of this thesis
This business history methodology combines the features of case study research and 
longitudinal analysis (Hendry, 1992) and like most case study research (Yin, 1984), to 
which it is most closely related, it is situationally and temporally context sensitive, 
embraces multiple data sources and cross checks the validity o f different sources 
through a process o f triangulation i.e. the use of different research approaches, 
methods and techniques in the same study (Hussey and Hussey, 1997). It differs from 
longitudinal case study research in adding to its own primary methodological concern 
with the relative status of different types of source material (primary documentary, 
but also physical and recollective) and with the limitations of justifiable inference
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from such materials. As part of this concern it seeks to satisfy the scientific principle 
of replicability, placing its raw data in the public domain, referencing its statements in 
detail to this data and so opening up its analysis to critical cross examination
In relation to the social sciences in general, the methodological strength of the 
business history approach lies in its ability to apply the longitudinal approach to 
research with the contextual sensitivity and richness of the case study approach, and 
in its ability to bring to case study research both a longitudinal dimension and 
critically, a highly developed (if largely implicit) set o f standards and principles of 
evidence (Hendry, 1992).
The limitations o f  the business history approach are essentially those associated with 
the impossibility o f  real time observation, interrogation or experiment, together with 
those o f the case study approach in general. Though historians can and do employ 
quantitative techniques drawn from social sciences, their discipline is essentially an 
interpretative one, in which general conclusions are established by the subjective 
interpretation and comparison of specific instances rather than by the analytic 
reduction of data from multiple events.
Historical comparison may be used for hypothesis testing, and in particular for 
testing the robustness of a hypothesis generated from one branch o f  the social 
sciences or one type of data with respect to considerations drawn from other 
disciplines and other data sources Of all the areas of management research, business 
strategy is one, that is most reliant on cross disciplinary perspectives, and this 
suggests that both the critical and synthetic aspects o f business history should be of 
particular relevance to theory building in this area (Hendry, 1992).
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2.3.4. Research Process
As presented above research can take many forms, but there is a common 
characteristic - systematic inquiry. For systematic inquiry to take place, a researcher 
should develop plans and project management, because research, like any other 
project is a series of highly interconnected activities subject to time and cost 
restraints The stages in the research process overlap continually and it is an 
oversimplification to state that every research project follows a neat and ordered 
sequence of activities Nevertheless, research can often follow a generalised pattern. 
The six stages observed by Zikmund (2000) are ( 1 ) defining the problem, (2) planning 
a research design, (3) planning a sample, (4) collecting data, (5) analysing data, (6) 
formulating the conclusion and preparing the report. These six stages are shown in 
Figure 2-1 as a cyclical process or as a circular-flow concept, because conclusions 
from research studies usually generate new ideas and problems that lead to further 
investigations.
Figure 2-1 Cyclical research process
Source: Zikmund (2000), pg 54
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2.3.5. Research Process o f the Present Research
The research process that was followed to conduct this research is shown in Figure 
2- 2 .
2.3.5.1. Formulating the research problem
This stage involves the identification o f the area of interest and includes establishing 
a boundary and purpose for the general area of study (drug discovery strategy) and the 
development of research questions to be addressed. This stage is reported in chapters 
1 and 3.
2.3.5.2. Formulating the research approach
This stage involves the identification and justification of the approach that will be 
used to meet the aims o f this research (i.e this chapter -  Chapter 2). More 
specifically, it explores the various research approaches found in the literature and 
then rationalises and selects those which are viable to this research.
2.3.5.3. Conducting the literature review
Once the topic of interest and the research approach are defined, the next step is to 
conduct the literature review. The aim of this stage is to interpret and synthesise the 
published research (Merriam, 1988 in Hussey and Hussey 1997 p.109) and thus 
identify and confirm a potential area of novelty. To achieve this a literature review 
was conducted in the following areas, drug discovery (chapter 3), strategic 
management (chapter 4), and biological evolution (chapter 5).
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2 .3 .5 4 . R e fo rm u la te  resea rch  q u estio n s
The completion of the above stages provides a thorough and scholarly understanding 
of the topic of interest. This understanding permits the research questions to be 
reformulated i.e. they are evaluated and rewritten to become more specific on the 
subject The final form o f the research questions is the one reported in section 3.3 of 
this thesis
2.3.5 5. Development of hypotheses
This stage involves the development of guesses about what lies behind the ‘how ' in 
the research question (Robson, 1993, p. 29). The third research question o f this thesis 
(How can an evolutionary and classification approach be used to study drug discovery 
strategies?) requires the investigation of how the requirements of evolution (chapter 
5) relate to drug discovery strategy. To achieve this, four hypotheses are developed, 
one for each requirement (chapter 5).
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Figure 2-2 Research process of this thesis
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2 .3 .5 6 . R esearch  d esig n
This stage involves the design of the activities that are carried out to test the four 
hypotheses developed in the previous stage. These activities include the collection of 
data and the framework used to analyse the collected data i.e. the evolutionary 
classification technique cladistics. In chapter 6 the rationale for using cladistics and 
the detailed methodology to be used is reported.
2.3.5 7. Collection of data
This stage involves the collection o f  data about the pharmaceutical industry It was 
collected from three sources: books, journal papers, online papers, industrial articles, 
historical databases, and company annual reports. The data was gathered and stored 
in a chronological order. Chapters 7 and 8 report how the data was collected, the 
sources used, and the criteria imposed. Once this stage was complete, the research 
design stage was revisited to ensure that the limitations of the data collection method 
were taken under consideration.
2.3.5.8. Construction o f  cladistic classifications
This stage involves the construction of the cladograms i.e. the cladistic 
classifications Two cladograms were constructed The first (population cladogram) 
used data from available historical secondary data to identify and classify types or 
forms drug discovery strategies. The second (organisation cladogram) used data from 
the pharmaceutical industry to identify and classify drug discovery strategies found in 
individual organisations This stage is reported in chapters 7 and 8
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2.3.5 9. Testing hypotheses
This stage involves the validation o f the four hypotheses using the two cladograms 
This stage is reported in chapters 7 and 8
2.3.5.10. Conclusions and report writing
This is the final stage o f this research process and includes the conclusions of the 
study and the writing of the current report. It also evaluates to  what degree this thesis 
has addressed the research aims, questions and hypotheses. It reviews the limitations 
o f the research and outlines future areas of work. This stage is reported in chapter 9.
2.4. Conclusions
This chapter selects, justifies and introduces the reader to the research methodology 
and process used throughout the thesis i.e. the business history approach. This 
provides a method to conduct a systematic investigation into the research problem -  
understanding the evolution o f  drug discovery strategies Developed from a general 
research model, this research can be divided into ten stages For each stage, the 
research activities and its outcomes are discussed
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3. INTRODUCING AND DEFINING THE RESEARCH PROBLEM
3. I. Introduction
This chapter introduces the subject area of this thesis -  drug discovery strategies, and 
presents and justifies the overall research aim and research questions. This is 
achieved by reviewing the modern process of drug discovery, along with its defining 
stages and key characteristics. This review illustrates (i) that modern drug discovery 
is a highly automated and sophisticated process, and (ii) provides the theoretical basis 
by which to study the diversity of drug discovery strategies and how they have 
evolved To confirm the research questions and contribution made by this thesis, the 
final section of this chapter provides a review of the existing literature, which 
straddles the areas of strategic management and drug discovery. This is followed by a 
discussion of each of the research questions in detail.
3.2. Introduction to Drug Discovery Process
The average cost to research, develop, and bring to market a prescription drug in the 
US has reached $802 million (this figure was calculated by the Tufts centre for the 
study of drug development (Tufts, 2002)). This figure has tripled in nine years 
(allowing for inflation) and includes the cost o f  failures and research on compounds 
abandoned during development as shown in Figure 3-1.
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Figure 3-1 Average cost to develop a new drug, from discover}' to Approval
For every 5,000 compounds tested only five make it to clinical trials according to the 
Pharmaceuticals Research and Manufacturers of America (PhRMA, www.phrma.org). 
Of these five, only one is eventually approved for patient use. On average it takes 12 
years from the time a new compound is synthesised in the lab until it receives 
approval from the Federal Drug Administration (FDA) to be marketed.
Much time and effort is spent yearly by large pharmaceutical organisations 
attempting to reduce the required time and the resulting high costs Any shortening of 
the time required to produce a drug could produce large benefits for an organisation. 
In fact one pharmaceutical organisation estimated that getting a new drug to market a 
year earlier increased revenues by $580 million, and this excludes the benefits 
associated with the strengthening of the company’s competitive position (Schneider, 
2000).
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Pharmaceutical organisations seek to achieve higher performance o f  their drug 
discovery process to maintain their current revenue and growth trajectories. Just to 
keep pace with an annual industry growth rate of 10 percent, the top 10 global 
pharmaceutical players will need to launch at least five significant NCEs (new 
chemical entities) per year. Thus, even modest growth objectives present an 
unprecedented challenge for drug discovery. Allocating more people and money for 
research does not achieve the necessary performance gains (Reuters, 2000). The 
research and development function needs to fundamentally rethink their approach to 
drug discovery, their organisational models, processes, utilisation of technology and 
information/knowledge management capabilities to achieve higher growth objectives
A popular view o f the discovery of new therapeutic drugs is that o f a random and 
unplanned process (Cox et al, 1975), but the reality is that most pharmaceutical 
companies cannot afford to share this view. To survive in the long term modern 
pharmaceutical companies need to create a continuous flow of drugs into the market. 
This means that pharmaceutical organisations must provide and manage adequate 
resources and commitment to their drug discovery process. This was demonstrated 
using empirical evidence very early on in pharmaceutical history (Comanor, 1995), 
where the relationship between research and development, and the rate of new 
product technical change was investigated
Over the last quarter of the 20th century the process o f  drug discovery has gone 
through a revolution, which has been triggered by advances in biological science 
(Henderson at al., 1999). Progress in the ability to understand the mechanism of 
action of some o f the existing drugs and the biochemical and molecular roots of many 
diseases made it possible to design significantly more sophisticated drugs or, to use 
Henderson’s (1994) analogy, i f  the action o f  a drug on a  'receptor' in the body is
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similar to that o f  a key fitting into a lock, advances in scientific knowledge have 
greatly increased knowledge o f  what the locks' may look like (p. 614). In addition 
new technologies such as combinatorial chemistry and high throughput screening 
have increased an organisation’s experimentation capacity as shown in Figure 3-2.
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threshold functional activity on a given target 
Source: Thomke and Kuemmerle (20021 p 628
Figure 3-2 Growth in output as measured by the number of hits
A typical modern drug discovery process consists of four stages as illustrated in 
Figure 3-3. The first two stages are devoted to the discovery and optimisation o f one 
or a few ‘lead’ chemical compounds that appear to hold sufficient application promise 
and thus merit investment in the next stage - clinical development The process of 
clinical development typically consists o f three phases aimed at determining and 
documenting the safety and the efficacy of the proposed drugs During these phases 
the proposed drug undergoes controlled trials on humans. When the three phases are
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complete the information collected is submitted to the relevant authority for 
regulatory approval (Thomke et. al, 1998).
The flowchart presented by Figure 3-3 serves to define the boundary and scope of 
the subject under investigation by this thesis and is used as a reference hereafter. In 
accord with Figure 3-3, the following sections describe each of the stages o f  the drug 
discovery process.
3.2.1. Target Research
The aim of this stage is to identify the molecular targets associated with a specific 
disease process (Williams and Malick, 1987). The selection of targets depends on a 
number of organisational and technological issues. Organisational issues include 
commercial validity and strategic issues such as alliances, franchises, and patents. 
While, technological issues would include the specialisation/expertise o f a given 
company to a certain therapeutic area, the link to a disease, and technical feasibility 
(Williams and Nadzan, 1987, Williams and Malick, 1987).
Once the target has been selected, the process moves onto the synthesis o f  chemical 
entities using techniques like combinatorial chemistry. This technique involves the 
generation o f a large number of organic compounds from chemical building blocks 
(Reuters, 2000) that are screened to identify desired biological activity that could 
trigger further development.
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Figure 3-3 Flowchart of drug discovery process
3.2.2. Discovery
Once the active compounds have been identified the next stage involves their 
optimisation, evaluation, and the first stages of clinical testing. Prior to this stage a 
research team has knowledge about the basic chemical and biological properties of a 
new compound and a basic understanding (based on theoretical assumptions and some 
animal testing) of its therapeutic properties (Drews, 1988 p. 126). The optimisation of 
the compound involves screening out negative characteristics i.e. making sure that the 
compound is free of toxicity and does not cause any significant side effects. The aim 
of the clinical studies is to establish safety and effectiveness in human beings in 
relation to the substance under investigation.
Before moving onto the first stages of clinical development the new compound is 
evaluated both technically and commercially. Technical evaluation involves 
exploring how the new substance acts on living tissue and organisms, how the 
organism alters the substance, how the new substance is distributed into the organism, 
and by what pathways and mechanisms they again leave the body (Drews, 1988 
P 127).
The commercial validation of the drug consists o f activities that examine the 
business-related dimensions and market potential of the drug to the company i.e. it 
addresses the question: how will the company benefit from the development o f the 
drug under question? The answer to this question is vital and primarily decides the 
future of the project.
The discovery stage also includes the first phases o f clinical studies In total there 
are three phases. Phase 1 primarily examines the safety of a new compound and tests 
are carried out on several healthy patients (Drews, 1988) Such tests are usually
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clinical-pharmacological studies i.e. the medicine under test is administrated as a very 
small single dose and the patients are monitored carefully, since at this point there is 
no information about the safety of the new drug to humans. If the subjects show no ill 
effects the dosage is increased in small increments and the test repeated until side 
effects appear
3.2.3. Clinical Development and Regulatory approval
This stage of the drug discovery process is the last before it is produced in large 
numbers and becomes available to the public. It involves the later phases of clinical 
studies, regulatory approval and chemical and pharmaceutical development.
Phase II seeks to determine the effectiveness of the drug using tests with target 
patients i.e. those patients who are carrying the disease that the drug aims to cure 
(Krogsgaard-Laarsen, and Bundgaard, 1996). These studies are normally carried out 
with two or three different dosage levels as well as a placebo control group (a group 
of patients who are prescribed a medicine with no therapeutic effects in order to 
compare the results in their treatment with another group that has been prescribed the 
medicine under trial and to eliminate any effects due to the mind-body connection 
(Hart, 1999)). In many cases, where the disease is serious such as AIDS, and severe 
hypertension, the placebo part o f the study is replaced with various dosages of already 
established drugs. One issue that is tackled whenever a new drug reaches this stage, 
is the definition of its effectiveness In the case of AIDS for example the aim of the 
drug would be the prolongation of life. Such an experiment would require years of 
data and this would make the experiment itself impossible Therefore, alternative 
criteria are identified and used to indicate the effectiveness of a drug
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The final stage of clinical studies, Phase III, involves testing a new drug to larger 
and more diverse populations. These trials are normally controlled, multi-clinic 
studies, enrolling several hundred to more than a thousand patients, and designed to 
establish the efficacy of the drug and define its diverse effect profile as precisely as 
possible. During this phase, some evidence of uncommon side effects and adverse 
laboratory changes may be obtained (Reines and Fong, 1987). Therefore once this 
phase is completed, a more accurate picture o f the drug behaviour is available 
Similar to Phase II, Phase III involves testing of two or three different dosages against 
a placebo and/or against comparison treatments. To achieve the numbers required for 
such a study, usually a number of institutions participate, all of which must follow the 
same data collection rules and procedures. These trials are called multi-centre trials.
Once the clinical and pre-clinical data have been collected, the next stage is to apply 
for approval from the relevant authority of each country. This stage is a very 
expensive, laborious and time-consuming process which can take up to two years and 
often results in disapproval. The document that is submitted for approval includes 
information on drug chemistry (how it will be manufactured and all related control 
processes), validation (packaging and labelling), pre-clinical pharmacology and 
toxicology, pharmakokinetics and bioavailability, clinical data, and clinical safety.
3.2.4. Manufacture and Supply
This final stage of the drug discovery process involves those activities involved in 
the preparation of the pharmaceutical organisation to manufacture, supply and market 
o f the new drug. These activities are seen as part of the drug discovery process 
because they can include the construction of a new chemical plant (to develop and 
provide the active compounds), market research, long-term safety and efficacy
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3.3. Review o f Drug Discovery Strategy Literature
The scope of this thesis is to relate and transfer the discipline o f strategic 
management to the process of drug discovery, to understand the change and diversity 
of drug discovery strategies. As will be shown and verified by this section, there is 
relatively little in the way of existing literature and studies that focus on drug 
discovery strategies, and what does exist is fragmented across a number o f disciplines 
including technology management, chemistry, automation, marketing, knowledge 
management and strategy.
Existing studies of drug discovery focus on the optimisation of the drug discovery 
process mainly through the use of new knowledge and technology (e g. FitzGerald, 
2000, Harvey, 1995, Jensen, 1998, Kniaz, 2000, Koretz and Lee, 1998, Krantz, 1998, 
Merritt, 1998, Bernhardt and McCulley, 2000, Danheiser, 1997, Erickson et al., 1990, 
Schneider, 1999, 2000, Spence, 1999). Although knowledge and technology are 
fundamental to the formation of strategy, there is limited application of the principles 
of strategic management to drug discovery.
Some work has been carried out on the effect of organisational networks on the 
process of drug discovery. For instance, Gambardella (1992) studied the effect of in- 
house scientific programs and the exploitation of outside scientific information. In 
particular, he examined the proposition that in-house scientific research raises the 
ability of organisations to take advantage of public science i.e. science that is 
developed by the academia and other non-profit scientific institutions The findings 
of this research suggest that organisations with better in-house scientific capabilities 
have been able to make better use o f  both internal and external science. He concludes 
by suggesting that to be part of a network and to be able to effectively exploit the
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information that circulates in the network, has become even more valuable than being 
able to generate new knowledge autonomously (Gamardella, 1992)
In a study carried out by Arora and Gambardella (1990) on biotechnology firms it is 
suggested that the locus of innovation in biotechnology should be thought of as a 
network o f  interorganisation relations (p. 374). In their paper they explored the 
relations among the strategies of external linkage of the large chemical and 
pharmaceutical producers in the new biotechnology business Their findings suggest 
that agreements with other organisations, research agreements with universities, 
minority participations in new biotechnology firms, are positively correlated. They 
concluded that these strategies are complementary to each other as they target distinct 
and complementary sets o f resources (Arora and Gambardella, 1990).
Oliver (2001) analysed the relationship between organisational lifecycle and the 
formation o f  strategic alliances of biotechnology organisations. In particular she 
tested the propositions that the inability of dedicated biotechnology organisations to 
form strategic alliances is associated with organisational death and that organisational 
growth makes it possible to reduce network learning through alliances allowing an 
organisation to enter a period of exploitation. Her findings suggest that firstly, there 
is no increasing linear pattern in the odds for forming new alliances as biotechnology 
organisations grow. Secondly, the lack of alliances was indeed associated with 
organisation death.
In a similar study Deeds and Hill (1996) also found evidence to support that an 
entrepreneurial biotechnology organisation can increase its rate of new product 
development by entering into strategic alliances with organisations that possess 
complementary assets. They argued that the rate of an organisation’s new product 
development increases the number of strategic alliances an organisation has entered.
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but in a non-linear fashion. In fact they suggest that the relationship between the 
number o f alliances and the rate of new product development may be an inverted U- 
shape (Deeds and Hill, 1996).
Other empirical work in this area includes studies about the absorptive capacity of 
pharmaceutical organisations i.e. an organisation’s ability to recognize the value o f 
new, external knowledge, assimilate, and apply it to commercial ends (Cohen and 
Levinthal, 1990, p. 128). For instance, Lane and Lubatkin (1998) examined the 
factors that influence an organisation’s absorptive capacity by testing the ability of 
one organisation to learn from another They found that the absorptive capacity in 
this respect (from one organisation to another) is positively correlated to the similarity 
of the two organisations’ i) knowledge bases (a general understanding of the traditions 
and techniques upon which a discipline is based), ii) organisational structures (the 
degree of formalisation and centralisation used by an organisation when allocating 
tasks, responsibilities, authority, and decisions) and compensation policies, and iii) 
dominant logics (the common thread running through an organisation’s commercial 
objectives).
Cockburn and Henderson (1998) further studied the absorptive capacity of 
pharmaceutical organisations by focusing on the interface between for-profit and 
publicly funded pharmaceutical research. They argue that the relationship between 
the public and private sectors cannot be described by a waterfall model in which the 
public sector produces knowledge that spills over costlessly to downstream 
researchers (Cockburn and Henderson, 1998, pp. 179-180). In the contrary, they 
found that the ability to take advantage of knowledge generated in the public sector 
requires investment in a complex set of activities that, taken together, may change the 
nature of private sector research (Cockburn and Henderson, 1998).
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Lee and Harrison (2001) examined the US pharmaceutical industry bifurcation into 
groups o f innovative and imitative strategies. They labelled innovative those 
strategies pursued by organisations who survive by seeking innovative drugs and 
selling them at premium prices. On the other hand they labelled imitative the 
strategies of the organisations that survive by producing me-too drugs and selling 
them at me-too prices. They developed a model of industry evolution and found that 
strategic group emergence is dependent on low exit rates and thus, they concluded, 
innovative strategies are most viable when organisations are somewhat shielded from 
short-term survival pressures.
A series of empirical studies have focused on the effects of mergers, acquisitions and 
firm size in research productivity. Graves and Langowitz (1993) suggest that mergers 
in the pharmaceutical industry may yield less innovative productivity than managers 
expect. They studied the innovative output of 16 US pharmaceutical organisations. 
Their results indicate that there is a positive relationship between the research and 
development expenditure and the innovative output (measured in new chemical 
entities produced). However, the proportion of that output decreases as research and 
development expenditures generally related to organisation size increase i.e. 
innovative effectiveness decreases with increasing organisational research and 
development budget and with organisation size. They suggest two reasons for this 
phenomenon. The first is that possibly large organisations may undertake more risky 
research. However, Mansfield (1981) has found that there is no statistically
significant relationship between large corporations and risky research and 
development. The second reason is that large organisations are inherently inefficient 
so that their size stands as an impediment to innovative results. This may be due to
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bureaucracy and the conservative nature of large organisations (Graves and 
Langowitz, 1993).
In a contrasting study Henderson and Cockburn (1996) examined the relationship 
between firm size and research productivity. They investigated the internal records of 
ten pharmaceutical organisations. The level of their investigation was the individual 
research program that covers the range of major research and development 
performing pharmaceutical manufacturers Their results indicate that large 
organisations appear to have an advantage in the conduct of research. Also, they 
suggested that superior performance flows from economies of scope (by say 
combining the multiple groups of researchers under the same roof) as well as from 
economies of scale. The main reason for this is that large pharmaceutical 
organisations are able to sustain an adequately diverse portfolio of research projects, 
and to capture and use internal and external spillovers of knowledge. However, 
Henderson (2000) in a later article argues that drug industry mergers will not 
necessarily benefit their research and development. She argues that there is a 
threshold in the size of organisations beyond which there are diseconomies of scope 
This threshold size is six to seven major research programs As this size has now 
been reached even by medium sized organisations, she argues that it is unlikely that 
large mergers will benefit research and development
Henderson et al (1999) attempt to gain insight into the national systems of 
innovation. They examine the regional differences in the impact of biotechnology on 
pharmaceutical industry structure and the nature of competition. Biotechnology may 
be used as a production technique and as a research tool (McKelvey, 1996). They 
found that when used as a production technique, biotechnology made several of the 
core competencies of existing organisations, particularly those related to process
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development and manufacturing, obsolete Biotechnology as a research tool was 
adopted by pharmaceutical organisations as a way to use molecular biology to 
enhance the value and productivity of their existing assets and competencies. 
However, Henderson at al (1999) found that the new techniques enhanced the 
competencies only of those organisations that were already oriented towards high 
science research and were already firmly embedded in the scientific community.
Henderson (1994) studied the evolution of integrative competence, i.e. the ability to 
integrate knowledge across both organisation and disciplinary boundaries, as a factor 
in productive research She found that these competencies are readily identifiable and 
include the use of cross-disciplinary teams in the management of research, the 
promotion of individuals on the basis of their standing in the scientific community, 
and the organisation of research by discipline rather than by therapeutic area 
However, her conclusions suggest that these findings are complex entities that evolve 
slowly over time and thus it may be difficult to develop normative prescriptions from 
cross sectional analyses of competencies Therefore, she concludes, those 
organisations that were fortunate to have focused early on more rational modes of 
drug discovery have been much more successful in developing the integrative 
capabilities than those that initially achieved it by the more traditional random method 
of drug discovery These capabilities are fundamental to modern drug discovery 
(Henderson, 1994).
In a continuation of this study Henderson and Cockburn (1994), distinguish between 
component (unique disciplinary expertise and expertise in particular disease areas) 
and architectural (the ability to integrate the component competencies) competence 
and examined the variance in research productivity across organisations. Their 
findings suggest that competence is important as a source of advantage in research
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productivity. In particular, they conclude that research productivity increases with 
historical success. Moreover, they suggest that the differences in local capabilities,
i.e. resources, knowledge and skills, or technical systems, may play an important role 
in shaping enduring differences between organisations. Finally, their findings suggest 
that in organisations in which publications records are important criteria for 
promotion and in organisations which use committees to allocate resources the 
research productivity is higher.
In a later study Cockburn et al (2000) investigate the origins of competitive 
advantage and they explore two possible hypotheses. The first suggests that 
competitive advantage is largely determined by factors put in place at an 
organisation’s founding This hypothesis is inline with the population ecology theory, 
which suggests that most performance differentials can be explained by differences in 
initial conditions and that these initial conditions are largely the result of difficult to 
explain differences in each organisation’s initial allocation of resources and 
capabilities (Hannan and Freeman, 1977) (population ecology theory is explained in 
greater detail in chapter 4). The second hypothesis suggests that competitive 
advantage results from an organisation’s strategic response to changes in the 
environment or to new information about profit opportunities. This hypothesis is 
inline with the planned view of strategy making that suggests that organisations 
respond to and exploit environmental signals (Porter, 1980) (planned strategies are 
also explained in greater detail in chapter 4). To test these hypotheses they evaluate 
the adoption of science driven drug discovery strategy in the worldwide 
pharmaceutical industry. Their findings are consistent with a perspective in which 
both population ecology and planned strategy have an important role to play in 
explaining patterns of organisational heterogeneity. They argue that initial conditions
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on the one hand play an important role because the differences observed at the 
beginning of the period of their study persisted for many years On the other hand 
their findings suggest that organisations that were furthest from best practice at the 
beginning of the period moved aggressively to adopt it.
In a similar study Thomke and Kuemmerle (2002) investigated the micro-level 
mechanisms by which assets are built and the reasons why some organisation assets 
are more difficult to imitate and trade than others. In particular they examined the 
dynamic process of accumulating chemical libraries and related technology assets 
used for drug discovery in nine pharmaceutical organisations. Their findings 
indicated three primary causes i) difficulty of imitating a particular asset, because of 
interdependence with other assets, ii) difficulty of trading assets, because of some 
structural inertia in adoption with an organisation’s core, and iii) difficulty of fully 
specifying all factors affecting imitation or adoption, because of rapid technological 
change (Thomke and Kuemmerle, 2002).
Although these studies (a summary table of which is provided in Table 3-1) provide 
valuable theoretical and empirical research about the drug discovery business, and its 
effectiveness (profitability and innovation) in terms o f networks, mergers and 
structural organisation, there is almost no information about the defining strategies 
and the strategic management process that accompanies and influences such practice 
There is no existing introductory account to and definition of drug discovery strategy,
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Tabic 3-1 Summary of drug discovery strategy literature
Topic Key finding Authors
Optimisation of drug Related to technological and FitzGerald, 2000, Harvey,
discovery process knowledge advances 1995, Jensen, 1998, Kniaz, 
2000, Koretx and Lee, 1998, 
Krantz, 1998, Merritt, 1998, 
Bernhardt and McCulley, 
2000, Danheiser, 1997, 
Erickson et al., 1990, 
Schneider, 1999, 2000, 
Schneider, 2000, Spence, 
1999
Effect of organisational Exploitation of outside Gambardclla (1992)
networks information
Complementary strategics Arora and Gambardclla 
(1990)
Organisational life cycle and 
organisational networks
Oliver (2001)
New product development and 
strategic alliances: U-shape 
relationship
Deeds and Hill (2001)
Absorptive capacity Ability of two organisations to 
lcam for each other
Lane and Lubatkin (1998)
For-profit and publicly funded Cockbum and Henderson
research (1998)
Innovative and imitative Strategic group emergence is Lee and Harrison (2001)
strategics dependent on low exit rates
Mergers, Acquisitions, Reduction of innovative Graves and Langowitz
organisational size productivity (1993)
Larger size means better Henderson and Cockbum
research (1996)
Existence of threshold size Henderson (2000)
Integrative competence Complex entities that evolve 
slowly over time
Henderson (1994)
Research productivity is a Henderson and Cockbum
function of historical success, 
local capabilities, and promotion 
criteria
(1994)
Effect of adoption of Biotechnology enhances Henderson ct al. (1999)
science driven drug competencies only of high
discovery science oriented organisations
Both initial conditions and 
strategy planning important in 
drug discovery success
Cockbum at al (2000)
Asset accumulation Three cause for causes difficulty Thomkc and Kuemmerke
of imitating (2002)
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let alone a working classification that would help identify and understand different 
drug discovery strategies, and the possible relationships and connectivity between 
them This gap is the motivation and aim of this thesis. It seeks to define and map 
the evolution of different drug discovery strategies, while understanding the factors 
that influence and shape different strategies. Addressing these issues requires a 
comprehensive and robust link between the discipline of strategic management and 
the process of drug discovery Such a link could provide the platform for further 
empirical research and the development and validation of theories related to drug 
discovery strategies.
The research carried out and presented in this thesis aims to provide such a link by 
examining and classifying the change of drug discovery strategies
Thus, the research questions addressed in this thesis are:
1. How does the discipline o f strategic management relate to the process o f  drug 
discovery and what is the definition o f  a drug discovery strategy ?
This research question requires the investigation of the links between strategic 
management and drug discovery strategies. As it was argued in the previous 
paragraphs there is little information that rigorously links the two disciplines. Critical 
to the investigation of any such link is the definition of the concept o f drug discovery 
strategy. This definition should encompass the thinking on strategic management, the 
purpose of drug discovery in pharmaceutical organisations, and the thesis o f the 
present enquiry.
Chapter 4 deals with this question by reviewing the literature on organisational 
strategy and relating it to the process of drug discovery. It concludes by creating a 
working definition of the term drug discovery strategy within the scope of this thesis.
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2. What are the factors (internal and external) that influence and define different 
drug discovery strategies?
As it will be shown in chapter 4 existing literature in strategic management explores 
the factors that influence and define different organisation strategies. These factors 
originate both from within and outside an organisation. Also, as this thesis seeks to 
define and map the evolution of different drug discovery strategies, the identification 
of such internal and external factors specific to drug discovery strategies is essential 
for addressing the aim of this enquiry and this is the scope of this research question
The review of literature in chapter 4 identifies four generic factors that influence the 
formation of organisational strategies regardless of industry These factors are 
knowledge, technology, organisation, and environment These are defined and related 
to the drug discovery process to help identify and classify different drug discovery 
strategies as required by the following research question
3. How can an evolutionary and classification approach he used to study drug 
discovery strategies?
Evolutionary and classification approaches have provided useful insights in studies 
in several disciplines such as biology (eg  Dawkins, 1989, Ridley, 1996), 
organisations (e g. Aldrich, 1999, McKelvey, 1982, Allen, 2000), and economics (e g 
Metcalfe, 1997, Nelson and Winter, 1990). Having defined the concept o f drug 
discovery strategies (1st research question) along with the factors that influence their 
change (2nd research question), this third research question seeks to investigate how 
such an approach may be used to study these strategies.
Chapter 5 identifies four requirements of evolution: existence in populations, 
variation, heredity, and selection. Following a review of the literature on strategic
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evolution the four requirements are converted into four hypotheses. Chapters 7 and 8 
address this research question by providing two cladistic classifications of drug 
discovery strategies.
4. What are the characteristics o f  the fittest drug discovery strategies?
This research question is not directly linked to the aim of this thesis. However, the 
process followed to address the previous research questions has revealed that some 
characteristics of drug discovery strategies are more sustainable than others i.e. they 
lead to more successful drug discovery and this leads to a higher frequency of 
appearance of these characteristics in future strategies. It is therefore, almost 
unavoidable, due to both academic curiosity and potential industrial implications, to 
investigate these characteristics. As explained in chapter 2 the research questions 
were reformulated following the completion of the literature review. This research 
question was added at this stage.
To address this research question chapter 5 defines the term fitness as the condition 
where the configuration o f  an organisational strategy matches that o f  the environment 
and the frequency o f  its characteristics appearing in future strategies is high. The 
classification created in chapter 8 provides a list of characteristics, which are in line 
with that definition, and thus addresses this research question
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4. STRATEGY FORMATION IN DRUG DISCOVERY
4.1. Introduction
This thesis seeks to define and map the evolution of different drug discovery 
strategies, while understanding the factors that influence and shape different 
strategies. To understand such issues it is vital to comprehend and adopt an 
appropriate school of strategic study (in this case evolutionary), along with the 
underlying mechanisms and drivers that govern the formation and implementation of 
strategy. Such knowledge relates strategic management to  the drug discovery 
process, and is the subject o f the first research question (How does the discipline of 
strategic management relate to the process of drug discovery and what is the 
definition o f a drug discovery strategy?) and the aim of this chapter. In addition, this 
chapter identifies and justifies the factors that influence and define the change of a 
strategy. These factors are then related to drug discovery to address the second 
research question (What are the factors (internal and external) that influence and 
define different drug discovery strategies?).
In summary, this chapter reviews the literature on strategic management in terms of 
the origins o f strategy, the strategic levels, the strategic types, and the strategic 
classifications. It shows that the factors that influence how strategy changes are the 
environment, resources, and organisation These are related and translated into a drug 
discovery context.
Thus the objectives of the chapter are:
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•  To examine the relevance and value o f existing strategic management 
literature to the area of drug discovery.
• To identify and justify the factors that influence the change of drug discovery 
strategy.
• To propose a definition o f drug discovery strategy.
4.2. What is Strategy ?
Strategy is a concept that has been in existence for thousands of years and the word 
strategy comes from the Greek, strategos, strictly meaning a general in command of 
an army (Evered, 1983). Strategos is composed of two other words: stratos (the 
army) and agein (to lead). By extension the concept of strategy implies the art o f the 
general to conduct war (Costin, 1998 p. x). Yet despite its ancient origins, strategy 
did not become a field of academic interest until the 1960s when key texts by 
Chandler (1962) and Ansoff (1965) examined and developed theories on how 
strategies are created and what makes them successful
Strategy is a process and way of thinking for achieving goals in war, politics, and 
nowadays business. Henderson, (1989) argues that elements of strategy can be 
recognised ever since humans combined intelligence, imagination, accumulated 
resource, and co-ordinated behaviour to wage war. Political and military leaders have 
always had to make choices about direction and policy, and how best to distribute the 
resources at their disposal in pursuit of certain objectives (Segal-Horn, 2000). Classic 
texts such as Sun Tzu’s the Art of War written in China 2,500 years ago, the political 
strategy of Machiavelli who wrote The Prince in 1513, or German military strategists 
such as Clausewitz in the nineteenth century, are still well known and highly 
influential (see Clausewitz, (1908), Clavell, (1981), and Machiavelli, (1992)). Also,
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numerous books have been published that explicitly focus on the analogies that can be 
drawn between these military and political works, and modern management
Not surprisingly, the first business definitions of strategy can be found in military 
books To illustrate this, a definition of the term strategy in connection with the 
activities of the German army in WWII, is given below:
'Strategy is defined as conceptual planning tied to options and directed towards 
success, normally embracing the fields o f  politics, military activities, economics and 
technology. Strategic planning in essence, offers various possibilities o f  action based 
on the concrete evaluation o f  a  given situation, combines calculation with prognosis, 
and finally covers the execution o f the plan with a view to achieving the objective. ’ 
(Magenheimer, 1999, p. 10)
Although this definition has been abstracted from a military book that studied 
Hitler’s strategic decisions, its context and relevance to business is obvious. To 
illustrate this, two popular definitions of business strategy are listed below:
'Strategic management is concerned with determining the future direction o f  an 
organisation and implementing decisions aimed at achieving the organisation's long 
term and short term objectives’ Boseman and Phatak, 1989 p. 4)
Corporate strategy is the pattern o f  major objectives, purposes or goals and 
essential policies and plans fo r  achieving those goals, stated in such a way as to 
define what business the company is in or is to be in and the kind o f  company it is to 
be (Andrews, 1971 p. 28)
These two business strategy definitions, together with many others, illustrate the 
view that the study of organisational strategy may be seen as a continuation of the 
study of war. In addition, although the two definitions are very representative and
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have been produced by influential writers in the field, they do not cover the whole 
spectrum of strategy, as it currently exists. Also, they suggest that strategy is a linear 
process that involves identifying-planning and executing. This rational view of 
strategy has been critically debated (e g. Mintzberg et. al 1998, Whittington, 1993).
Mintzberg and Quinn (1996) presented five definitions of the term strategy in a 
framework called the Five Ps fo r  Strategy. The five Ps stand for plan, ploy, pattern, 
position, and perspective. Strategy as a plan is a consciously intended course of 
action set to deal with a situation Strategy as a ploy is a specific manoeuvre intended 
to outwit an opponent or a competitor. Strategy as a pattern implies consistency in 
behaviour regardless of whether this strategy is intended or not. The fourth term, 
position, views strategy as a way of matching the environment with the organisational 
intentions. Lastly, the content of strategy as a perspective consists not just o f a 
chosen position, but also of an ingrained way o f perceiving the world.
Hax, (1990), in an attempt to define the concept o f strategy assumes that it embraces 
all the critical values of an organisation, while it provides a sense o f unity, direction, 
purpose and facilitates the necessary changes induced by an organisation’s 
environment. Based on these assumptions he describes six critical dimensions that 
must be included in the definition of the concept of strategy. The first dimension 
views strategy as a coherent, unifying, and integrative pattern of decisions. Strategy 
in that respect provides a blueprint for an organisation as a whole and it is conscious, 
explicit and proactive. In reality however, this is usually not the case, because to 
identify and understand a strategy, requires an examination of the history of an 
organisation and how the decisions were taken. Historical changes or discontinuities 
discern an organisation’s strategic pattern and may be used to identify the future 
direction of an organisation. The second dimension that Hax (1990) identifies,
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examines strategy as a means of establishing an organisation’s purpose in terms of its 
long-term objectives. The third dimension views strategy as a definition of an 
organisation’s competitive domain i.e. the businesses that an organisation intends to 
be in. The fourth dimension views strategy as a response to external opportunities 
and threats, and to internal strengths and weaknesses. According to this perspective, 
the aim of a strategy is to establish a long-term competitive advantage over its rivals. 
The fifth dimension examines strategy as a logical system for differentiating 
managerial tasks at corporate, business and functional levels. The sixth and last 
dimension described by Hax, (1990), views strategy as a definition of the economic 
and non-economic contribution an organisation intends to make to its stakeholders i.e 
those who directly or indirectly receive benefits or sustain the costs from an 
organisation’s actions.
The preceding paragraphs provide a brief discussion on the origins and current 
thinking o f strategic management with the aim of understanding and defining drug 
discovery as a strategic process. To help achieve this aim, the next section reviews 
the different levels of strategy that exist within an organisation. It also argues that 
drug discovery strategy as viewed from within an organisation is a business strategy.
4.3. Levels of Strategy within an organisation
Hay and Williamson (1997) define six levels o f strategy. These are vision, mission, 
plan, key initiatives, individual objectives and budgets. Vision has two dimensions 
external and internal The external vision involves sharing an understanding 
throughout an organisation of what makes the market tick, what drives the customers, 
who are the most important competitors, and how the dynamics of competition are 
changing The internal dimension involves a vision of how an organisation sees itself
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developing, what capabilities it must acquire to succeed competitively, and what in 
essence it sees itself becoming. Mission, involves the expression o f purpose of an 
organisation (Hay and Williamson, 1997) and is usually summarised in a document 
called the mission statement. The mission statement defines the guiding purpose of an 
organisation, the destination at which the purpose leads, and the rationale behind the 
purpose. It delineates the directions an organisation wants to pursue or avoid (Drew, 
1999). However, one of the common problems with mission statements is that they 
are often too generic (Simpson, 1998) and fail to focus on specific goals. The second 
level, plan , focuses on how the mission will be achieved by defining the specific steps 
that are to be taken and the sequence of these steps. The next level of strategy 
requires each step of the plan to be broken down into specific initiatives; tasks that 
individuals can both relate to and believe to be actionable. The individual objectives 
are derived from the set o f initiatives being pursued; the individuals relate directly to 
the initiatives and are wholly consistent with them The final level o f  the strategy, 
budget, relates these initiatives to everyday expenditure and management accounting.
The process of discovering new drugs as described in chapter 3 consists of 4 clearly 
defined steps (i) target research, (ii) discovery, (iii) clinical development and 
regulatory approval, and (iv) manufacture and supply. Also, the aim of the drug 
discovery process is to be the innovation engine that creates new products consistent 
with the mission of the pharmaceutical organisation Since the second level of the 
above categorisation, plan , is associated with the definition of the specific steps that 
will be followed to achieve the aims o f the mission it may be argued that drug 
discovery can viewed as a plan with initiatives, individual objectives and a budget.
The categorisation provided by (Hay and Williamson, 1997) permits strategy to be 
analysed bottom-up The more traditional top-down view examines strategy from
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three distinct levels corporate strategy, business strategy, and functional strategy 
(Figure 4-1) (Boseman and Phatak, 1998, Grant, 1998, Clarke-Hill and Galister, 1995, 
Thakur, 1998). Corporate strategy defines the scope of an organisation in terms of the 
industries and markets in which it competes. It identifies the portfolio for an 
organisation to be engaged in (Clarke-Hill and Glaister, 1995) and is concerned with 
the identification of objectives for an organisation and the best way that these may be 
achieved in terms of the strategic orientation of an organisation. For instance, the 
decision made by the pharmaceutical organisation Glaxo in the 1980s to concentrate 
on ethical pharmaceuticals (Jones, 2001) is part of the corporate strategy.
Corporate strategy seeks to address the following questions (Boseman and Phatak, 
1998, p. 86):
1. What business or businesses are we in?
2. Will our current business or businesses enable us to achieve our long and short­
term strategic objectives, particularly growth, profitability, and financial 
performance?
3. Should we get into a new business area that will enable us to achieve our strategic 
objectives?
4 Which and how many resources do we have at our disposal now; which and how 
many resources that could be allocated to our businesses are we capable of 
gathering in the near future?
5. Which and how many o f our resources should we allocate to each of our 
businesses? Are there any businesses that do not deserve to receive resources in 
the future at the same level as in the past?
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Analysis and planning of corporate strategy requires an organisation to fully 
understand its current strategy and then develop a balanced portfolio of options that 
enable it to achieve certain corporate objectives, e g. profitability, growth, and market 
share. To achieve this, the corporate strategists employ analysis techniques such as 
what i f  analysis, analysis o f key or critical success factors, financial analysis of 
competitors and Strengths Weaknesses Opportunities Threats (SWOT) analysis 
(Glaister and Falshaw, 1999, Boseman and Phatak, 1998).
The second level o f strategy, business strategy, is concerned with how an 
organisation competes within a particular industrial market (Grant, 1998, p 19). For 
an organisation to prosper within a certain industry it must develop a competitive 
advantage over its rivals (Porter, 1980). A successful business strategy is one that 
provides an organisation with the competitive approach that enables it to achieve its 
business objectives as defined by an organisation’s corporate strategy (Boseman and 
Phatak, 1998). Hence this area of strategy is also referred to as competitive strategy 
(Grant, 1998). Porter (1980) has identified three generic approaches for obtaining a 
competitive advantage These are overall cost leadership, differentiation, and focus. 
The first, overall cost leadership, involves the construction o f efficient operations, 
cost minimisation, cost and overhead control, etc. The second, differentiation, 
focuses on creating a unique product or service This is the objective o f the drug 
discovery process, which seeks to develop and maintain an appropriate and relatively 
constant stream of new pharmaceutical products The third, focus, aims at serving a 
particular target market exceptionally well by focusing an organisation’s attention on 
a particular buyer group, segment of the product line, or geographic area
An example of a business strategy in the pharmaceutical industry is the sale of 
Glaxo’s subsidiaries like Vestric in 1984 (Glaxo’s wholesaling organisation), and
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Matburn in 1985 (a group of surgical engineering companies). The sale of these 
subsidiaries helped realise the corporate strategy of the organisation, which was to 
concentrate on the discovery and manufacture o f ethical drugs (Jones, 2001). Another 
example is the focus of Glaxo on the discovery of new drugs as opposed to the 
manufacture and distribution of generics (Jones, 2001)
The third level o f strategy functional strategy, is concerned with the elaboration and 
implementation of business strategies through functional areas as production, research 
and development, marketing, human resources, and finance as shown in Figure 4-1 
(Grant, 1998, p. 20, Clarke-Hill and Glaister, 1995). The main aim of functional 
strategies is to obtain the maximum productivity from the available resources. The 
functional level o f strategy requires an organisation to conceptualise itself as a series 
of business processes (Armistead et al., 1999). This requires the development o f a 
matrix of functions and processes to clarify the roles and responsibilities of the people 
responsible for completing these functions.
Critical to the overall success o f an organisation is the synchronising of the three 
levels of strategy
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Figure 4-1 Classification of levels of organisational strategy 
In the case of pharmaceutical organisations, the same levels o f strategy also apply 
(Figure 4-2). Corporate pharmaceutical strategies examine and assess the markets an 
organisation might concentrate on Business strategies focus on the development and 
acquisition of new technologies, the type of diseases research groups would focus on, 
the termination or continuation of R&D projects, etc. Finally, at the functional level, 
the strategies focus on day-to-day operational problems that deal with tasks such as 
scientific research, manufacture and the supply of drugs
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Figure 4-2 Pharmaceutical strategy categorisation 
Thus, drug discovery strategy could be classified at either the functional or the 
business level Classifying the strategy at the functional level implies that drug 
discovery is seen solely as a process within an organisation whose aim is to 
materialise the business strategy. Although this would clearly be the case in 
manufacturing dominated industrial sectors e g electronics and automotive, the 
pharmaceutical industry focuses on and allocates the majority of its resources to the 
process of drug discovery, whilst processes such as manufacturing, marketing, and 
distribution are very much secondary. Therefore, the ability of an organisation to 
discover new drugs within certain therapeutic areas may provide a pharmaceutical 
organisation with the competitive advantage required to sustain its presence within the 
industry Thus within the scope of this thesis the drug discovery strategy is seen as a 
business strategy responsible for effectively materialising the corporation’s goals and 
policies to achieve a competitive advantage. The functional strategies would 
therefore, focus on the policies towards daily research activities e g the management
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of personnel, the allocation and management of resources such as knowledge and 
technology.
4.4. Schools of thought on strategy
One of the objectives of this thesis is to classify drug discovery strategies. To 
achieve this it is important to review and learn from existing classifications of 
organisational strategies, because any classification is heavily dependent on both the 
objectives and underlying assumptions of the classifier. Prior to that however, the 
philosophies, i.e. schools of thought, which have led to the development of these 
strategic types must also be reviewed. This will aid understanding of the dimensions 
of existing strategy classifications and thus determine and justify the key components 
of the drug discovery classifications created in chapters 7 and 8
Bowman (1995) divides the work on strategy into three major categories, the 
institutionalists, the economists, and the behavioural scientists The institutionalists 
describe the issues facing organisations from the inside out. The economists draw on 
the background of industrial organisational economics to analyse the problems of an 
organisation. This category has recently developed to include game theory. Finally, 
the behaviouralists focus on the function and survival of an organisation and the 
behaviour of its people. Bowman (1995) further argues that the relative impact of 
these three groups has followed an historical progression.
McKiernan (1997) divides the modern contributions to strategy into four schools of 
thought, planning and practice, learning, positioning and resource based. The 
planning and practice school is analogous to military strategy i.e. it is essentially 
about large and long term decisions which require very careful planning and 
assessment of the organisational and environmental conditions The learning school
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assumes that the environment is so unpredictable that synoptic models do not provide 
protection from the constant buffeting organisations have to face. Therefore, 
organisations are forced to adapt and survive The positioning school sees the root of 
competitive strategy as linking an organisation to its environment. Industry structure 
should be analysed and an organisation should position itself within the industrial 
sector where it can best defend its capabilities. Finally, the resource-based school 
emphasises the accumulation of scarce resources through skill acquisition and 
learning, thus placing an organisation at the centre stage.
Finally, Mintzberg et. al’s book Strategy Safari (1998) describes ten schools of 
thought as shown in Table 4-1.
Tabic 4-1 The schools of thought from Min/.bcrg et al. (1998) p. 5
G
ro
up
 1
Design school 
Planning school 
Power school
Strategy formation as a process of conception 
Strategy formation as a formal process 
Strategy formation as a process of negotiation
Positioning school Strategy formation as an analytical process
Entrepreneurial school Strategy formation as a visionary process
3g Cognitive school Strategy formation as a mental process
o Learning school 
Cultural school 
Environmental school
Strategy formation as a process of negotiation 
Strategy formation as a collective process 
Strategy formation as a reactive process
G
ro
up
 3 Configuration school Strategy formation as a process of transformation
The ten schools fall into three groupings. The first group is prescriptive in nature i.e. 
concerned more with how strategies should be formulated than how they necessarily 
do form. The design school introduced in the 1960s presented the framework on 
which the planning and positioning schools were built Its main premise is that it
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focuses on strategy formation as a process of informal design, essentially one of 
conception. The planning school formalised this perspective, seeing strategy making 
as a more detached and systematic process of formal planning. The positioning 
school focuses on the selection o f strategic positions in the marketplace, while it is 
less concerned with the process of strategy formation and more with the content of the 
strategy.
The second group is less concerned with prescribing ideal strategic behaviour and 
focused on how strategies get made. The entrepreneurial school describes the process 
of strategy making in terms of the creation o f a vision by a great leader. The 
cognitive school uses the messages of cognitive psychology to ‘enter the strategist’s 
mind
The learning school describes strategy making as an emerging process where an 
organisation adapts or learns in a complex world. The power school treats strategy 
making as a process of negotiations either between the members of an organisation or 
between organisations of a certain environment The cultural school views strategy as 
collective and co-operative. The environmental school describes strategy as a reactive 
process where the initiative lies outside an organisation in its environment.
The final group, configuration, includes only one school of thought and is considered 
a combination o f the other nine. It views the process of strategy formation as a series 
o f  episodes that an organisation goes through i.e. the organisational life cycle 
(Kimberly and Miles, 1980). For example the leadership of a start-up organisation is 
likely to belong to the entrepreneurial school, but when the organisation matures the 
entrepreneurial spirit may give way to a more prescriptive strategy as professional 
managers become involved in an organisation.
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4.5. Classifications o f Strategies
Following the above review of the schools of thought, this section evaluates the most 
influential classifications of organisational strategies. There are two aims of this 
review. The first is to provide the theoretical background that justifies the value and 
need for a classification. The second aim is to identify and propose a rigorous 
structure for reviewing and classifying different drug discovery strategies, which is 
one of the aims o f this thesis.
McKelvey (1982) classifies organisational theories, and the way organisational 
strategies are created, according to the source of organisational variation i.e. the 
change or alteration in form, appearance, function or substance (McKelvey, 1982 pp. 
75). He defines two broad theoretical categories into which these theories fall These 
are autogenic and allogenic theories. Autogenic theories suggest that variation is self- 
generated or caused by forces within an organisation, while allogenic suggest that 
organisational variation is caused by forces found in the environment of an 
organisation. According to McKelvey (1982) the strategies developed vary according 
to the emphasis on the allogenic or autogenic sources. Most of the theories that have 
been developed to date are autogenic i.e. they are based on the decisions and actions 
taken from within an organisation.
From these two broad categories, McKelvey (1982) identified various models that 
explain the formation of organisations. The autogenic category led to the rational 
model, the natural system model and the market process model. The rational model 
views organisations as bureaucratic institutions that consist of a set o f people who 
continuously work towards the achievement o f pre-defined goals. The natural system 
model views an organisation as a ‘natural whole’. The emphasis is on inherent forces
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towards survival, which give rise to several organisational needs, while organisational 
change is the result o f unplanned responses of the system. Finally, the market process 
model views organisations as places where people exchange a variety of things, 
thereby satisfying their own desires and in the process creating cognitive maps, 
perceptions of externalities, social relations, norms, values, social and organisational 
structure, and ultimately collective organisational behaviour (McKelvey, 1982 p 83).
Mckelvey’s allogenic category includes three statements made by Warriner (1978), 
Hannan and Freeman (1977), and Aldrich (1979) on the use o f  population ecology 
theory as derived from natural selection. According to this theory the environment 
consists of certain levels of resources and constraints Within this environment a 
population of organisations, which have relatively similar characteristics emerges, 
survives, and grows until it is no longer able to compete effectively for additional 
resources. At this point the population will stabilise both in size and in characteristic 
form (McKelvey, 1982). The population ecology theory is further discussed in 
section 4.5 later in this chapter.
Whittington (1993) in his influential book "What is Strategy and does it matter?' 
discusses four approaches to strategy, which vary along two dimensions, its outcomes 
and the processes by which it is made. The four approaches are classical, 
evolutionary, processualist, and systemic as shown in Figure 4-3.
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Figure 4-3 Generic perspectives on strategy (Whittington, 1993 pp.3)
The classical approach relies on rational planning and execution of the plan using 
methods outlined in dominant strategy textbooks. The aim of these plans is to 
maximise profitability and consequently a large influence in the development of these 
plans, is the discipline of economics as well as that o f military strategy.
The evolutionary approach suggests that businesses are like biological species and 
that the fittest will be selected in, and while the rest will be selected out. Profit 
maximisation is a result of the influence of the markets rather than the managers 
Similar to the allogenic models of McKelvey (1982), the most influential work of the 
evolutionary approach is population ecology theory (Hannan and Freeman, 1977). In 
practice, change management programs will always manifest emergent and 
unpredictable properties, but managers are paid to make decisions that ensure current 
and future survival of their organizations, and therefore change management will 
involve some form of rational planning and identification of alternative 
configurations, and potential impediments.
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The processualist approach suggests that long range planning is, as in the case of the 
evolutionist, futile, but is more optimistic about the fate of the business than the 
evolutionist approach The original plan designed at the beginning of the strategy 
process often changes as business and market circumstances change. The final 
strategy (or realised strategy (Mintzberg and Waters, 1998)) is a result o f  bodging, 
learning, and compromising and not of a rational series of grand leaps The 
processualists radically downgrade the importance of rational analysis; as it limits the 
search for strategic flexibility; and it reduces expectations of success (Whittington, 
1993). Strategy is not just about choosing markets and then policing performance, but 
about carefully cultivating internal competencies.
Finally, the systemic approach suggests that strategy is the reflection o f the particular 
social system in which strategists participate i.e. defining for them the interests in 
which they act and the rules by which they survive. Similar to the classical view the 
systemic view places faith in an organisation’s capacity to plan forward and act 
effectively. However, this view refuses to accept the forms and ends of classical 
rationality as anything more than historically and culturally specific phenomena 
Systemic theorists insist that the rationales underlying strategy are peculiar to 
particular sociological contexts (Whittington, 1993 pp.28).
Along the same lines as the above classification, Mintzberg and Waters (1998) 
discuss a classification of strategies based on eight categories They vary according to 
the degree of planning encountered, along with how closely they match the original 
intentions of the strategy maker. An organisational strategy is born whenever an 
organisation seeks to move from one state to a different state in the future. Depending 
on the nature of the origins of a strategy, it can be an intended or a realised strategy 
(Mintzberg et. al, 1998). An intended strategy is one where organisations develop
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plans for future (e g. the introduction of research for a new therapeutic area), whereas 
a realised strategy is one where patterns are evolved from an organisations’ past (e g 
the entrance to a new market segment due to the serendipitous discovery of a new 
drug) (Mintzberg et. al, 1998, p. 10). Ideally, intended strategies should match the 
realised strategies. However, environmental uncertainties and complexity often 
inhibit the realisation of intended strategies (Figure 4-4). Depending on how closely 
the intended strategy matches the realised, the strategy could be entirely deliberate 
(perfect match) or entirely emergent (total absence of the intended strategy).
Figure 4-4 Types of Strategies from Mintzberg and Waters (1998) pp. 21 
Within the deliberate and emergent strategy spectrum, Mintzberg and Waters (1998) 
identify eight different types of strategy; planned, entrepreneurial, ideological, 
umbrella, process, unconnected, consensus, and imposed. The eight-category strategy 
classification suggested by Mintzberg and Waters (1998) will be used in the 
remainder o f this section to further discuss various strategy types. The reason for this 
is that this classification provides a well-structured rigorous framework that 
encompasses the plethora of organisational strategies implemented by organisations 
and analysed by the scholars. It also provides a categorisation of the different 
strategies along the continuum deliberate-emergent, which helps justify the 
evolutionary paradigm that is later presented and adopted by this thesis
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A planned strategy holds that strategy makers are able to carefully plan and 
implement their intentions The aim of strategy making is to match the internal state 
with the external expectations (as defined by the environment) (Learned et. al 1965). 
A milestone in the development of the planned strategy type is Michael Porter’s book 
Competitive Strategy (Porter, 1980). Porter’s (1980) model holds that there are only a 
few key strategies that are desirable for an industry. An organisation has to position 
itself competitively within a profitable industrial sector to be successful. To do this it 
should develop a competitive advantage, that flows from the creation, ownership, 
protection and use of difficult to imitate knowledge assets. Superior performance 
depends on the ability o f organisations to innovate, to protect intangible knowledge 
assets and to use knowledge assets (Teece, 2000).
A branch of the planned strategy is the resource based theory. This approach 
suggests that defining the capabilities o f an organisation provides a more durable 
basis for strategy than defining what the business seeks to satisfy. Focusing on the 
unpredictable environment does not provide a foundation for establishing long term 
strategy planning. In the contrary, an organisation’s resources and capabilities 
provide a much more stable foundation for effective strategy planning (Grant, 2000, 
Barney, 1986, 1991, Prahalad and Hamel, 1990, Dierickx and Cool, 1989, Rumelt, 
1987). Therefore for managers, the challenge is to identify, develop, protect and 
deploy resources and capabilities (an organisation’s capacity to deploy resources) in a 
way that provides an organisation with a sustainable competitive advantage and 
thereby a superior return to capital (Amit and Schoemaker, 1998).
A more recent development of the resource-based view of an organisation is the 
dynamic capabilities framework (Teece et al. 1997, Eisenhardt and Martin, 2000, 
Spanos and Lioukas, 2001, Foss, 1996), which focuses on capability building rather
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than resource picking (Makadok, 2001). Dynamic capabilities are specific to each 
organisation and may include identifiable processes such as drug discovery, strategic 
decision-making, creating alliances and interpretative flexibility (the degree to which 
users of a technology are engaged in its constitution during development and use 
(Dougherty et al 1998)). The essence of an organisation’s dynamic capabilities and 
competitive advantage depends on the organisational processes, shaped by the 
organisation’s asset positions (Helfat, 1997) and moulded by its evolutionary and co- 
evolutionary paths. Common features are also included in the organisation’s specific 
dynamic capabilities that are associated with effective processes across organisations 
(popularly known as best practice) (Eisenhardt and Martin, 2000).
Despite the criticism o f the planning strategy type (Mintzberg, 1998, Quinn, 1989, 
Simpson, 1998) strategic planning is still considered to be of benefit (Glaister and 
Falshaw, 1999, Brews and Hunt, 1999, Bowman and Helfat 2001, McGahan and 
Porter, 1997).
The second strategy type, entrepreneurial, holds that one person is in control of an 
organisation and attempts to realise his or her vision of the organisation. This type of 
strategy is usually found in new entrepreneurial organisations where one individual in 
personal control o f an organisation is able to impose his or her vision of direction on it 
(Mintzberg and Waters, 1998). It may also describe situations o f personalised 
leadership For instance, several organisations consist o f several business units that 
are managed as independent companies Within such units entrepreneurial strategies 
may also appear (Oijen and Douma, 2000). Their objective is to create something 
new and different (Drucker, 1985) by aiming to be highly flexible and responsive 
(Teece, 2000), alert to opportunities, and proactive in trying to control events (Day et 
al., 1998). Due to the flexibility of entrepreneurial strategies established organisations
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find it difficult to emulate them, this in turn causes variance in the performance 
(Walker et al., 2002). The gap an entrepreneur identifies provides an initial strong 
position. However, early entrants are often overtaken by competitors with more and 
better resources or capabilities (Liebermann and Montgomery, 1998). The ability, 
however, o f an organisation to be positioned as an early entrant, depends on its 
relative degree of strategic agility2 (Webb and Pettigrew, 1999).
An entrepreneurial strategy is less deliberate than the planned type. The person in 
control has some strategic intentions, and although these may not be clear to all the 
persons involved, they may be deliberate as long everyone follows the lead of the 
person in charge There is evidence, however, to support that those small 
organisations that use strategic planning perform better than those organisations that 
leave things to chance and deal with problems as they occur (Smith, 1998).
The next strategy type, ideological, takes place both at the individual and collective 
levels. The members of an organisation share and embrace a vision, which consists of 
the unwritten rules they pursue as an ideology or culture (Womack et al., 1990, 
Crosby, 1980). A strategic vision is a coherent and powerful statement o f what the 
business can be ten years hence (Wilson, 1992). The mechanism, by which the 
individuals acquire the beliefs o f the organisational ideology and culture, is a tacit and 
non-verbal process of acculturation or socialisation (Mintzberg et al, 1998 p. 267). 
This results in the origins and the explanations of the ideology being obscure 
Sources of the origins of this strategy could be the original philosophy and strategy of 
an organisation’s founder (Thorelli (1995) refers to this as the entrepreneurial
2 This agility depends on managers finding apprpriatc solutions while at the same time maintaining an 
ability to detect change in their environment and mobilise an appropriate response
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philosophy), or the institutional environment that surrounds an organisation (Oliver, 
1991, 1997, Meyer and Rowan, 1977). Adaptation to this type of strategy requires a 
change in culture i.e. the collective mind. Thus adaptation is not impossible and 
therefore an ideology strategy is not considered to be entirely deliberate
An umbrella strategy type relaxes the condition of tight control imposed by the 
previous types Here, leaders have only partial control o f the actions of the members 
of an organisation. Their role is to set the guidelines and define the boundaries of 
behaviour and let other members manoeuvre within them. Whenever this is not the 
case, the leadership takes corrective action. In a complex, uncertain, environment it is 
presumed that various members o f  an organisation should be able to respond to it. 
These members are allowed to apply their own strategy and therefore strategies 
emerge within the boundaries set by the leadership. In all types of strategy there is 
some degree of umbrella behaviour in the sense that there is a centre leadership with 
intentions, which tries to direct others with their own ideas. The organisational 
structure that is most capable o f applying these strategies is the network organisation 
(Quinn et al., 1998) where lateral ties are substituted for vertical ones Strategy 
emerges incrementally firstly to handle urgent matters, and then to start longer term 
sequences whose specific future branches and consequences are perhaps unclear
Although the boundaries of action are often set by one central leader, the actions of 
an organisation are not set deliberately. Therefore, this type o f strategy may still be 
characterised as deliberate although its main driving force is emergent This type of 
strategy emerged in the 1960s, due to the extensive diversification of the information 
required to make strategic decisions, thus making it unavoidable to delegate some 
strategic functions to lower levels (Thakur, 1998). This in turn triggered a more
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decentralised planning approach leading many organisations towards a divisional 
structure (Mintzberg et al, 1976).
The next type of strategy type, process, (Mintzberg and Waters, 1988), goes a step 
further in removing control from the making of strategy In this case the leadership 
does not set any boundaries or targets as in the case of umbrella strategies. Instead, it 
controls the process of strategy making, while leaving its content to the members of 
an organisation who are involved with it. Since the leadership selects both the people 
that will work in the organisation and the process of strategy making the process type 
of strategy is characterised as deliberate. This is because the leadership may 
indirectly impose its intentions. However, this type is also one of the most emergent, 
since members of an organisation regardless of how they find themselves in that 
position can implement their own strategies and respond to the environmental as 
quickly and as effectively as they are able to.
The unconnected strategy is one where a sub-unit of an organisation (maybe a single 
department or person), which is loosely coupled to an organisation, applies its own 
behaviour pattern through a stream of actions. This type is usually found in 
organisations like universities, hospitals or national and private research laboratories 
where individuals have the ability to follow their own way of thinking while still 
under their organisation’s protection.
Simpson and Powell (1999) have produced a classification of organisation 
archetypes focusing on research-based organisations such as pharmaceutical 
organisations. Their classification may be seen as a sub-classification of the 
unconnected strategies. They identify four archetypes the solitary genius, the 
technology push, the market pull, and the multiple project The solitary genius views 
an organisation as a set of isolated scientists working long hours Inspiration and
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insight come in sudden and unexpected ways and the new knowledge generated in 
this process cannot be foretold. The role of management is to provide the needs of the 
individual, but otherwise to stand back and allow the creative process to unfold at its 
own pace. The technology push archetype is characterised by objectives and 
motivations similar to those of the solitary genius with the main differences being the 
reliance on collegial interactions to cultivate experience Therefore, the new recruits 
of a technology push organisation can reasonably expect that the ongoing 
development of their expertise will be fostered through their associations with more 
experienced colleagues The market pull archetype stands as an antithesis to the 
technology push It explicitly recognises the market, rather than the scientific 
expertise as the sole arbiter of innovation requirements as the sole arbiter of 
organisation requirements. Therefore an organisation is designed to maximise the 
efficiency with which it can respond to market requirements. Finally, the multiple 
project archetype is a combination of the technology push and market pull archetypes 
The most apparent characteristic o f this organisational form is its constantly changing 
structure. The members of these organisations combine specialist expertise with a 
breadth of experience arising from frequent interactions with customers and market 
specialists (Simpson and Powell, 1999).
Although unconnected strategies are emergent, to a degree they are also deliberate. 
To meet an organisation’s goals a certain pattern of activities should be followed. 
This pattern may exist in the members’ minds i.e as an ideological strategy that 
influences the institutional environment or the socialisation between the members of 
the organisations Nevertheless, the freedom o f the individuals to act based on their 
own pattern, which in extreme cases may be opposite to the pattern of the overall 
organisation, clearly offers an emergent character.
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The consensus strategy holds that different stakeholders converge on the same theme 
or pattern so that it becomes pervasive in an organisation, without the need for any 
central direction or control (Mintzberg and Waters, 1998, p. 28). Therefore, this 
strategy emerges without any prior intention. This strategy type resembles the 
ideological strategy in that a number of organisation members converge to seek the 
goals of an organisation following a tacit pattern. However, unlike the ideological 
strategy, in which the tacit pattern comes from a system of beliefs, the consensus 
strategy comes from mutual adjustment among the various members of an 
organisation This adjustment results in the development of a common and 
unexpected pattern that suits them The resulting pattern could of course be affected 
from the influence that one individual exerts to the members of an organisation. Even 
in this case, however, the resulting strategy is not the product of collective intention, 
rather it is the product of collective action.
The section o f the literature that views the formation of strategy as the result of order 
emerging from chaos (Allen, 2000, Stacey, 1995) also falls within this category. 
According to Stacey (1993), chaos has been described as the unpredictable variety 
within recognisable categories defined by irregular features (Stacey, 1993, p 14) and 
the irregular, unpredictable behaviour of deterministic nonlinear dynamical systems 
(Stewart, 1984). Strategy emerges as the members of an organisation respond to the 
feedback they receive about the effect of their actions. This condition is referred to as 
self-organisation and is defined as the spontaneous clustering and reorganisation o f  
spatial configuration that occurs as a system runs (Allen, 2000, p 85).
Using chaos theory in organisational science denotes the perception of an 
organisation as a complex evolving system i.e a system that is neither rigidly ordered 
nor highly disordered. According to this perception organisations are not only
87
systems created and controlled by those who manage them, but also self-organising 
entities that evolve through learning (Price, 1995). Complexity theorists are 
interested in non-linear systems whose behaviour falls in the region between fixed 
order and deterministic chaos and whose behaviour is influenced by, and takes 
advantage of random noise (Arrow et al., 2000).
Competence theory is also another type of strategic thinking that falls in this 
category (Sanchez, 1997). According to competence theory strategic management 
becomes an effort to reduce the complexity and uncertainty on organisations by 
devising simple rules for ordering organisational processes in ways capable of 
maintaining quasi-stability while an organisation adapts to a complex dynamic 
environment (Sanchez, 1997). An important distinction in competence theory is 
between competence building and competence leveraging Competence building is 
any process by which an organisation achieves qualitative changes in its existing 
stocks of assets and capabilities. Competence leveraging is the application of these 
competencies. Therefore, strategy as leverage means that an organisation has to 
compete now by leveraging its current competencies to the greatest possible effect 
(Post, 1997).
The final type of strategy identified by Mintzberg and Waters (1998) is the imposed 
strategy, in which the environment imposes actions. With all the strategy types 
discussed so far, there was some form of direction from within an organisation, while 
the environment has been considered acquiescent. With this type o f strategy the 
environment is the dominant force that imposes a strategy on an organisation while 
the organisation is unable to resist. The imposed strategy in effect becomes 
deliberate, since the organisation knows the pattern to follow from the start.
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A classic work associated with this type of strategy is the population ecology theory 
o f  organisations, which was created in the mid-seventies by Hannan and Freeman 
(1977). Hannan and Freeman (1977) argued that there are limitations in the ability of 
an organisational structure to adapt to these environmental changes. They called 
these limitations structural inertia. Structural inertia is a function of both the internal 
(organisational) structure and the external (environmental) pressures. Examples of 
the internal structure include organisational assets, and political and history 
constraints. Examples of the external structure include legal and fiscal barriers, 
incomplete information, legitimacy constraints, collective rationality problem, and 
interorganisational networks. Also, structural inertia increases with population 
density (Ruef, 1997) i.e the size of the population relative to the carrying capacity of 
the pertinent niche (Delacroix and Swaminathan, 1989). The higher the structural 
inertia, the lower the ability o f an organisation to adapt. Therefore, according to the 
population ecologists, the adaptation of individual organisations cannot be the main 
force for change in an organisational population. In fact this is the difference between 
population ecology theory and other theories. It focuses on the effect of the 
environment on organisations rather than the intra-organisational factors. It has been 
argued that population ecology models provide potentially powerful explanations for 
the phenomena of organisational birth, mortality, and evolution (Betton and Dess, 
1985).
The third research question of this thesis (How can an evolutionary and classification 
approach be used to study drug discovery strategies?) requires the examination of how 
an evolutionary and classification approach can be used to study drug discovery 
strategies This question is addressed in more detail in the following chapters. 
However, it is important to note that population ecology theory is related to this
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research question, as it deals with the issues of populations, variation, selection and 
heredity. As will be explained in chapters 5 and 6 these issues are key to the 
evolutionary approach. Consequently, it is important to examine the population 
ecology theory in greater detail
Population ecology explains organisational change by examining the nature and 
distribution of resources in an organisation’s environment. The competitive intensity 
increases both innovation and refinement (Mezias and Eisner, 1997). Therefore, 
competition for resources becomes the main force for organisational change A 
general model that explains how organisations are created, survive or fail, and are 
diffused in a population is the ‘variation selection and retention' model illustrated in 
Figure 4-5 (Aldrich 1979 p 28).
Figure 4-5 Variation Selection Retention Model from Aldrich (1979)
Variation both between organisations and environments is the first requirement for 
organisational change The likely sources of variation could be error, chance, luck 
and conflict. Stinchcombe (1965), in his attempt to summarise the reasons why 
people form organisations, lists five conditions that lead to the formation of new 
organisations and thus generate variation within an organisational population These 
conditions are
a) The finding of alternative and improved ways of doing things that are not easily 
done within existing social arrangements,
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b) The belief that the future will be such that an organisation will continue to be 
effective enough to pay for the trouble of building it and for the resources 
invested,
c) The better way o f doing things will be received by either the founders or some 
other social group,
d) The allocation of the resources required to build an organisation is possible, and
e) The existing opponents of an organisation are less competent and therefore they 
may be defeated (Stinchcombe, 1965, p i46).
In any case, variation provides the raw material for the selection (internal and 
external) process that is the next stage of the population ecology model. The external 
selection process can be affected by three types of variation:
a) Selective survival or elimination of whole organisations,
b) Selective diffusion or imitation of successful innovations of partial organisation 
structure or activities, and
c) Selective retention of successful activities resulting from variations in behaviour 
over time.
According to population ecology theory, selection of organisations depends on 
environmental constraints. Those organisations that are well suited (i.e. a good fit) to 
their environment will survive, while those that are not, will fail Environments are 
described in terms of the resources and the information they provide to organisations 
A successful organisation will be one that has both better information and a better 
position in the environment in terms of the acquisition of the resources.
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The third stage of the organisational change model is retention Retention o f 
organisational species3 depends on the environmental and organisational 
characteristics (organisational structure). This stage can be interpreted as the stability 
in organisational forms or in specific structures and activities of individual 
organisations.
Selection pressures may support or eliminate entire organisations or forms o f  
organisations. The organisations that are more likely to survive are the ones that are 
more successful in a particular environment. Similarly, those organisational forms, 
which are more successful, are the ones that are more effective for a particular 
environment. In this situation a variety of forms may survive in a particular niche. 
The niche of a population is defined as that area in constraint space (the space whose 
dimensions are levels of resources etc.) in which population out-competes all other 
local populations (Hannan and Freeman 1977). Therefore, the environment could be 
viewed as numerous distinct niches.
Hannan and Freeman (1989) make a distinction between specialist and generalist 
organisations. Generalist organisations to some degree customise their output for 
individual customers using flexible techniques. In contrast, specialists create a 
competitive advantage by efficiently serving a narrower market with a more 
standardised and more stable product line (Miller, 1991). Specialists are considered 
to be fitter in continuously changing environments (coarse grained) while generalists 
are fitter in stable environments (fine grained). Specialism and generalism are 
relatively comparative notions that vary by degree among competitors (Miller, 1991).
3 An organisational specie is defined as a form of organisation which exists through generations which 
arc members of the specie (McKclvcy 1978).
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This distinction is clear when considering the pharmaceutical industry. A 
pharmaceutical organisation that focuses on the research and development of new 
drugs will not necessarily gain a competitive advantage by investing in technology 
and knowledge for producing generics (those drugs that can only be launched after an 
innovative drug has lost its patent protection). For instance, Syntex Corporation, an 
organisation which is on the boundary between being a ‘pure ’ research company and 
a 'true' drug manufacturer (Gambardella, 1995, p. 100), intensified its research into 
the process of manufacturing one o f its key drugs Naprosyn to eliminate competition 
from generic manufacturers (Gambardella, 1995). Syntex patented various processes 
to produce Naprosyn, and thus it became more difficult for generics producers to 
manufacture the product after its patent expires. Being a generalist organisation, 
Syntex chose to focus on its current research to strengthen its competitive advantage, 
rather than entering the generics market
4.5.1. Strategy as a dialectical process
Strategic thinking and strategic planning may also be seen as two interrelated modes 
in a dialectical process, where both are necessary for effective strategic management 
and each mode on its node is necessary, but not sufficient (Heracleous, 1998) 
According to this view, the above strategies may be seen as different phases of the 
organisational change rather than different organisational modes. Wilson (1998) 
suggests that these different strategic modes or strategic opposites must coexist within 
an organisation Harnessing with the strategic opposites provides an organisation 
with a long-term objective and short-term attention required to succeed (Wilson, 
1998).
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4.5.2. Classifications o f strategy: concluding remarks
The above discussion reviewed the literature on strategic management in terms of 
the origins of strategy, the strategic levels, the strategic types, and the strategic 
classifications This reviewed has provided the background for meeting the aim of 
this chapter i.e to relate strategic management to the drug discovery process.
Although the classifications discussed above provide frameworks for understanding 
and studying different strategic types they do not allow the comparison of the 
strategic configurations that they represent This is because the strategies that are 
included in these classifications are in a conceptual form i.e they are not related to 
organisational strategies or specific organisations. Therefore, it is not possible to 
directly compare the effectiveness that these strategic types offer Some of these 
classifications have been developed into classifications of manufacturing systems 
(e g. see Fernendez, 2002, and Leseure, 2001). Yet, there exist no classifications of 
drug discovery strategies. The creation of such a classification is a key objective of 
this thesis and as it will be shown in chapter 6, is achieved using an evolutionary 
technique cladistics.
4.6. Factors that influence the change of business strategies
The aim of this section is to identify and justify the factors that influence the change 
in organisational strategies These factors will be used in this chapter, to develop a 
working definition of drug discovery strategy. Furthermore, they will be used in 
chapters 7 and 8 to search and select the data needed to construct a classification of 
drug discovery strategies
The strategies discussed in the above classifications cover a wide spectrum of the 
strategic literature These strategies vary along the continuum of entirely deliberate
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to entirely emergent (Mintzberg and Waters 1998). A key difference between the two 
ends of the spectrum is how strategists conceive and achieve strategic planning and 
strategic thinking. Supporters of the deliberate strategy view support the idea that 
strategic thinking is based on analytical frameworks (e g. Porter’s five forces of 
analysis). At the other end o f  the spectrum strategists believe that strategic thinking 
and strategic planning are two distinct thinking modes, and strategic thinking should 
precede strategic planning (Mintzberg 1994a, Mintzberg 1994b).
A common theme of these strategic types is the desire to align the organisational 
configuration with that of the environment. Central to this alignment are (i) an 
organisation’s environment, (ii) an organisation’s formal and informal structure and 
processes, and (iii) the resources of an organisation (Farjoun, 2002). A change in 
these factors leads to a change in the resulting strategy. Depending on the strategic 
type that is adopted the change could be seen as the result of either careful design or 
reaction to the new environmental status. For instance, change of imposed strategies 
would imply that changes o f the environment have not favoured certain organisational 
strategies.
The first factor, the organisation’s environment, is the pattern of all the external 
conditions and influences that affect the organisation’s life and development 
(Andrews, 1980). The environment consists o f other organisations and their 
strategies, technologies, and knowledge (Farjoun, 2002), the market, and possibly 
legislation The relationship of an organisation with the environment depends on the 
interactions of the organisation with the environment’s elements. Baden-Fuller and 
Stopford (1998) argue that this interaction also shapes the environment and thus the 
organisation’s task is to recognise the economic signals and recognise the potential 
opportunities to shape and harness tastes, technology, and competitor behaviour.
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Understanding the dynamics of the environment is a focal point in all the strategy 
types discussed in the previous section. With planned strategies the environment 
comprises of threats and opportunities and thus strategy making involves the 
identification o f these and the design of appropriate action (Boseman and Phatak, 
1989, Learned et al., 1965, Porter, 1980). With entrepreneurial strategies the 
environment changes quickly and therefore a responsive and flexible approach to 
strategy is more appropriate. According to the imposed strategies the environment 
imposes constraints such as legal and fiscal barriers, incomplete information, etc. 
Therefore, strategy making is unable to avoid environmental pressures (Hannan and 
Freeman, 1977, Aldrich, 1979).
The second factor, organisation structure and process, represents the people involved 
in the implementation of a strategy, and the mechanisms for allocating and 
coordinating organisational resources i.e. the organisational routines. These 
mechanisms can be both formal (e g. governance structure) and informal (e g. culture, 
politics, control) (Farjoun, 2002). The organisational actions and routines depend on 
the history of prior resource allocation and on the nature of the political coalitions 
(Hannan and Freeman, 1989). Therefore, the formation of organisational routines 
depends on the history of an organisation. Stinchcombe (1965) suggests that the 
social structure of an organisation is also a function of its history ... fo r  example, 
textiles have been manufactured in the United States much longer than have 
automobiles. It turns out that textiles (and other industries developed about the same 
time) have quite a different social structure in their social firm  than do automobile 
plants (and other industries founded during the twentieth century)...(Stinchcombe, 
1965, p. 230). The structure of an organisation depends on the devices employed for
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the allocation of the resources essential to their purpose. Since these devices differ 
during the formation of an organisation so are their structures (Stinchcombe, 1965).
The third factor resources includes the internal means and developments that can be 
drawn upon to accomplish the firm’s goals, and especially those unique features 
called distinctive competencies (Selznick, 1957). Resources are converted into final 
products or services by using a wide range o f  other organisation assets and bonding 
mechanisms such as management information systems, trust between management 
and labour etc. (Amit and Schoemaker, 1998). Barney (1986) argues that for 
organisational resources to hold the potential o f sustained competitive advantage they 
must have four attributes:
1. they must be valuable, in the sense that they exploit opportunities and/or 
neutralise threats in an organisation’s environment,
2. they must be rare among an organisation’s current and potential competition,
3. they must be imperfectly imitable, and
4 there cannot be strategically equivalent substitutes for these resources that are 
valuable, but neither rare or imperfectly imitable.
Such organisational resources may include the accumulated knowledge (Helfat, 
1997, Drew, 1999, Krogh et al., 2001), the technology (Dougherty et al., 1998, 
Arthur, 1989), and the physical assets (Amit and Schoemaker, 1998)
Figure 4-6 provides a summary form o f  the elements that influence and shape 
business strategies
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F ig u re  4-6  F a c to r s  in f lu e n c in g  b u sin e ss s tra te g y
The following section considers and relates these three factors to the drug discovery 
process and accompanying strategies.
4.7. Drug discovery strategies
This chapter has so far presented a discussion on the origins and diversity and 
classifications of organisational strategies. The previous section identified three 
factors that influence the change of organisational strategies. This section will relate 
these factors to the drug discovery strategies.
The pattern by which pharmaceutical research is being carried out has changed 
remarkably over the previous century. In the past the focus of pharmaceutical 
research was on symptomatic relief, while today the focus has shifted towards the 
treating of an underlying pathology (Ratti and Trist, 2001). As understanding of 
human biology has progressed, research has shifted from an emergent pattern to a 
more predictable and less risky behaviour where an organisation can often statistically
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predict the outcome of research and its market potentials. This fact has affected the 
way organisational strategies have been formed and implemented throughout the 
history of the pharmaceutical industry. In accordance with chapter 5 it is suggested 
that these strategies follow an evolutionary pattern.
Organisational strategies are formed according to three factors (see section 4.6): 
resources, organisation, and environment The resources that have played a key role 
in the change of drug discovery strategies include technology (FitzGerald, 2000, 
Henderson et al., 1999, Janzen, 2001, Kniaz, 2000) and knowledge (Henderson, 1994, 
Henderson et al., 1999, Jensen and Sandstad, 1998, Nightingale, 2000). Naturally, 
these two resources are tied to the competitive advantage of pharmaceutical 
organisations (Yeoh and Roth, 1999) Therefore, in the remainder of this chapter, 
knowledge and technology will constitute two of the factors forming organisational 
strategies replacing the resources factor.
An organisation consists of people and managerial processes that seek to project 
manage the discovery of new drugs Finally, the environment o f drug discovery 
consists of characteristics such as diseases, legislation, knowledge and the technology 
capabilities o f competitors (Sedlaceck et al., 1996).
The remainder of this section analyses the following four factors, to justify their 
selection as the basis for studying drug discovery strategies:
• Knowledge,
• Technology,
• Organisations (structure and processes), and
• Environment.
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4.7.1.1. Knowledge
Knowledge has emerged as the most strategically-significant resource o f the firm  
(Grant, 1996 p.375, Janszen, 2000). Scientific knowledge is generated by the social 
practice of exploring, mapping and mathematically codifying patterns in the 
behaviour of nature. When these patterns are recognised they can be used for 
prediction by extrapolating them from known starting conditions to unknown end 
results (Nightingale, 1998). During the age of botanicals (pre 1800s), scientific 
knowledge was limited. The discovery of new drugs was based not on scientific 
exploration, but on a mixture o f empiricism and prayer (Lesney, 2000). As 
civilisation progressed, the information that was available on how the human body 
functioned and its reaction to various chemical entities generated the foundations of 
this scientific knowledge.
An organisation’s knowledge capital is accumulated through interrelated and 
independent functions such as R&D, technology acquisition, experiential learning, 
organisational learning, and network knowledge. These functions are generated both 
internally and externally to an organisation. Drug discovery requires that knowledge 
once obtained, is available for decision-making. This is important for two reasons 
Firstly, unsuccessful projects should be terminated as soon as possible, and secondly 
hundreds of individuals should be aware of the reasons (Koretz and Lee, 1998) 
However, the exponential growth o f scientific knowledge and skills, makes the issue 
of availability of knowledge complex (Liyanage et al. 1999). Therefore, techniques 
aimed at improving the coordination of research methods, knowledge utilisation and 
assimilation processes are continuously being developed (e g bioinformatics).
Within an organisation two types of knowledge may be distinguished (Janszen, 
2000, Helfat and Raubitschek, 2000)
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• Explicit, core or systematic knowledge. This is knowledge that can be expressed 
and codified. It relates to the scientific knowledge that is at the heart of and forms 
the foundation for, a product or service,
• Tacit, uncodified, intuitive, or integrative knowledge That is intangible 
knowledge that may include personal insights, intuition, hunches and is acquired 
through informal processes of learning rather than through manuals and 
procedures (Price and Shaw, 1998). This type of knowledge may be transferred 
only by interaction and integrates different activities, capabilities, and products in 
one or more vertical chains (Helfat and Raubitschek, 2000).
An illustration of the use of knowledge as a core competency in pharmaceutical 
organisations, is the recovery of the European pharmaceutical industry after the 
Second World War. The war had destructive effects on the capital stock and physical 
asset investment in European pharmaceutical organisations. However shortly after 
the War various new products quickly emerged helping to revitalise the industry 
(Bogner and Thomas, 1996 p.90). The ability o f this industry to quickly recover 
technological and business momentum suggests that the core competencies o f the 
firms were not in their physical plant and technology, but in the collective knowledge 
they possessed about organic chemistry and the associated techniques o f  their 
research laboratories’ personnel (Bogner and Thomas 1996 p.91).
It has been suggested that the generation of tacit and codified knowledge follows a 
cyclical path. Most knowledge starts as tacit, but is later codified Codification is 
defined as the individual and collective processes through which knowledge and 
experience may be structured and made explicit (Moenaert et al, 2000). After 
codification, this knowledge is combined with other previously codified knowledge 
and is then applied and internalised within an organisation. The codification of
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knowledge happens mainly through the development of prototypes and 
communication (Nonaka and Takeuchi, 1995 in Janszen, 2000). The development of 
prototypes allows testing and modelling and therefore enables the codification of 
knowledge. Communication on the other hand helps articulate and communicate tacit 
knowledge and thus results in organisational learning This learning enables
organisations to perform their activities in improved ways (Deeds et al., 1999).
The communication channels are not limited to internal activities only. 
Pharmaceutical organisations establish external strategic links with other 
organisations and institutions to gain access to a specific set of tangible and/or 
intangible resources necessary for the development of innovations (Estades and 
Ramani, 1998). Additional reasons for collaborations between organisations include 
complementarity, learning, speed, flexibility/reversibility and trust/reciprocity (Senker 
and Sharp, 1997). Arora and Gambardella (1990) have identified four types of link 
for biotechnology firms. These are:
• Research and/or joint development agreements with other firms,
• Research agreements with universities,
• Investments in the capital stock of new biotechnology firms, and
• Acquisitions o f  new biotechnology firms
Although their focus was on new biotechnology firms (Arora and Gambardella, 
1990), these links can be generalised to the wider industry. In their paper they 
conclude that these four types are complementary to one another and suggest that the 
development o f new knowledge should be thought as a network o f  inter- 
organisational relations. In addition Yli-Renko et al (2001) have also found a 
positive relationship between social interaction and network ties and knowledge
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acquisition. To be part of such a network and to be able to effectively exploit the 
information that circulates in the network has become "even more valuable than being 
able to generate new knowledge autonomously' (Gambardella, 1992). Being part of 
such a network may depend on something as simple as its location Organisations 
that are located close to other organisations in the same industry could reap benefits 
from knowledge spillovers (Deeds et al., 1999). In another research project conducted 
by Deeds and Hill (1996), it has been suggested that an inverted U-shaped 
relationship exists between the number of networks or strategic alliances that an 
organisation is associated with and the number of new products that they develop 
Therefore, there is an optimal point o f strategic alliances that an organisation may 
enter before the benefits begin to decrease. This optimal number depends on 
idiosyncratic organisation-specific factors like the kinds of complementary assets and 
knowledge that an organisation needs to access through alliances given the nature of 
its product development efforts and its existing resource base, the quality of an 
organisation’s management, and an organisation’s experience at selecting partners and 
managing alliances (Deeds and Hill., 1996, Graves and Langowitz, 1993). Finally, 
knowledge transfer in strategic alliances depends on two sets of variables, namely, the 
knowledge specific variables and partner specific variables (Simonin, 1999). The 
knowledge specific variables include tacitness and complexity o f knowledge while the 
partner specific ones include prior experience, cultural distance, and organisational 
distance.
The ability of an organisation to acquire, analyse, store, retrieve, and communicate 
knowledge is a critical success factor (Jensen and Sandstad, 1998). The ability to 
value assimilate, and apply new external knowledge to commercial ends has been 
called absorptive capacity (Lane and Lubatkin, 1998, Cohen and Levinthal, 1989,
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Cockburn and Henderson. 1998) and it is largely a function of an organisation’s level 
of prior related knowledge (Cohen and Levinthal, 1990). This absorptive capacity can 
potentially be maximised if the following conditions are met. The organisation that is 
acquiring the new knowledge (student) and the organisation that provides the new 
knowledge (teacher) must share some common basic knowledge, whilst having 
different specialised knowledge To facilitate the intended transfer, the knowledge 
holder, or teacher organisation, should be responsible for the codification effort. 
When scientific knowledge is not or cannot be codified in a meaningful way like a 
formula of a complex chemical compound, learning from experience and learning by 
doing in the presence of knowledgeable partners becomes a sine qua non for 
circumventing ambiguity and favouring knowledge transfer (Simonin, 1999). In 
addition Lane and Lubatkin, (1998) suggest that the ability to assimilate new external 
knowledge depends partly on the similarity of the student and teacher organisations’ 
compensation practices. The compensation practices of a pharmaceutical organisation 
provide an indication of the organisation’s emphasis on external reputation. 
Henderson and Cockburn (1994) have convincingly argued that the rate of new drug 
development increases when the emphasis on the publications and the external 
reputation increases when evaluating the research staff The absorptive capacity also 
depends on the similarity of the structure of the two organisations The structure of an 
organisation is important in its learning capacity because it is related with an 
organisation’s problem solving behaviour, it reflects an organisation’s perception of 
the environment and finally represents the codification of an organisation’s historic 
pattern of roles (Lane and Lubatkin, 1998, Stork, 1998). Therefore, absorptive 
capacity links knowledge with organisational structure, another element of drug 
discovery strategy.
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The link between industrial research and academic or government funded research 
has been the subject o f extensive research (Ward and Dranove, 1995, Cockburn and 
Henderson, 1998). Academic research is usually concerned with so-called basic or 
“blue sky” research. Basic pharmaceutical research identifies chemical and/or 
biological properties of a newly synthesised or previously known substance Once a 
pharmaceutical organisation identifies a therapeutic use for the new substance it takes 
over the research and is now called applied research and development Ward and 
Dranove (1995) suggest that these two types of research are linked in such a way that 
government funded research generates industrial funded one after several years 
However, the precise mechanisms by which this effect is driven are not known. The 
transfer of knowledge from the academia to industry cannot be simply described as a 
waterfall model in which the public sector produces knowledge that spills over 
costlessly to downstream researchers (Cockburn and Henderson, 1998).
Each organisation has its own set of product groups it is focusing on, or in Porter’s 
(1980) words a group o f segments. Diversity of therapeutic areas and disease states is 
often regarded as a means o f reducing risk (Tiggemann, 1998). To further reduce risk 
and increase profitability, organisations have gradually diversified into related and 
non-related markets such as over the counter drugs, diagnostics, veterinary products, 
specialised chemicals, and cosmetics and toiletries (Omta et al. 1994). Over time 
organisations try to develop a competitive advantage over their competitors by 
specialising in those target segments Within those segments it appears that there are 
only four areas in which to build a competitive advantage (Tiggemman, 1998):
•  Safety (which incorporates quality of life issues),
•  Efficacy (which also incorporates quality of life issues).
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• Patient convenience,
• Economics (which incorporates pharmaco-economics issues).
The demand for pharmaceutical products depends on the uses which drugs are put. 
Drugs in different therapeutic classes generally are not substitutable in consumption 
Even drugs within the same general class are not necessarily interchangeable. The 
relevant markets are, therefore, determined by diseases or conditions that the drugs 
are used to treat Consequently, many organisations choose to focus their efforts on 
developing competencies in specific therapeutic areas Prior success in particular 
fields and programme specific expertise within an organisation can also result in 
trends in innovation at the organisation level These innovations are at least partially 
dependent on the paths that individual organisations may achieve in developing 
dominant drugs in one or several therapeutic categories (DiMasi, 2000).
In summary, the scientific knowledge acquired by an organisation, is a resource 
critical to the success of the discovery of new drugs Such knowledge is generated 
tacitly, but is then codified and combined with other existing knowledge The 
resulting knowledge is then communicated both within an organisation and with other 
organisations and institutions. The absorptive capacity o f  an organisation is also 
critical in the formation of the drug discovery strategy as it reflects the ability of an 
organisation to use the external knowledge and convert it into new drugs.
4 7 1.2. Technology
The second factor the influences and shapes drug discovery strategy is technology. 
Technology is driving innovation in manufacturing, defence, aerospace, transport, 
financial services, leisure, education, and of course medicine (Anderson, 1997). The 
rate o f technological change particularly in the pharmaceutical industry is high and is
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constantly accelerating The more a technology is adopted (or in evolutionary terms 
“selected” and “retained”) the more experience is gained by it and the more it is 
improved (Arthur, 1989). Technological innovation processes are important because 
they introduce dynamics into economic growth and impact the wider society 
(McKelvey, 1996). Technology represents the systematic utilisation of knowledge; it 
is the application of scientific information (Roman, 1968). Therefore, there is a 
strong link between knowledge and technology. In fact the role of knowledge in 
technical change has been the subject of increasing attention in the 1990s 
(Nightingale, 2000). Recent studies have documented that the most frequent 
motivation for alliance formation is the development of new technologies (Deeds and 
Hill, 1996)
New technology has facilitated the development o f new drugs through the 
development of sophisticated instrumentation. Since the WW1I the rate of 
technological advancement in pharmaceutical R&D has been dramatically 
accelerated The development of computers and their use into mainstream research 
has also increased the momentum of technical change Nowadays, technologies allow 
pharmaceutical products to be designed by identifying potential drugs at the level of 
the human genome. In addition, advancements in IT have led to the development of 
super-efficient tools for the collection, assimilation and analysis o f large amounts of 
data.
The following advancements are considered to be the key technologies of the 
pharmaceutical industry in the last two decades (Reuters, 2000, Ratti and Trist, 2001, 
Bellott et al., 1997), genomics, proteomics, rational drug design, combinatorial 
chemistry, high throughput screening, and pharmacogenomics. These technologies are 
used by most pharmaceutical companies (Ratti and Trist, 2001). A detailed
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description of these technologies is outside the scope of this thesis However, a brief 
explanation is provided in Table 4-2.
T a b ic  4-2 K ey  e n a b lin g  techno log ies
T e c h n o lo g y D e s c r ip t io n
G e n o m ic s T h e  s tu d y  o f  th e  g e n e tic  in s tru c tio n s  th a t  c h a ra c te r ise  liv ing  o rg an ism s  
(S c o t t  a n d  W e n d t, 1 9 9 8 ). It p ro v id e s  th e  k n o w led g e  on  h o w  v a r ia tio n s  in 
g en e  se q u e n c e  a n d  e x p re ss io n  c a u s e  d isease . A lso , u n d e rs ta n d in g  the 
g e n e tic  b a s is  o f  a  d is e a s e  s ta te  o r  e v en  th e  b io ch em ica l p ro ce sse s  in 
h e a lth y  in d iv id u a ls  h e lp s  to  b u ild  a  p ic tu re  o f  th e  c a s c a d e  o f  ev en ts  th a t  
le ad  to  illn ess  (B a b a , 2 0 0 1 )
P ro tc o m ic s T h e  s tu d y  o f  p ro te in s  a n d  th e ir  e x p re ss io n  p ro file s . I t is u se d  fo r 
id e n tify in g  th e  d is e a s e  sp e c ific  p ro te in s  invo lved  in th e  g en e ra tio n  o f  
d is e a s e  s ta te s . A d v a n c e s  in  th e  a n a ly s is  o f  p ro tc o m s u sin g  ro b o tic s  a n d  
h ig h  th ro u g h p u t a u to m a te d  p ro c e s s e s  h av e  rev ita lis e d  th is  d isc ip lin e
R a tio n a l d ru g  
d e s ig n
C o m b in a to r ia l
c h e m is try
U tilis e s  m o le c u la r  m o d e llin g  a n d  in fo rm a tio n  g a th e re d  fro m  p ro te in  
s t r u c tu re  a n a ly s e s  to  d e s ig n  a n d  d e v e lo p  new  d ru g s .
T h is  is  a  m e th o d  fo r  sy s te m a tic a lly  c o m b in in g  im m en se  n u m b ers  o f  sm a ll 
m o le c u le  ch em ica l b u ild in g  b lo c k s  to g e th e r  to  m ak e  a ll  p o ss ib le  
c o m b in a tio n s  a c c o rd in g  to  a  s p e c if ie d  ch em ica l re a c tio n  seq u en ce  (B c llo tt 
c t  a l , 1997).
H ig h  th ro u g h p u t 
sc re e n in g
T o  h a n d le  th e  la rg e  n u m b e r  o f  n e w  d ru g  ta rg e ts  a n d  n ew  ch em ica l e n ti t ie s  
p ro v id e d  b y  c o m b in a to r ia l  te c h n o lo g y  high throughput screening w a s  
d e v e lo p e d  a s  a  m e th o d  fo r  ru n n in g  u p  to  1 0 0 ,0 0 0  sc ree n s  a  d ay  (K n ia z , 
2 0 0 0 ) . It c o n s is ts  o f  th e  u se  o f  a u to m a te d  a s s a y s  (L csn ey  a n d  M ille r, 
2 0 0 0 )
P h a rm a c o -
g c n o m ic s
U ses  th e  k n o w led g e  g a in e d  fro m  h u m a n  D N A  se q u en c in g  to  g e n e tic a lly  
ty p e  p o te n tia l p a t ie n t  p o p u la tio n s  fo r  d ise a se  su scep tib ility . T h e  s c ie n c e ’s 
s tre n g th  lies in its  a b i l i ty  to  link  a  p a t ie n t’s re sp o n se  to  a  p a r tic u la r  d ru g  
w ith  th a t  p a t ie n t ’s g e n o ty p e
Technical change may require organisational rearrangements, which renders changes 
in structures and routines (Thomke, et a!., 1998). For example, suppose that a firm 
wishes to replace some physical and lab based experimentation methods with 
computer simulation methods To do this it must typically hire or develop people 
with new skills and reorganise the relationships between the various specialists who 
jointly carry out experiments (Thomke et al., 1998). In fact the adoption of a new 
experimental method and technique can serve as a long-term competitive advantage
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The reason being, that new methods require (i) the transfer of significant amounts of 
new skills and (ii) some reorganisation of a firm’s R&D activities (Thomke et al., 
1998).
The development of scientific knowledge over the last century has resulted partly in 
the development o f  new technology. New technology in turn has altered the pattern 
by which new drugs are discovered. This alteration has influenced both the success 
rates of drug discovery and the structure of pharmaceutical organisations since new 
capabilities are now required Consequently, technology is similar to scientific 
knowledge in that it constitutes an important asset o f a pharmaceutical organisation, 
and is critical to any drug discovery strategy
4.7.1.3. Organisation (structure and process)
'This (the pharmaceutical) is a business that's basically driven by people. I f  you look 
at the market capital o f  Pfizer I think we're the fifth-most valuable company now 
it's $250 billion, some mind-boggling number. Our balance sheet assets, the number 
is less than 10% o f  that. And so the delta is basically our intellectual property and the 
expectations o f  what our people can do.' (Norton, 2002) Senior Vice President, 
Corporate Human Resources, Pfizer Inc in The Economist 2002
http://www.economist.com/media/audio/eanorton.ram)
The above quote demonstrates the importance that is placed on the management and 
coordination o f  people within pharmaceutical organisations. The scientific 
knowledge required to discover new drugs can be divided into subject areas, which 
can be composed in a modular fashion to define larger pieces of knowledge This 
culture of rationalisation, encourages division o f labour amongst individuals into 
specialised segments of the drug discovery process (Valle and Gambardella, 1993)
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The scientific disciplines that underpin drug discovery include molecular biology, 
physiology, biochemistry, analytic and medicinal chemistry, crystallography, and 
pharmacology (Cockburn and Henderson, 1994, Stork, 1998). Having individuals 
from these disciplines working together to ensure that resources from different 
functions are present is considered one of the most important factors in achieving fast 
development (Dorabjee et al., 1998). It has been estimated that R&D costs are now 
$175,000 per person (this figure was calculated by USA’s pharmaceutical 
manufacturers association in 2002 (PhRMA, www.phrma org)).
Research should be organised with great attention so as to encourage creativity. In 
the past when new compounds were the result of long screening procedures, the 
volume of experimentation determined the number of successes. Nowadays however 
the design of theoretical compounds is possible and creativity is no longer linked with 
the economies o f scale of laboratories (Arrow, 1983). The individuals involved in 
research teams should be given autonomy to organise their own activities, whilst 
following their choice of research along the strategic objectives set by the managers 
(Valle and Gambardella, 1993). Therefore, the management challenge of 
pharmaceutical organisations is to exercise appropriate control on a research team 
without influencing its creativity. Omta et al. (1994) have suggested that the arguably 
greater success of the Anglo-American organisations in comparison to continental 
European firms is partly due to the greater emphasis on human resources 
management
In addition, the trend for mergers, acquisitions and alliances in the pharmaceutical 
industry has made the issue of managing the individuals even more critical. 
Organisations with different histories, symbols, ideologies, ways of doing things, and 
ways of thinking about things have now been joined together. These differences often
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make working together a difficult task to manage (Stork, 1998). This difficulty has 
led to the development of techniques for managing innovation such as project 
management. The aim of project management is to develop a sound overall plan that 
includes contingency plans, rapid identification of bottlenecks, and vigorous 
resolution of each bottleneck when it appears This in turn could create an efficient 
development process (Anderson, 1996).
Formal project management procedures were introduced to the pharmaceutical 
industry about thirty years ago when workers with limited responsibilities were given 
the title - project managers (Allen, 1997). According to Allen (1997) the 
pharmaceutical industry lags behind other industries in implementing true project 
management He identifies two reasons for this (i) the high level of specialisation 
which makes it difficult for people from different disciplines to collaborate, and (ii) 
the regulation which defines the steps by which drug development progresses. In 
addition other management techniques such as Total Quality Management which are 
widely used in other industrial sectors (e g. automotive manufacturing) have not yet 
been fully adapted by the pharmaceutical (Rowley and Sneyd, 1996). Anderson 
(1996) identifies six common sources of inefficiency; lack of motivation; 
inconsistency of funding; lack o f coordination, unproductive research; unfocused 
development, and slow project termination.
With pharmaceutical project management there are two trends, that of the virtual 
project and that of the empowered project team (Case, 1998). The former is where 
the locus of the project and the project work can be off-sight and potentially at 
considerable distance from functional management Also, the ownership and 
responsibility of a project can be shared among several parties either directly or 
indirectly employed by an organisation (contractors, consultants, and partners). The
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latter is that of a project team that has been given the authority to take most o f the 
decisions, while being allocated significant resources to pursue the project goals 
(Case, 1998). The more effective form is one that combines empowerment o f the 
project team with relaxation of the traditional ties in favour of more virtual 
organisations (Case, 1998).
As the availability of scientific knowledge and technology increases so does the need 
for specialised individuals capable of carrying out the necessary tasks. This has led to 
the development o f  organisational teams where scientists from different disciplines 
and departments come together to develop and bring to bear the appropriate 
specialised capabilities to develop new drugs. Within each team, data, information 
and strategic knowledge are widely dispersed across individuals from different 
functions within an organisation (Bernhardt and McCulley, 2000, Jensen and 
Sandstad, 1998). Success of these organisations requires much more than ‘naming’ 
the team and setting up a regular schedule o f team meetings (Clark and Wheelwright, 
1993 p. 522). It requires the definition and coordination of the functions that are 
required for the successful completion of the organisation’s goals.
To summarise, the growth of the body of scientific knowledge and technology in the 
pharmaceutical sector, have created the need for specialisation This specialisation in 
turn has created the need for communication interfaces between these individuals and 
the teams they are part of. The management techniques, which have emerged to 
address these issues, face the challenge o f exercising control without influencing 
creativity. Over the last century, these techniques together with scientific knowledge 
and technology have played an important role in the formation of drug discovery 
strategies.
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4.7.14. Environment
The fourth factor that affects the formation of drug discovery strategies is that of an 
organisation’s environment In section 4.3 of this chapter it was argued that drug 
discovery strategies are located at the business level Therefore, the elements o f the 
environment that affect the formation of drug discovery strategies are those that are 
directly associated with the competitive advantage of an organisation i.e. the drug 
discovery process The environment of the drug discovery process could be described 
as consisting of the technology and knowledge of other organisations, the legislation 
and political situation that directly influence the drug discovery process, and the 
diseases that are targeted
The issues of knowledge and technology and their effect on strategy making were 
addressed in the previous sections. Legislation and political policies affect drug 
discovery strategy by imposing a set of rules and routines that have to be followed to 
ensure that the drug is safe and efficient (Drews, 1998). Finally, diseases constitute 
the most critical part o f  the environment since the discovery of a successful cure for a 
disease can provide an organisation with a competitive advantage The number of 
diseases that are still uncured and could therefore provide potential targets for 
research of the pharmaceutical organisations is still high. History has indicated that as 
one disease is eliminated or controlled another takes its place AIDS is a recent 
example of a disease that has emerged, whereas obesity has made the progression 
from a cosmetic preoccupation to a topic of major concern (Williams and Mallick, 
1987). In addition, the increase in the geriatric population will result in an increase of 
the occurrence of diseases like arthritis, senile dementia, and Alzheimer’s (Williams 
and Mallick, 1987).
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4.8. Conclusion
The previous chapter introduced and defined the drug discovery process and 
summarised that its evolution was characterised by significant change from a 
relatively unplanned and emergent process, based on scientific enquiry and motivated 
by curiosity and academic freedom, to a modern, high technology, market targeted, 
rational and planned business process. Nowadays, the drug discovery process is no 
longer a '...random procedure in which inspired scientists, working around the clock, 
come upon breakthroughs in the middle o f  the night ’ (Henderson, 1994)
To help understand this evolution for the purposes of classification, this chapter has 
reviewed several schools of strategy and existing strategy classifications, to identify 
an appropriate framework for researching and classifying drug discovery strategies 
The chapter used Mintzberg and Waters’ (1998) eight-category strategy classification 
to understand and define strategy for the purpose of understanding and defining drug 
discovery strategy. As explained in section 4.5 the reason for this is that this 
classification provides a well-structured rigorous framework that encompasses the 
plethora of organisational strategies implemented by organisations and analysed by 
the scholars. It also provides a categorisation of the different strategies along the 
continuum deliberate-emergent, which helps justify the evolutionary paradigm that is 
later presented and adopted by this thesis.
A key element o f the resulting framework, and also a stance of this thesis, is that 
strategy making in the drug discovery context is seen as a process of leaping from one 
state to another (Mintzberg, 1998). As it will be discussed in the following chapters, 
drug discovery strategies are patterns of management behaviour that transform due to 
changes of the four strategic factors technology, knowledge, organisation and
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environment. In particular, advances in scientific knowledge and technology have 
driven organisations to transform their strategic configurations to a more rational 
approach
The framework is based on the following and summarised in Figure 4-7:
• Drug discovery strategy is seen as a pattern of behaviour rather than a 
predetermined plan. Viewing drug discovery strategies as plans would not allow 
for serendipity, a crucial factor in any research activity and particularly in the 
discovery of new drugs In contrast, the use of the term pattern allows for a more 
emergent or evolutionary behaviour and therefore complies more with the history 
of drug discovery that, as it will be shown in chapter 7, has been highly influenced 
by external factors such as diseases, technology, political, and social 
circumstances.
• Drug discovery strategies are seen as business rather than a corporate strategies.
• The formation of a drug discovery strategy is achieved using the strategic factors: 
knowledge, technology, and organisation. The environment within which the 
drug discovery strategies are formed and executed consists of the corporate 
strategy, the strategies of the competitors, the available knowledge and technology 
and finally legislation. Knowledge, technology, and organisation are used to 
create and protect an organisations’ competitive advantage and consequently to 
meet the goals set by the corporate strategy.
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F ig u re  4-7 F a c to rs  in f lu e n c in g  th e  d r u g  d isc o v e ry  s tra te g y  
This chapter has provided the background for relating strategic management to the 
drug discovery process and has therefore addressed the first part of the first research 
question (How does the discipline of strategic management relate to the process of 
drug discovery?). It has also identified four factors, knowledge, technology, 
environment, and organisation that influence and define the change of a drug 
discovery strategy. It has also addressed the second research question (What are the 
factors (internal and external) that influence and define different drug discovery 
strategies?). Finally, the chapter has addressed the second part o f the first research 
question (What is the definition of a drug discovery strategy?) by providing the 
following definition of the term drug discovery strategy
'A drug discovery strategy is a pattern o f  behaviour defined or adapted by the 
management o f  a pharmaceutical organisation, within a certain environment, to 
effectively materialise the corporation’s goals and policies in order to achieve a
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competitive advantage through the application o f knowledge and technology on the 
discovery o f new drugs. ’
The following chapter (chapter 5) reviews the concepts of evolution and fitness 
within the scope of this thesis and develops four hypotheses for the evolution of drug 
discovery strategies.
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5. E V O L U T IO N  R E Q U IR E M E N T S , F IT N E SS , A N D
H Y P O T H E S E S  D E V E L O P M E N T
5 .1. Introduction
The third research question presented in chapter 1 seeks to examine how can an 
evolutionary and classification approach be used to study drug discovery strategies. 
To address this it is important to understand the meaning and process o f  evolution. 
This chapter aims to provide this understanding by undertaking a review of the 
literature of evolution and identifying and justifying the requirements systems 
(biological and non-biological) should meet for evolution to explain their change 
The four requirements identified are existence in populations, variation, heredity and 
selection. To address the third research question the requirements are then developed 
into four hypotheses for the evolution of drug discovery strategies These hypotheses 
will be validated in chapters 7 and 8 by using the classification methodology 
cladistics which will be explained and justified in chapter 6
The fourth research question (What are the characteristics of the fittest drug 
discovery strategies?) is linked to the concepts of strategy, evolution and the 
identification of the fittest strategies and their defining characteristics. Prior to 
addressing this question it is important to understand and define the term fitness 
within the scope of this research. Therefore, the second aim of this chapter is to 
undertake a review of the literature on fitness and develop a working definition of the 
term.
It is important to note that even though the theories and analogies presented in this 
chapter stem from biology, they are still relevant to organisations However, in
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organisational science the use of the terms evolution and fitness is related to, but not 
the same as the terms used in a biological context. Evolution is often synonymous 
with change (Leseure, 1998), while fitness is synonymous with success (Venkatraman 
1989). This chapter will clarify and define these terms in accordance with the overall 
research objectives and theoretical stance adopted by this thesis
In summary, the objectives of this chapter are:
•  To review evolutionary theory (biological and organisational) and identify 
the requirements of evolution for the purpose of classifying drug discovery 
strategies,
• To develop hypotheses for the evolution of drug discovery strategies based 
on these requirements, and
•  To provide a definition of the term fitness in the context o f organisational 
strategy.
5.2. Introduction to Evolution
This section describes the process of evolution and develops four hypotheses for the 
evolution of drug discovery strategies
Charles Darwin introduced his theory of evolution in 1859 by the publication o f his 
book The Origin o f  Species (Darwin, 1968). Darwin argued that organisms come 
about by evolution, and provided a scientific explanation of how evolution occurs and 
why is it that organisms have features, such as wings, eyes and kidneys, clearly 
structured to serve some features Darwin defined evolution as descent with 
modification where the word descent refers to the way evolutionary modification 
takes place in a series of populations that are descended from one another Therefore,
evolution is change in the form and behaviour of organisms between generations and 
within populations of species (Ridley, 1996). Hence, examining the evolution of 
species requires the identification of populations they are members of, and this is the 
first requirement for evolution A fundamental concept in Darwin’s explanation of 
evolution was natural selection
The central argument o f  Darwin's theory of evolution starts from the existence of 
hereditary variation. Nature’s variations occur because they are favourable or useful 
in some way to an organism in its struggle for existence. Struggle for existence takes 
place because the number of individuals that are produced is higher than that that can 
possibly survive Favourable variations are those that increase chances for survival 
and procreation They are then preserved and multiplied from generation to generation 
at the expense of less advantageous ones This is the process known as natural 
selection.
Evolution therefore, can be seen as a two-step process. First, hereditary variation 
takes place, second, selection is made of those genetic variants that will be passed on 
to following generations. Hereditary variation also entails two mechanisms: the 
spontaneous mutation of one variant to another, and the sexual process that 
recombines those variants to form a multitude of variations The variants that arise by 
mutation or recombination are not transmitted equally from one generation to another. 
Some may appear more frequently because they are favourable to an organism; the 
frequency of others may be determined by accidents of chance, called genetic drift 
Therefore, for natural selection and thus evolution to occur it is essential to have 
variations within a population. Also, a mechanism must exist that allows these 
variations to be inherited to later generations. Hence, the third and fourth 
requirements are variation and heredity.
120
Research in organisational theory has derived considerable inspiration from 
biological evolution over the last forty years. Several scholars (e g. Hannan and 
Freeman, 1977, McKelvey, 1982, Aldrich, 1979, 1999, McCarthy, 2000) have 
employed ideas and concepts like natural selection and biological classifications to 
understand the operation and development of organisations and their strategies. 
Aldrich (1999) has argued that if processes generating variation and retention (or 
heredity) are present in a system and that system is subject to selection processes 
evolution will occur (p.21). In an organisational context, the consumer and market 
forces influence the role of natural selection. Fitter organisations edge out the less fit 
organisations by reducing their ability to win business contracts and orders. 
Therefore, the market environment acts as a form of natural selection, linked to the 
organisations ability to survive and grow in that environment (Nelson and Winter, 
1982).
Although these evolutionary approaches have been insightful and have inspired 
several debates in academe (e g. Donaldson, 1995) there are important distinctions to 
be made For instance, when studying biological organisms evolutionary changes 
over long periods are easier to observe. Aquatic worms have evolved into mammals, 
birds, reptiles, amphibians and fish over the last 600,000,000 years, and bacteria have 
evolved into plants and animals over the last 3,000,000,000 years etc. (Britannica, 
2002). In strategic management however, evolutionary changes are a phenomenon 
less straightforward to observe despite the fact that strategy can be viewed as an 
evolutionary process (Hannan and Freeman, 1977).
Another difference is the control and motivation of humans They have long-term 
objectives, a certain amount of foresight and the ability to plan and administer change. 
Man and the organisation he creates are to a certain extent the masters of their own
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destiny To a degree humans may shape their own environment, and are not merely 
shaped by it (Thorelli, 1995).
Allen (2000, 1994) also argues that whereas in biology genetic mechanisms ensure 
that different possibilities are explored and the offspring spreads them in 
characteristic space over time, in human systems techniques and behaviours are never 
passed on exactly. This is because in human systems there are imperfections and 
subjectivity o f existence which leads to curiosity and desire to experiment i.e. human 
systems are not mechanical (Allen, 1994). Therefore, exploration and innovation are 
always present as a result of the individuality and contextual nature of experience.
Finally, Penrose (1959) cautioned care in the use of the concept of natural selection 
to organisations. In biological studies the offspring should have an inheritable 
variation from the previous population. Penrose pointed out that organisations do not 
possess genetic material in DNA form, so it is not simply a case of transferring these 
concepts from biological studies to organisations. Other researchers suggested 
however that although organisations do not posses DNA, it may be possible to encode 
this type o f information in the form of configurations and routines. For example, 
Miller (1996) and Maguire (1997a, 1997b) proposed that configurations included the 
strategy and structures of an organisation. Also, Nelson and Winter (1982) used the 
term routine to refer to a repetitive pattern of activities which are consistent and 
predictable about business behaviour in an entire organisation Thus, routines range 
from specific technical procedures to strategies and policies In their book, they also 
suggest that as an organisation grows, it would retain past successful experience in the 
form of routines. Aldrich (1999) used routines as a generic term that could be used to 
describe an organisation. Hence, these routines or configurations could be treated as 
heritable just like the genetic information that an individual has in its DNA
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Rothschild (1992) compares the role o f DNA information with technological 
information. He argues that as genetic information is the basis o f all life in the 
biological environment, so in the economic environment technological information is 
the source of all economic life.
As developed by Campbell (1969), the natural selection model for organisations 
identifies three processes: variation, selection and retention that underpin the 
evolution of organisations. This concept has been further developed by researchers 
such as Pfeifer (1982) and Aldrich (1999). Aldrich (1999) added a fourth process, the 
struggle for resources.
In accord with the third research question, this thesis examines whether an 
evolutionary approach can be used to study drug discovery strategies Therefore, it is 
important to carefully review such an approach and to propose the requirements that 
systems should meet for evolution to explain their change, while considering the 
distinctions between drug discovery strategies and biological organisms. Four 
requirements are identified and discussed in the following section. These are 
existence in populations, variation, heredity and selection.
5.2.1. Requirements fo r  evolution
This section will analyse the four requirements that any species (biological and non- 
biological) must satisfy for evolution to explain their change i.e existence in 
populations, variation, heredity, and selection
5.2.1.1. Existence in populations
The first requirement of evolution is that of existence in populations (Ridley, 1996, 
Stearns and Hoekstra, 2000). Changes in biological evolution do not happen to 
individual organisms, but to populations over long periods (Dawkins, 1986). A
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population is defined as a subset of individuals of one species that occupies a 
particular geographic area and, in sexually reproducing species, interbreeds 
(Britannica, 2002). The frequency of this change depends on the members of a 
population i.e. the species as well as the environment they inhabit An approximation 
of the size of a population would be the number of individual organisms that are 
included in the population (Ridley, 1996 p 146)
Populations of species are relatively straightforward to identify, as living organisms 
can be easily distinguished from each other. However, such is not the case with 
organisational strategies, or drug discovery strategies. The configurations of 
organisational strategies are similar. For instance, the identification of populations of 
patterns by which pharmaceutical organisations have been applying new technologies 
cannot be easily distinguished. Existing empirical work found in organisational 
literature focuses on the distinction of organisational forms and the definition of 
populations of organisations (e g Hannan et al. 1995, Hannan, 1997, Carper and 
Snizek, 1980), but not populations of organisational strategies This issue is a research 
question and area of novelty for this research
Before proceeding with the argument of populations of drug discovery strategies, it 
is important to briefly review the literature on organisational forms and organisational 
strategies. Hannan and Freeman (1977) define organisational forms as blueprints for 
organisational action, for transforming inputs into outputs. Whilst, drug discovery 
strategy as defined in chapter 4 is a pattern adapted by the management of the 
pharmaceutical organisations Similar to the organisational form, this pattern is also 
responsible for transforming inputs into outputs. Within this context the concepts of 
organisational forms and organisational strategies are interchangeable
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In ecology there are three levels o f analysis, individual, population, and community. 
In organisational analysis there are at least five levels i) members, ii) sub-units, iii) 
individual organisations, iv) populations of organisations, and v) communities of 
(populations of) organisations (Hannan and Freeman, 1977). Lovas and Ghoshal 
(2000), on the other hand, defined two units o f analysis in their study of evolution in 
social and cultural systems. These are strategic initiatives and human and social 
capital. The former relates to any deliberate effort by an organisation to create or 
appropriate economic value from the environment, which is organised as an 
independent project with its own profit and loss responsibility. The latter refers to the 
knowledge skills and values that are embodied in people and the relations among 
people which have the potential to facilitate productive activity.
Hannan and Freeman (1977) refer to populations as aggregates of organisations 
rather than members. The organisations o f a population must be similar in their 
response to exogenous shock. In ecology this response is almost identical 
Organisations and their strategies however, are distinctive and thus no two are 
affected identically by any given exogenous shock. Nevertheless, classes of 
organisations may be identified which are relatively homogeneous with regard to 
environmental vulnerability. The nature of a population also depends on the 
investigation. Therefore, in the case of drug discovery strategies, populations could 
consist o f organisational strategies (or forms), which are located in the pharmaceutical 
industry. The pharmaceutical industry as a whole could also constitute a population, 
if the investigation was focused on different industrial sectors. However, this is not 
the case in this thesis as it focuses on the strategies of the individual organisations.
The formation of populations as well as their size depends on various factors, which 
include geography, technological competencies, regional market conditions, price
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reductions, and innovations. Carroll and Hannan (1989) argue that the size of a 
population of organisational forms follow a concave pattern o f  growth and decline 
(Carroll and Hannan, 1989 p. 524). That is, when the population emerges the number 
of organisations within that population is small However, this number increases 
rapidly in size and then stabilises or declines (Carroll and Hannan, 1989). They 
identify and test three different causes to this phenomenon, which are discussed in the 
‘selection’ section of this chapter. Furthermore, the size of a population also depends 
on its legitimation (Hannan et al. 1995). Initial increases in the size of a population,
i.e. increased density, enhances a population’s legitimation, thereby raising its 
founding rate and lowering its mortality rate (Hannan, 1997). These effects initially 
induce further growth in the density. However, persistent increases in density 
eventually generate intense competition, which depresses founding rates and elevates 
mortality rates. If the effect o f competition and legitimation balance, then density is 
in a steady state (Hannan, 1997).
Organisational and more specifically drug discovery strategies are formed by 
organisations that occupy a particular area in the competitive landscape. The use of 
the word area is more metaphoric than literal, as it does not refer to a geographic area, 
but to a symbolic business area whose size depends on the number of organisations 
that implement the strategies into their system. Therefore, it could be argued that 
drug discovery strategies form populations whose size depends on the number of 
organisations that exist within the area of investigation.
To summarise, drug discovery strategies could form populations in an environment, 
which is described by competitive forces and pressure for introduction to the market 
o f as many new drugs as possible In addition, the size of a population could be 
greater or at least equal to the number of organisations that implement similar
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strategies. In contrast to populations of biological species, populations of strategies 
for drug discovery would not be limited to a geographical area. Although regional 
variations in strategies do exist, mainly due to factors like local legislation and 
culture, the strategies that are pursued by pharmaceutical organisations have a global 
nature. Recent global trends for mergers and acquisitions (O’Reilly, 2001, DiMasi, 
2000) also support this view.
Thus, as part o f the work that seeks to address the third research question the first of 
four hypotheses is presented below:
There are similar drug discovery strategies employed by different pharmaceutical 
organisations to form  populations whose (the population’s) size follows a concave 
pattern o f  growth and decline.
5.2.12. Variation
The second requirement for evolution to occur is variation. The infinite variations in 
life are the fruit of the evolutionary process (Britannica, 2002). Variation may be 
caused by both genetic and environmental factors. Genetic factors are those factors 
found inside the organism and include mutation (the accidental introduction of an error 
in the replication of the parental DNA (Ridley, 1996)) and recombination (the process 
during which genes are shuffled, Ridley, 1996)). Variation must exist between 
members o f a population, because in its absence evolution would be impossible 
(Smith, 1993). For instance, if the object of study is body size, then individuals within 
a population must have different body sizes This form of variation is called heritable 
variation (Stearns and Hoekstra, 2000). In biological organisms heritable variation 
exists across various levels It can be found at the morphology level (e g. body shape),
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the cell level, the biochemical level and naturally at the DNA level The more genetic 
variation that exists in a population, the greater the opportunity for evolution to occur. 
In addition, variation must exist between the fitness o f organisms. In evolutionary 
theory fitness means the degree to which individuals contribute offspring to the next 
generation i.e. that body of living beings that constitutes the next step in the line of 
descent (the concept and definition of fitness is addressed in more depth in the next 
part of this chapter). Therefore, variation between the organisms’ fitness means that 
those individuals of a population that possess certain characteristics are more likely to 
reproduce than others are The production of surviving offspring is achieved through 
the number of offspring born, their survival, the survival of the parents to reproduce 
again, the number o f offspring they have in their second and subsequent breading 
attempts, the survival o f those offspring, and so forth. Variation in reproductive 
success is made up of variation in all these components (Stearns and Hoekstra, 2000).
The correlation between the two types of variation (between the members and 
fitness) causes variation. Heritable variation causes the most favourable 
characteristics to be transmitted to later generations. Following this, reproduction 
success will ensure that this attribute is reproduced in large quantities to dominate a 
population over time.
In organisational theory there must be some variation for the environment to select 
differentially among organisational forms (Aldrich, 1999). Any kind of change is a 
variation Aldrich (1999) and, as argued by Price and Shaw (1998), it is related to the 
interruptions of established equilibrium when new patterns of action that threaten, and 
eventually replace, old ones. The evolutionary process can begin with variations that 
may be intentional or blind (Aldrich, 1999). Variation is said to be intentional when 
an organisation deliberately sets out to resolve problems or exploit opportunities it
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faces Within organisations, there may be formal programs of experimentation and 
imitation, such as research and development. Such programs are intentionally created 
to promote innovative activities that can change the current routine of an organisation 
to a better functioning or more effective working style Another source of intentional 
variation is said to be the incentives provided for innovative employees Working 
groups can be created deliberately within an organisation to intensify internal 
competition and thus promote better functioning. The working groups are then 
appraised and rewarded when better innovations are created.
Blind variation as cited by Aldrich (1999), occurs independently of environmental or 
selection pressures This can include trial and error learning, luck, imitation, mistakes, 
misunderstanding, surprises, idle curiosity and so forth. It can also take the form of 
new knowledge or experiences introduced into an organisation by newly recruited 
employees.
Similar to the identification of populations o f drug discovery strategies, the 
identification o f strategic variations within a population is not straightforward As 
explained in chapter 4, organisations try different strategies in an endeavour to be 
successful Therefore, at any given time it is not easy to distinguish at which strategic 
state an organisation is In addition, since the identification of populations of drug 
discovery strategies is not yet clear, it is not possible to define different strategies that 
exist within such population.
Thus, the second requirement of evolution is that for the species to evolve they must 
be different to each other i.e. variation must exist. In social systems it has been 
argued that for the evolutionary process to function satisfactorily there must be 
enough variance for the selective forces to operate on (Campbell, 1969). If there is no 
variance, then no new forms will be selected and the older forms will be retained
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Biological variation is caused by two factors, environmental and genetic, while it 
happens along two dimensions, between the members, and between the fitness levels 
o f the individuals Hence, to assert that drug discovery strategies meet the 
requirement of variation, the two factors (genetic and environmental) and the two 
dimensions (between the members and between the fitness) must be explained in the 
context o f drug discovery strategy.
The environmental factors that cause variation are any factor found outside the 
organism. With regard to drug discovery strategies these factors can be the elements 
of the environment that surrounds organisations. These would include price 
reductions, fit to regional market conditions, innovations in the therapeutic areas and 
the technology (Sedlacek et al. 1996 p. 13), pressure o f generic competition, the 
influence o f  patient advocacy groups and consumer organisations (Anderson, 1996 
p.81), and the changes in the structure of the environment (Prahalad and Bettis, 1996).
The environmental factors may be divided into external and internal industry 
pressures (Reuters, 2000).
The internal industry pressures exerted on the pharmaceutical industry are:
• Increasing competition,
• The presence of me-too’s and generics,
• Quality, efficacy and tolerability issues,
• First to market advantage.
Large pharmaceutical organisations face increasing competition, not only from each 
other, but also from the biotechnology industry and spin-off groups initiated by 
academic institutions (Bogner and Thomas, 1996). Me-too drugs are those drugs that
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exhibit similar efficacy and tolerability profiles to  their first-to market competitors 
and because they are separate chemical entities gain patent protection Generic drugs 
are those drugs that can only be launched after an innovative drug has lost its patent 
protection Competition from generic drugs has become more intense and this results 
in greater pressures on R&D returns (Gambardella, 1995). These two types of drugs 
(me-too and generics) have driven pharmaceutical organisations to seek more 
innovative products, so that they can penetrate a particular market and, once achieved, 
maintain market share These innovative products however, must show improved 
tolerability and efficacy over existing products (DiMasi, 2000) Failure to do so 
results in the product not being recognised as providing improved therapeutic 
intervention and therefore is not utilised in preference to existing drugs Finally, the 
launch of a novel compound with enhanced therapeutic benefit results in the ability o f 
an organisation to effectively and deeply penetrate the market, thereby ensuring a 
certain level of sales (O’Reilly, 2001). Any subsequent me-too products, which are 
not significantly differentiated from the first drug, will find it difficult to penetrate the 
market and achieve significant market share without first reducing their price (Lu and 
Comanor, 1998, Agrawal and Thakkar, 1997)
Lee and Harrison (2001) also support the view that market competition causes 
strategic variation or, using their terminology, industry bifurcation. The driver for 
research intensive industry bifurcation is innovation Short term survival pressures 
force organisations to seek more innovative strategies and thus cause strategic 
variation. Baum (1990) adds institutional and environmental forces those that may 
cause variation. The simultaneous action of institutional, competitive and 
environmental forces may result in both increasing diversity in some organisational 
forms and decreasing diversity in some others.
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The external industry pressures exerted on the pharmaceutical industry are (Sedlacek 
et al., 1996):
• Healthcare cost containment measures,
• Pharmaceutical product price controls,
• The introduction of formularies.
Cost containment measures are used by healthcare providers to limit or reduce 
escalating healthcare costs Price controls are present in markets where healthcare 
services are either public or private. In countries such as the UK, where the 
government predominantly covers the cost o f healthcare, strict price regulations exist. 
The aim of these regulations is to ensure that pharmaceutical organisations do not 
demand excessive price premiums for their innovative products. Table 5-1 includes a 
list of UK government policies, which have been implemented in the past.
Tabic 5-1 Previous UK government policies that may rise again from Earl-Slater (1998)
• Government demands £25m saving on NHS drugs bill, twice in 1983. There is no 
robust evidence that any such savings were made.
• Government announces agreement on price reductions: NHS drug prices to be 
reduced by an average of 2.5% in 1993 and the reduction was to hold until September 
1996.
• Government switches drugs from being available only on prescription to being 
available without prescription. Eleven drugs switched between 1983 and 1992, 40 
drugs switched between 1993 and 1995. This switching means that the patient or 
their insurer pays for these drugs
• The increased availability of cheaper drugs from other EU countries (e g. Spam
Portugal and Greece)_______________________________________________ _
In countries where healthcare services are provided predominantly by private 
insurers such as the US, free market principles exist which result in natural price 
ceilings Within those markets there is no single healthcare provider. Instead 
numerous insurers control the provision of healthcare services. Despite the fact that
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there is no single purchaser wielding ultimate power over pharmaceutical drug prices, 
prices are regulated by internal competition. As the majority of individuals have their 
healthcare services provided by these organisations, these organisations can exert a 
level o f control over pharmaceutical prices. Finally, the introduction of formularies, 
the list of drugs physicians are allowed to prescribe, requires new innovative products 
priced at a premium to offer significant therapeutic benefits over existing products 
Failure to do so will result in the drug not being included on the formulary list and 
thus will not be available for prescription by physicians employed by the particular 
healthcare payer.
The identification of the genetic factors that cause variation o f drug discovery 
strategies is a more complicated issue. Genetic factors, are those factors that are 
inside the organism. Chapter 4 identified four factors that influence the change of 
drug discovery strategies These are scientific knowledge, technology, organisation, 
and environment The first three could be classified as genetic factors and could 
include, the structure of the research, the position of a team within an organisation, 
the technology available to the researchers, the culture, the organisation history (path 
dependence) (Helfat and Raubitschek, 2000), and the sources o f new ideas (Lovas and 
Ghoshal, 2000). Consequently, internal factors are those that affect the organisational 
structure and organisational capabilities Genetic factors cause some strategies to be 
stronger than others i.e. they are fitter for the particular environment and therefore 
they are more likely to survive.
An illustration of the genetic factors is provided by the work carried out by 
Cockburn et al. (2000) who suggest that the pursuit of science driven strategies is one 
reason that certain pharmaceutical organisations achieve a competitive advantage over 
their rivals especially during the 1980s. However, the positive response to such a
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strategy is ‘only half the battle' (Cockburn et a l , 2000). The other half is the original 
positioning of an organisation in a way that it is able to diffuse the science driven drug 
discovery more effectively. Although it is not certain whether this positioning is the 
result o f smart strategic moves or luck, it is a reason for internal variation. The initial 
conditions imposed on an organisation when it was founded, create a unique strategic 
configuration, which regardless of the changing efforts of an organisation, will be a 
blueprint of its operation.
Prahalad and Bettis (1996) suggest any element that causes variety, originates inside 
an organisation and might therefore, be labelled a genetic factor of variation This 
factor is the addition of a new business either through internal development or 
acquisition. In such instances the organisational structure is leveraged by the 
structure of the new unit
In addition, internal strategic variation may be caused by the available methods and 
techniques At any given time the strategy pursued by one organisation will seek to 
obtain resources essential to its strategic mission To achieve this it utilises methods 
and techniques available at the time Since these methods and techniques differ 
between organisations the strategies of the organisations also differ (Stinchcombe, 
1965).
So far the causes of variation have been discussed. How it occurs, is based on two 
dimensions: between the members and between the fitness Variation between the 
members in organisational strategies means that the characteristics formulating the 
strategy (such as plan, pattern, position, perspective, response, stakeholders and 
contribution to stakeholders, (see chapter 4)) must have different visible 
characteristics i.e. the characteristics that shape their operation must vary These 
characteristics do indeed vary within a population of organisations Different
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circumstances and different perceptions of the environment cause each strategic 
attribute of an organisation to be different. Pattern, for instance, is an attribute of 
organisational strategy that is unique to each organisation and hence to each strategy 
as it is determined by leadership, market, technological, or political forces and so on 
(Mintzberg, 1996).
The second dimension requires variation to happen across fitness. As will be 
discussed later in this chapter fitness is ‘ the condition where the configuration o f an 
organisational strategy matches that o f  the environment and the frequency o f  its 
characteristics appearing in future strategies is high'. Therefore, this dimension 
firstly requires the configuration of a drug discovery strategy to match that of the 
environment. The environment of a drug discovery strategy as described and justified 
in chapter 4, consists of the technology and knowledge o f  other organisations, the 
legislation and political situation that directly influences the drug discovery process, 
and the diseases that are targeted. Drug discovery strategies utilise an organisation’s 
resources and capabilities, which in turn enhance its sustained competitive advantage 
in therapeutic differentiation and global NCEs (New Chemical Entities: the novel 
chemical or biological compounds, excluding esters or salts unless they conferred a 
major therapeutic advantage Jones, (2001) p 241) (Yeoh and Roth, 1999). 
Therefore, drug discovery strategies that are more fit to the environment will be the 
ones that utilise an organisation’s resources and capabilities in a way that allows the 
organisation to develop a competitive advantage and be successful in an environment
Secondly, for variation to occur across the fitness of a drug discovery strategy, the 
frequency of its characteristics in future generations should be high This process of 
transferring characteristics through strategic configurations over time is addressed in 
more depth in the next section, heredity. That section identifies three correlated
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mechanisms by which the transfer of characteristics may occur, coercive 
isomorphism, mimetic processes, and normative isomorphism
In summary, variations in drug discovery strategies are caused by two factors genetic 
and environmental. The genetic factors are those whose origin is inside an
organisation, while environmental are those whose origin is external to the 
organisation. In addition, the resulting variation must exist both between the 
members and the fitness of drug discovery strategies
Therefore, the second hypothesis that underpins the third research question is:
Within a drug discovery population, there are strategies that differ to each other in 
terms o f  their characteristics and their fitness.
5.2.1.3. Heredity
Heredity is the third requirement for evolution to happen. It is the inheritance o f  
physical or mental characteristics from parents to offspring (Simpson and Weiner, 
1989). This requirement o f evolution asserts that offspring should resemble their 
parents. In biological systems inheritance is produced by the Mendelian process (for a 
comprehensive explanation of the Mendelian process, see Ridley (1996) pp 35-38, and 
Smith (1993) pp. 53-75) and it is now understood down to the molecular level (Stearns 
and Hoekstra, 2000).
Smith (1993) views heredity as a way of transmitting information. He also 
distinguishes between systems of limited and unlimited heredity. In systems of 
limited heredity only a few states can be transmitted Systems of unlimited heredity 
are capable o f transmitting an indefinitely large number of messages. This distinction 
is important because the amount of information transmitted from one generation to the 
next determines the speed o f selection Heredity is also the cause for adaptation The
136
effectiveness of the adaptation depends on how far the differences between 
individuals which are responsible for their success are inherited by their offspring 
(Smith, 1993).
In contrast to the previous two requirements, the transfer of characteristics to future 
strategic configurations has been examined by the strategic management literature 
Several mechanisms and theories have been developed to examine and control 
inheritance of strategic configurations (e g. Oliver (1988), DiMaggio and Powell 
(1983)).
In biology, the distinction between generations is clear, but with the evolution of 
drug discovery strategies it is not Identifying and understanding these distinctions is 
a key area of novelty for this research Drug discovery strategies within the same 
population may have shorter or longer life cycles depending on their success and the 
rate o f change of the environment they inhabit. In fact, a central problem of evolution 
in cultural and social systems is the tension between the creation of new variants 
versus the retention of previously selected variants. The process that best resembles 
biological heredity is the one that preserves, copies or imitates the strategic 
configurations or memes of one member in a population (McCarthy, 2002). This 
process is also known as retention (McCarthy, 2002, Campbell, 1969, Pfeifer, 1982, 
Aldrich, 1999) and as isomorphism (Hawley, 1968, DiMaggio and Powell, 1983, 
Oliver, 1988). Price and Shaw (1998) use the term meme to convey an unit of cultural 
transmission such as a tune, idea, catch-phrase, fashion, recipe, or design
Retention is said to occur when selected variations are retained, copied or imitated, 
so that the selected activities are repeated on future occasions or the selected 
structures appear again in future generations (Aldrich, 1999). Retention can occur at 
two levels, organisational and industrial. Organisational retention can occur through
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the industrialisation and documentation of successful strategies, and through existing 
personnel passing on knowledge about strategies to new personnel. Successful 
strategies that provide organisations with some advantage in the marketplace survive 
because the organisations survive (Price, 1995). Industrial level retention can take 
place through the spreading of new strategies from one organisation to another This 
can happen through personal contacts, or through observers, such as academics or 
consultants publishing successful new technologies or management skills.
DiMaggio and Powell, (1983), have identified three mechanisms through which 
heredity or isomorphic change occurs. They call these coercive isomorphism, 
mimetic isomorphism, and normative isomorphism
5.2.14. Coercive Isomorphism
Coercive isomorphism is the result of formal and informal pressures exerted to 
organisations. The sources o f these pressures are, other organisations they are 
dependent upon, and cultural expectations from the society within which they 
function (DiMaggio and Powell, 1983). The form of these pressures may be force, 
persuasion or an invitation to collude. Examples include the direct enforcement of a 
new legislation by a government and a scientific breakthrough
With drug discovery coercive isomorphism can be illustrated by the genetics and 
molecular biology revolution that began more than forty years ago with the discovery 
of the double helix structure of deoxyribonucleic acid (DNA) and continued with 
Cohen and Boyer’s techniques of genetic engineering (Henderson et al 1999). These 
new discoveries marked the beginning of the biotechnology industry, but lay outside 
the older and established pharmaceutical organisations (Bogner and Thomas, 1996 
p.l 18). Established pharmaceutical organisations could acquire this knowledge either
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through acquisition or internal learning The latter option involved steep and long 
learning curves to thoroughly understand this technology. Therefore, the common 
option followed by large organisations was acquisitions or alliances. Hence, pressure 
forced organisations to adapt alliances as a strategy to develop capabilities in the new 
era
Another example of coercive isomorphism in drug discovery is the response of an 
organisation to a new legislation. New legislation often changes the context within 
which organisations in the pharmaceutical industry must compete (DiMasi, 2000). 
For instance, the introduction of the Food, Drug and Cosmetic Act of 1938 by the US 
congress required the testing of new drugs for safety before being granted approval 
It also created a new category of drugs that could only be dispensed to a patient at the 
request of a physician (Pizzi, 2000). These radical changes forced pharmaceutical 
organisations to rethink and restructure the methods o f discovering new drugs
5.2.15. Mimetic processes
The second mechanism of isomorphic change is through mimetic (copying) 
processes Organisational strategies and processes are reproduced through imitation 
(Lloyd, 1990). Successful strategies are imitated while unsuccessful ones fall victims 
to the market Lloyd (1990) draws on evolution genetics and ethics, to argue that 
companies are genuine alien form, 'the first our species have encountered’ 
Successful organisations frequently set the standard for others to follow, and the 
characteristics that these organisations possess are responsible for their success. 
Imitation leads to the relative increase of these more successful characteristics and to 
the decline of others.
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Less successful organisations tend to face an uncertain future, due to a poor 
understanding of technology, unclear setting of goals, economic and political trends, 
competitive actions, changes in societal values, and corresponding shifts in consumer 
preferences (Amit and Schoemaker, 1998). This uncertainty is a powerful force that 
encourages imitation (DiMaggio and Powell, 1983), even though the imitated 
organisation may or may not be aware o f  the imitation or may have no desire to  be 
copied.
The methods employed to understand and copy the desirable characteristics include 
benchmarking exercises, consultancy reports and surveys, and acquisitions o f  key 
people from other organisations. Moreover, the wave of mergers and acquisitions that 
has dominated the pharmaceutical industry in the last decade could also eventuate to 
imitation This trend has been triggered by various factors including the desire to 
improve the effectiveness of the drug discovery by understanding the operations of 
the acquired or merged organisation, the acquisition of new knowledge developed in 
the acquired organisation, and the increase of profits through diversification
A necessary prerequisite for the successful imitation o f a strategy is the clear 
understanding of the link between an organisation’s resources and its sustained 
competitive advantage (Barney, 1991). When this link is not known then 
organisations that attempt to imitate will not know which resources to copy In the 
pharmaceutical industry the characteristics associated with the discovery of new drugs 
are highly complex and hence difficult to  replicate (Yeoh and Roth, 1999) Therefore, 
drug discovery serves as a competitive advantage.
The imitation of successful strategies however does not suggest that all organisations 
tend to be the same If this were the case then there would be no variation In fact the
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process of selecting and implementing the strategies by competing organisations 
results in variation of realised strategic positions (Deephouse, 1999).
5.2.1.6. Normative isomorphism
The final form o f isomorphic change is normative. The source o f this form is 
professionalisation Professionalisation is defined as the collective struggle o f  
members o f  art occupation to define the conditions and methods o f  their work, to 
control the production o f  producers and to establish a cognitive base and 
legitimisation fo r  their occupational autonomy (Larson (1977) and Collin (1979) in 
DiMaggio and Powell, (1983)).
Professionalisation has two aspects that provoke isomorphic change namely, formal 
education and professional networks. Formal education and training provides 
organisational members with an institutional understanding of the application of the 
characteristics o f the successful strategies Strategy is conceptualised as an 
organisation’s realised position in its competitive market (Porter, 1980). Although this 
understanding is only conceptual and the application depends on the individual and 
the involved organisation, it provides stakeholders with a common basis for strategy 
making. This basis consists of the best practices of the preceding generation of 
strategies. The most effective configuration of the strategic characteristics is 
institutionalised through an iterative isomorphic process (Scott, 1995) and passed on 
to the next generation as the best (if not the only) way of doing things. Professional 
networks extend across organisations. New strategic initiatives diffuse across these 
networks and redefine the norms of organisational behaviour.
Recruitment programs and the careful filtering of new personnel serve as a method 
for encouraging normative isomorphism Such programs ensure that those who do
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not strike a prospective employer as likely to fit in are not employed (Price and Shaw, 
1998). Those who are likely to fit in are those that comply with certain codes 
conventions and rules accepted by the organisation. This policy helps to increase the 
speed of diffusion of the ideas and strategies, which are inline with the existing 
paradigm.
To summarise, the characteristics that underpin organisational strategies are 
transferred between and within populations over time The three mechanisms of 
isomorphic change introduced by DiMaggio and Powell (1983) could provide a 
framework for understanding the transfer o f characteristics and the process of 
heredity. However, the lack of distinct generations of organisational strategies allows 
the use o f the word heredity only metaphorically Nevertheless, the above discussion 
has established that mechanisms for the sustainability or retention of the successful 
strategic characteristics do exist.
Therefore, the third hypothesis is:
Those characteristics o f  drug discovery strategies credited with successful drug 
discovery performance are likely to appear in future strategic configurations, while 
those characteristics that are not are likely to he absent.
5.2.17. Selection
The fourth requirement for evolution to occur is selection and is derived from the 
theory o f  Natural Selection as originally introduced by Charles Darwin (Darwin, 
1968). Natural selection can be defined as the differential reproduction of alternative 
hereditary variations. Differential reproduction is determined by the fact that some 
variations may increase the likelihood of survival and reproduction of some 
individuals Natural selection denotes that those individuals that are not suited to
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survive in certain environments do not survive (Hutchison, 1974, p i27). Selection 
may be due to variations in survival, in fertility, in rates of development, in mating 
success, or in any other aspect of the life cycle
Darwin maintained that competition or struggle for limited resources results in the 
survival o f the most effective competitors. In addition, competition can be either 
direct or indirect Direct competition means that individuals struggle with each other 
e g to defend territories. Indirect competition means that they are consuming the 
available resources first. Competition for survival creates the prerequirement for 
natural selection to operate (Stearns and Hoekstra, 2000).
Natural selection occurs not only as a result of competition, but also as a result of 
some aspect of the physical environment, such as inclement weather Moreover, 
natural selection occurs even if all the members of a population died at the same time 
Natural selection can be directional or stabilising depending on the effect it has on 
characteristics. When the environment favours a certain characteristic, which is 
inheritable, the number of individuals that possess this characteristic, will increase At 
the other end, the number o f those that do not will decrease. In this case natural 
selection is directional. Directional selection also explains adaptation of a population 
to the environment. Over generations a population adapts to the environment by 
increasing the frequency o f  those characteristics which are selected in. Stabilising 
selection occurs when the environment favours the average form of a population more 
than the extremes.
With natural selection, the criteria for survival is not consciously selected by the 
environment or the population. There is no long-term goal or mission statement, 
because nothing is involved that could conceive o f a goal There is only short-term 
relative reproductive success, producing both short and long term change.
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Characteristics increase or decrease in frequency because of their correlation with the 
reproductive success of the individuals that carry them (Stearns and Hoekstra, 2000). 
This in fact is the major difference between living organisms and organisational 
strategies Organisational strategies, which are formed and implemented by people, 
are consciously designed to have long-term objectives. Therefore, special care has to 
be made when drawing analogies o f biological selection in strategic management.
In organisational science, the entities that are selected are organisational routines 
(Aldrich, 1999). The process of variation creates new routines either blindly or 
intentionally. New organisational characteristics are selected according to how well 
they enable an organisation to  acquire resources in a competitive environment 
Selection is said to occur internally or externally (Aldrich, 1999). Internal selection 
criteria are set by promotion, incentive systems, imitation, internal diffusion, etc. or 
any activities that are controllable within organisations. These selections may or may 
not enhance an organisation's ability to survive. It is possible for new routines to be 
selected even though they do not conform to existing practices On the other hand, 
organisations may link promotion or incentive systems to out-dated criteria. This 
could promote the selection o f  old routines, as managers will be more prompt to use 
the old more established routines. Such measures could reduce the introduction and 
adoption of new routines. External selection criteria are set by market forces, 
competitive pressures, the logic of internal organisational structuring, and other factors 
usually beyond the control o f individual organisations Organisations with maladapted 
variations in technology, managerial incompetence, misunderstood customers' needs, 
etc are less likely to acquire competitive resources and are therefore more inclined to 
failure As a result, successful or surviving organisations will have comparable and 
similar characteristics, which are absent in failing organisations
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As with biological selection, organisations also compete (struggle) for resources that 
are limited This scarcity of resources fuels the selection process faced by an 
organisation. In new industries, the leading organisations have ample gain and enjoy 
fast growth. As a population in the industry grows, the resources become more 
limited, and as a result failure rates increase. This can cause a population to stagnate 
or decline.
As hypothesised in the previous sections, drug discovery strategies do exist in living 
populations, and differ to each other (the drug discovery strategies), whilst having the 
ability to transfer characteristics to future generations Thus, for selection to occur it 
is assumed that the environment favours the fittest strategies, while the rest will 
eventually cease to exist.
Henderson and Mitchell (1997) suggest that the formation and change of strategy 
follows a cyclic pattern where organisations develop organisational capabilities as 
they act in the competitive, institutional and cognitive environments Capabilities 
arise both by design and as the unexpected by-products o f  an organisation’s actions 
The capabilities, managers’ understanding of these capabilities, and the historical 
context that surrounds them, then condition an organisation’s responses to changes in 
their environment. The responses and organisation performance in turn affect the 
structure of the industry, and all the changes generate new information, which in turn 
creates new learning opportunities (Henderson and Mitchell, 1997). Therefore, those 
strategies that create capabilities that cause reactions that are not favoured by the 
environment will be selected out This does not necessarily signify the failure or 
death of an organisation that applies the failed strategy. Rather, an organisation may 
abandon the strategy in order to create new capabilities
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Carroll and Hannan (1989) also support the view o f a cyclical pattern (or concave 
pattern) on the number of organisations within a population. They also suggest three 
reasons for this phenomenon. Firstly, organisations exploit ephemeral resources, 
growing rapidly while the resource abounds and then declining as it fades. Secondly, 
newer populations with newer technologies emerge and social conditions change 
Finally, as the size of a population increases the number of competitive forces and the 
pressure for legitimation also increase.
However, abandoning a strategy and adapting a new one requires a degree of 
adaptation and flexibility by an organisation. Hannan and Freeman (1977) have 
argued that there are a number of limitations in the ability of organisations to adapt. 
They have called these limitations structural inertia. As discussed in chapter 4 the 
structural inertia depends on both internal and external considerations including, 
tangible assets of an organisation limited information in decision making (both 
internal and external), political constraints, established routines or norms, legal and 
fiscal barriers, and collective rationality.
To illustrate the application of selection forces on drug discovery strategies two 
examples of change in environmental conditions will be discussed The first one is 
the 1962 amendments to the federal food, drug, and cosmetic act of 1938 in the 
United States (Bogner and Thomas, 1996 p.91). This legislation changed the 
environment within which organisations in the pharmaceutical industry had to 
compete. Pre-market regulatory requirements increased as organisations had to 
demonstrate the efficacy of the new drugs before they were marketed. As a result the 
scope and expense of new drug development was substantially increased. Those 
organisations that were better equipped in terms o f  structure, financial capability, and 
organisation culture to adapt to the new environment had an advantage in the long run
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(DiMasi, 2000). Therefore, it may be argued that those strategic configurations that 
were favoured by the new environmental condition were sustained while the rest 
ceased to exist.
The second example comes from within the pharmaceutical industry. The revolution 
in genetics and molecular biology had an enormous impact on the nature of 
pharmaceutical R&D and on the organisational capabilities required to introduce new 
drugs (Henderson et al. 1999). The adoption of biotechnology required organisations 
to make a transition from blue sky to targeted and market led drug discovery. This 
transition required both the development of a large body o f  new knowledge and 
substantially new organisational capabilities in drug research. These capabilities 
included a reorganisation of the scientific workforce that was tightly connected to the 
larger scientific community and an organisational structure that supported a rich and 
rapid exchange of scientific knowledge across an organisation (Gambardella, 1995, 
Henderson and Cockburn, 1994). Those organisations that were fortunate enough to 
have adopted rational modes of drug discovery have been much more successful than 
those that initially achieved great success with more traditional random methods of 
drug discovery (Henderson, 1994).
In both of the above examples, the organisations that employed strategies favoured 
by the environment were sustained and served as a competitive advantage Other 
organisations had to change and adapt to the new conditions imposed by the 
environment. The characteristics that those strategies had acquired were not easily 
replicated and this gave them an advantage compared to the rest
To summarise, organisational strategies are being continually developed, used, and 
assessed. The characteristics of the successful strategies are being the subject of 
imitation, while eventually they become academically institutionalised
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Consequently, the characteristics that these strategies possess are passed on to the 
next generation (requirement of heredity) At the opposite end, the least successful 
strategies cease to exist either because they lead organisations to failure, or because 
they are abandoned by organisations. With both cases the environment does not 
favour least successful strategies and this forces them to extinction (selects them out). 
Therefore, their characteristics are not transferred to the next generation, which is 
consequently characterised by the characteristics of the successful strategies.
Following this line o f argument the fourth hypothesis is:
With a change in the environmental conditions those drug discovery strategies that 
remain are the ones whose strategic characteristics are favoured by the environment.
5.2.2. Process o f  evolution: a summary
Based on the above discussion, this section presents a diagram for understanding 
evolution and its key elements The diagram is shown in Figure 5-1
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The column on the left-hand side of the diagram is the population present at the first 
generation. It consists o f species whose main and common characteristic is their 
square shape. The shape varies in size across the population and like other 
characteristics such as colour is a potential source of variation between the members. 
The members of the population interbreed with each other and produce a second 
generation. As information about the shape is inherited from one generation to the 
next some errors occur (mutations). These errors result in the production of different 
shapes like stars, ellipses and circles At this point an assumption is made about 
which shape is favoured by the environment (i.e. the fittest). In this example and at 
the 2nd generation the fittest shape is assumed to be round.
Thus, the second generation again interbreed and generate new members, which tend 
to have a round shape, or a combination of the two shapes (square with rounded 
corners). Since the round shaped members are considered by the environment to be
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fittest, they are more likely to reproduce. Therefore, over several generations the 
dominant species of the population will be the ones with the rounded shape i.e. the 
rounded species will have been selected in.
5.3. Definition of Fitness
The fourth research question (What are the characteristics of the fittest drug 
discovery strategies?) revolves around the term “fittest”, which has already been 
mentioned several times in this chapter. To adequately address the fourth research 
question, it is necessary to define fitness in relation to drug discovery.
Dawkins (1982) identified five definitions of fitness, which are widely used in the 
biological literature. These are Darwin’s fitness, population geneticists’ fitness, 
ethologists and ecologists fitness, Hamilton’s (1964a, 1964b) inclusive fitness, and 
Hamilton’s (1964a) neighbour modulated fitness. As will be shown the last three 
definitions treat the subject o f interest as a form of agent trying to optimise something 
(Dawkins 1982). This section will introduce Dawkins’ five definitions and will 
conclude by providing an overview of the use of fitness in strategic management
The term fitness as used by Darwin and Spencer roughly meant the capacity to 
survive and reproduce, as they had not provided a precise technical meaning (Gould, 
1991). The term ‘fittest’ however referred to that individual that produces the largest 
number o f  offspring to survive to maturity and reproduce. Fitness in this context is 
known as Darwinian fitness (Allaby, 1999).
The population geneticists made an attempt to link fitness to the relative rate of 
change o f  the size of a population, but did not provide a definition of the term fitness 
(Fisher, 1930). For them fitness is a practical measurement that refers to the number 
of offspring that a typical individual is expected to bring up to  reproductive age, when
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all other variables remain unchanged or are averaged out. The focus of this 
measurement is in the changes in genotype frequencies and gene frequencies that 
occur in a population. For example, if two populations have different sets of genes 
and accordingly have a different relative rate of increase, the population which has the 
larger rate of increase also has greater fitness.
Ethology and ecology are two fields of biology that aim to study the reactions and 
relationships of a given organism to its environment. Organisms are viewed as 
integrated systems searching for an optimal solution in an open environment. Fitness, 
in this context, is seen as a property of the individual organism and is used as a 
measurement of how successful an individual is in reproducing offspring, or its 
success in passing its genes on to the future generations (Dawkins, 1982). A practical 
measurement of this type of fitness is the number of its offspring reared to adulthood 
as a means of showing the parental care of the organism.
The fourth definition of fitness identified by Dawkins (1982) is the inclusive, as 
proposed by Hamilton (1964a, 1964b) in an attempt to explain the evolution of 
altruism According to Hamilton, close relatives like siblings, parents, and children 
will have at least 50% of their genes in common. As a result, any sacrifice that could 
double the genetic benefit of a relative will have an indirect net productive benefit to 
the genes via the relative’s offspring Inclusive fitness can be defined as the sum o f  
individual reproductive success and the reproductive success o f  an individual's 
relatives, with each relative devalued in proportion as it is more distantly related. In 
other words, inclusive fitness is said to be the sum o f the individual’s own fitness plus 
half the fitnesses of each brother plus one-eighth o f the fitness of each cousin, etc 
Inclusive fitness is said to be maximised by the behaviours of the organism over a
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lifetime in such a way as to leave as many copies of its genes, or alleles to the coming 
generations as possible.
The fifth fitness definition identified by Dawkins (1982) as proposed by Hamilton 
(1964a p. 2-5) is known as the neighbour modulated fitness and refers to the expected 
number of direct offspring produced by an individual. The difference between 
inclusive fitness and neighbour modulated fitness is that the former tends to 
concentrate on the effects the individual has on the fitness of his relatives, whereas the 
latter tends to emphasise the effects that relatives have on the individual’s fitness For 
this reason, this type of fitness is also known as personal fitness (Orlove, 1975). Yet, 
when used carefully and subjected to certain assumptions, both inclusive fitness and 
neighbour-modulatedfitness arrive at the same conclusion (Hamilton 1964b)
In another categorisation of fitness definitions, Endler (1986) proposed five contexts 
in which the term fitness may be applied: Darwinian fitness, rate coefficient, 
adaptedness, adaptability and durability (Table 5-2).
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T a b ic  5-2 E n d lc r ’s (1986) c o n te x ts  o f  f itn e ss
Term Definition and measurement Remarks
Fitness The degree to which there are different 
rates of survival and reproduction 
amongst the individual organisms of a 
population. This is measured by the 
average contribution to the breeding 
population by a phenotype, or of a class 
of phenotypes, relative to the 
contributions of other phenotypes.
Also known as 
Darwinian fitness, 
relative fitness, and 
selective value. 
Selection coefficient 
and selection 
differential are 
algebraically related to 
fitness.
Rate coefficient The rate at which the process of natural 
selection proceeds. Measured by the 
average contribution to the gene pool of 
the following generation, by the carriers 
of a genotype, or by a class of 
genotypes, relative to the contributions 
of other genotypes.
Similar to the fitness 
defined above, but also 
includes the genetic 
response.
Adaptedness The degree to which an organism is able 
to live and reproduce in a given set of 
environments; the state of being adapted. 
Measured by the average absolute 
contribution to the breeding population 
by a phenotype or a class of phenotypes
Also known as absolute 
fitness. Is also applied 
to species, where it is 
known as the 
Malthusian parameter.
Adaptability The degree to which an organism or 
species can remain or become adapted to 
a wide range of environments by 
physiological or genetic means
The reverse of 
specialisation.
Durability Probability that a carrier of an allele or 
genotype, a class of genotypes, or a 
species will leave descendants after a 
given long period of time.
Best expressed for 
alleles, genotypes, or 
species by the expected 
time to extinction.
Adopted from Endlcr (1986). p. 40
From the above discussion of fitness, an organism's survivability and reaction 
through adaptability and durability to the changing environment are made clear 
Fitness is therefore defined as a measure of prediction of the composition of a 
population in terms o f  frequencies o f the characteristics in the long term. Such 
predictions aim at identifying the species that will prevail, or whether many species 
will remain present, on the basis o f the reproductive parameters that could be 
observed as associated with that type.
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5.3. 1. Fitness in organisational strategy
The concept of fit in strategic management has its roots in contingency perspectives 
found in both organisation theory and strategy literatures (Ginsberg and Venkatraman, 
1985). The main premise of these literatures is that o f matching and aligning 
organisational resources with environmental opportunities and threats (Andrews, 
1971, Chandler, 1962). In organisation theory the notion of fit is associated with the 
environment-structure relationship (Donaldson, 1995, Thompson, 1967, Forte et al., 
2000). Organisational forms or structures that match the environmental contingencies 
demonstrate superior performance (Forte et al, 2000). In the strategy literature the 
concept o f matching and alignment is not as clear The response of an organisation to 
changing environmental conditions does not necessarily imply a change in 
organisational strategy (Zajac et al., 2000). However, it should be noted that the use 
of the term fitness in the organisational literature (matching and aligning with the 
environment) differs considerably to the biological use (forecasting frequency of 
genes in the future).
Venkatraman (1989) identified six distinct perspectives of fit in strategic 
management These are, fit as moderation, fit as mediation, fit as matching, fit as 
gestalts, fit as profile deviation, and fit as covariation. These perspectives vary along 
two spectrums as shown in Figure 5-2. The first is the degree o f specificity of the 
theoretical relationships i.e. how precise the functional form of fit is The second is 
number of criteria used to specify the concept of fitness.
154
LOW MANYFit as profile deviation 
(V)
Fit as gestalts 
(IV)
Fit as moderation 
(I)
Fit as mediation
(ID
Fit as covariation
Fit as matching
on)
(VI)
CJ
-Q
O 3
i_ CT
0) <u
HIGH FEW
Criterion-specific Criterion-free
Choice of anchoring the specification 
of fit-based relationships
Figure 5-2 A classificatory framework for mapping the six perspectives of fit in strategy 
research, from Vcnkatraman (1989) p. 425
Fit as moderation. According to the moderation perspective, the impact that strategy 
has on a criterion variable is dependent on the level o f the environment or moderator. 
The fit between strategy and environment is the primary determinant o f the criterion 
variable.
Fit as mediation The mediation perspective specifies the existence of a significant 
intervening mechanism (eg. organisational structure) between strategy and 
performance
Fit as matching According to this perspective, a measure of fit between two 
variables is developed independent of any performance anchor.
Fit as gestalts When many variables are used to conceptualise and specify fitness, 
the degree of precision must be relaxed One such multivariate perspective is the 
identification of gestalts, which is defined in terms of the degree of internal coherence 
among a set o f theoretical characteristics.
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Fit as profile deviation In this perspective fit is the degree of adherence to an 
externally specified profile. This perspective allows a researcher to specify an ideal 
profile and to demonstrate that adherence to such a profile has systematic implications 
for effectiveness.
Fit as covariation. According to this perspective, fit is a pattern of covariation or 
internal consistency among a set o f underlying theoretically related variables.
5.3.2. Fitness: Concluding Remarks
Biological fitness is a measure that is used to quantify selection Therefore, in a 
biological sense, fitness is the relative probability that a heredity characteristic will be 
reproduced. Strategic organisational fitness on the other hand focuses on the match of 
an organisation’s characteristics with the surrounding environment. The view of this 
thesis is that fitness for organisational strategy may be seen as a combination of the 
two concepts.
With organisations there are mechanisms to achieve intraorganisational transfer of 
strategic characteristics e g isomorphism (DiMaggio and Powell, 1983). The genes 
or characteristics of successful organisational strategies are more likely to be 
transferred to later generations with these mechanisms. Successful strategies are 
those that create configurations that match the environment Therefore, the frequency 
of the genes o f the successful strategies into the future will be higher
With this background, the definition given to strategic fitness within the context of 
this thesis is the following:
The condition where the configuration o f an organisational strategy matches that o f  
the environment and the frequency o f its characteristics appearing in future strategies 
is potentially high.
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5.4. Conclusions
This chapter had two aims. The first was to provide an understanding on the 
meaning of evolution, which is important because the third research question 
presented in chapter 1 requires the examination of how an evolutionary approach can 
be used to study drug discovery strategies. To meet this aim the chapter undertook a 
literature review and identified four requirements that systems (biological and non- 
biological) should meet for evolution to explain their change These are existence in 
populations, variation, heredity and selection. The chapter also developed the 
theoretical background to convert the four requirements into four hypotheses for the 
evolution of drug discovery strategies as shown in Table 5-3.
Table 5-3 Hypotheses
Requirement Hypothesis
Existence in 
populations
There are similar drug discovery strategies employed by different 
pharmaceutical organisations to form populations whose (the 
population’s) size follows a concave pattern o f  growth and decline.
Variation Within a drug discovery population, there are strategies that differ to 
each other in terms o f their characteristics and their fitness.
Heredity Those characteristics o f drug discovery strategies credited with 
successful drug discovery performance are likely to appear in future 
strategic configurations, while those characteristics that are not are 
likely to be absent
Selection With a change in the environmental conditions those drug discovery 
strategies that remain are the ones whose strategic characteristics are 
favoured by the environment
If validated, the four hypotheses could define and map the evolution of different 
drug discovery strategies, which is the aim of this thesis To do this however, it is 
important to collect data that will provide insights about the change of drug discovery 
strategies Furthermore, it is important to arrange this data in a manner that will allow 
the comparison of the drug discovery strategies, their populations, and their
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characteristics. As it will be explained in chapter 6 such an arrangement may be 
provided by the classification methodology cladistics.
The second aim of this chapter was to develop a working definition of the term 
fitness because, as explained earlier in this chapter, to address the fourth research 
question presented in chapter 1 it is important to understand and define the term 
fitness within the scope of this research. To meet this aim the chapter reviewed the 
literature on biological and strategic fitness and created the following definition:
The condition where the configuration o f an organisational strategy matches that o f  
the environment and the frequency o f  its characteristics appearing in fu ture strategies 
is potentially high.
Given this definition chapter 8 will identify those characteristics that define a fit drug 
discovery strategy
158
6. U S IN G  C L A D IS T IC  C L A S SIF IC A T IO N S  T O  E X A M IN E
ST R A T E G IC  C H A N G E
6.1. Introduction
Chapter 5 identified four requirements for evolution and created four hypotheses that 
will be used to address the third research question. To validate these hypotheses it is 
necessary to select or create a rigorous framework that permits the collection and 
analysis o f  data about drug discovery strategies in a concise and consistent manner 
This chapter argues that such a framework may be provided by a classification, and in 
particular an evolutionary classification methodology called cladistics. This chapter 
introduces in detail and justifies the cladistic classification methodology This 
methodology is used in chapter 7 to present a classification of drug discovery strategy 
types (population cladogram) and in chapter 8 to construct a classification of drug 
discovery strategies of individual organisations (organisation cladogram)
Therefore, the objectives o f this chapter are to:
• Examine and justify the use of classifications
• Examine and justify the use of the cladistic classification methodology
• Explain the methodology for constructing cladistic classifications
6.2. Evolution and Classification
A basic problem when applying evolutionary theory to organisational science is 
understanding the fundamental differences between organisational strategies 
(Romanelli, 1991). Therefore, a formal (McKelvey, 1982) or informal (Hannan and 
Freeman, 1989) theory that explains these differences is required Differentiating
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between the similar and dissimilar has motivated and helped the quest for knowledge 
across all academic disciplines (McCarthy and Ridgway, 2000). Using a theory of 
differences and similarities could help identify the nature and degree of organisational 
differences that arise over time. Such a theory could be provided by taxonomy, i.e. 
the development of theories and methodologies for classifying entities (McKelvey, 
1982), and is central to this thesis, which seeks to define and map the evolution of 
different drug discovery strategies. It could therefore provide the framework for 
identifying populations o f strategies (1st hypothesis developed in chapter 5), studying 
variation (2nd hypothesis), and for understanding the processes of heredity and 
selection (3rd and 4lh hypothesis respectively).
The development of classifications, i.e. the action of arranging entities into formally 
recognised groups, is a common process that helps people to order and store both 
tangible and intangible entities In addition, classifications provide a system for 
storing and communicating knowledge Carper and Snizek (1980) argue that the most 
important and basic step in conducting any form  o f  scientific inquiry involves the 
ordering, classification, or other grouping o f  object or phenomena under 
investigation (p 65). In a similar view, Ulrich and McKelvey (1990) argue that all 
successful sciences are supported by a general classification that allows scientific 
development. Organisational strategies and management systems are best understood 
in terms o f overall patterns, rather than in terms of analyses of narrowly drawn sets of 
organisational properties (Rich, 1992).
The creation of classifications could place organisations into homogeneous 
populations. Identifying such populations is central to this thesis as it is related to the 
first hypothesis developed in chapter 5 (There are similar drug discovery strategies 
employed by different pharmaceutical organisations to form  populations whose (the
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population's) size follows a concave pattern o f  growth and decline). Furthermore, 
these populations could allow the generalisation of findings in a narrow population to 
a broader population. In other words, scientific findings from one population can be 
generalised to all the members o f  that population (McKelvey, 1975 and 1982, Haas, et 
al, 1966, Sanchez, 1993, Rich, 1992).
The process of developing a classification allows examination of the variation 
between entities within a population. The collection of data needed for the 
development of a classification could allow conclusions to be drawn about the nature 
and the sources of variation. This issue is the essence of the second hypothesis 
presented in chapter 5 (Within a drug discovery population, there are strategies that 
differ to each other in terms o f  their characteristics and their fitness).
The third hypothesis developed in the previous chapter is related to heredity (Those 
characteristics o f drug discovery strategies credited with successful drug discovery 
performance are likely to appear in future strategic configurations, while those 
characteristics that are not are likely to be absent). A classification that is 
transparent and includes data about the historical development of drug discovery 
strategies should allow the development of conclusions that could support or reject 
this hypothesis. For instance, such a classification could allow the comparison of 
mature configurations with those of more modern drug discovery strategies. If this 
comparison leads to the identification of patterns o f evolution then there should be 
evidence to support this hypothesis.
The final hypothesis developed in chapter 5 is related to selection (With a change in 
the environmental conditions those drug discovery strategies that remain are the ones 
whose strategic characteristics are favoured by the environment). Similar to the third 
hypothesis, a classification that allows a diachronic comparison o f  drug discovery
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strategies could provide evidence to support or reject this hypothesis. For instance, if 
only a small number of drug discovery strategies have survived a major historical 
development, such as the world wars, it could be argued that the characteristics of 
these strategies are favoured by the new environmental conditions.
Classification has always been an important issue, especially for biologists and thus, 
most of the formal taxonomical tools have been developed within this science. 
Consequently, organisational and management scientists (McKelvey, 1982, Goronzy, 
1969, McCarthy et al., 1997, McCarthy, 1995, McCarthy and Ridgway 2000, Leseure, 
1998, and Tsinopoulos and McCarthy, 2000) have borrowed taxonomical tools from 
biology to build classifications The application of biological taxonomic tools to 
organisational science could be regarded as useful since biological scientists have 
spent many years developing taxonomic theories and accompanying tools to create 
rigorous and robust classifications. The following section reviews some o f the 
theories of classification.
6.2.1. Theories o f  classification
Theories o f classification can be categorised into two broad types, special 
classifications and general classifications Special classifications are created to 
formulate knowledge about a given problem and therefore are narrower in scope 
whereas general classifications are created based on the assumption of the natural 
order of things and offer a broader scope (Leseure, 1998).
Mayr (1969), while reviewing the history of systematics in zoology, identifies five 
theories of classification. These are: essentialism, nominalism, empiricism, 
evolutionism and cladism Based on Mayr’s theories, McKelvey (1982) presented the 
following groups of theories: essentialism and typologies, nominalism; empiricism.
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numerical phenetics and numerical taxonomy; and phyletics, evolutionism and 
cladism. The two first theories are categorised as special classifications and the 
second two are classified as general classifications (Leseure, 1998) These reviews 
cover the spectrum of available classification theories and thus, the review in next 
section will be based on them (i.e. McKelvey 1982 and Mayr 1969). The analysis that 
is presented helps to identify which is an appropriate taxonomic tool for processing 
and presenting data (i.e. creating a classification of drug discovery strategies) to 
validate the four hypotheses developed in chapter 5.
6.2.2. Essenlialism and Typologies
Essentialism finds its origins in Aristotle and Plato’s thinking It is based on the 
philosophical foundation that two objects are classified in the same group if they 
share the same essence. Essence is defined as the reality that dictates observed 
properties Hull (1974) identified three things that can be known about an entity: its 
essence, its definition and its name Thus, the foundation is that the name describes 
the essence and the definition describes the entity. Essence, in the biological world, is 
defined as “a  hidden reality which can he defined, and (as a consequence) this reality 
dictates the organism's observed properties" (McCarthy, 1995; pg 6). The resulting 
classifications o f  this approach are called typologies (Leseure, 1998).
Typologies have been dismissed from the biological world because they 
oversimplify reality. Living organisms are compounded by many different 
characteristics and therefore an essentialist approach does not help to create useful 
groupings
As shown in chapter 4, the area of strategic management has created many 
typologies (e g Mintzberg and Waters, 1998, Whittington, 1993, Miller, 1991), but a
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common drawback is that just a few characteristics are selected as the classification 
variables. As a consequence, strategies (like biological organisms) are considered to 
be composed of many characteristics rather than just a few and therefore, more 
characteristics should be taken into consideration to make the classification robust. 
Leseure (1998) extends the criticism of this approach by arguing that two typologies 
cannot be merged because of the essences of each typology, thus replication of results 
are rarely achieved.
On the other hand, typologies offer some advantages. According to McKelvey 
(1982), the strength of this approach lies in the fact that everything is classified into 
“a or non-a or b or non-b, and so forth” (pg. 40), generating thus, mutually exclusive 
groups that create specificity.
6.2.3. Nominalism
Three basic arguments underline the philosophical approach o f nominalism These 
are: (1) only individual objects exist; (2) living and inanimate objects can be classified 
together and, (3) human minds are the generators of the groupings. Because the 
groups are created by human minds, nominalists do not recognise natural groupings. 
In biology, natural grouping is a principle that is accepted and therefore, nominalism 
was never seriously considered (McKelvey, 1982).
In organisational science, there have been no attempts to use nominalism to classify 
organisations. Moreover, McKelvey (1982) suggests that nominalism should be 
avoided because natural groupings o f organisations exist (i.e. restaurants; schools or 
car assemblers) and thus nominalism is an inappropriate classification philosophy
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6.2.4. Numerical Taxonomy and Phene lies
Phenetic classifications are created by collecting large amounts o f  data that are 
related to characteristics that typify the entities under study. Once data has been 
collected, it is processed and presented using numerical taxonomy methodologies 
such as cluster analysis (Kauffman and Rousseeuw, 1990). Cluster analysis aims to 
group a sample of elements in such way that the statistical variance among elements 
grouped together is minimised while variance between groups is maximised 
(Hartigan, 1975). The main advantage, of this approach, is that large numbers of 
characteristics are used to study the entities and thus, the classification is considered 
to be more robust. Also, researchers in this field claim that subjectivity is avoided 
since the collection of data is led by an influencing theory or pre-notion
The main criticism to this approach concerns the relevance of the characteristics 
selected for the classification. Since large numbers of characteristics are used, there is 
the potential to include characteristics that do not help to understand differences.
Cluster analysis has also been used in studies of strategic management in an effort to 
identify groups of similar organisations (Ketchen and Shook, 1996). There are 
however three concerns about its effectiveness. Firstly, in contrast to the use of 
cluster analysis in biology there is extensive reliance on researcher judgment As 
argued by Ketchen and Shook (1996), cluster analysis lacks a test statistic that would 
validate a set of results for a hypothesis of interest, and thus relies on a researcher’s 
judgment for the interpretation of the results. Secondly, as noted by Thomas and 
Venkatraman (1988), the clusters identified through empirical analysis may not be a 
significant research result unless they can be related to the expected grouping 
structure through extant theory. In other words, most applications of cluster analysis 
lack an underlying theoretical rationale Finally, as argued by Barney and Hoskisson
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(1990), cluster analysis guarantees the identification of clusters and thus, it cannot be 
used to test the existence of such clusters i.e there is a tautology.
6.2.5. Cladistics
Cladistics is a form of evolutionary taxonomy that seeks to determine phylogenetic 
relationships between entities, but also considers a degree of subsequent divergence, 
and presence of similar phenotypic characteristics (the observable physical 
characteristics of an organism) to create classifications The core concept o f cladism 
or phylogenetic systematics is the use of derived characteristics (apomorphies) to 
construct common ancestry relationships. Through the creation o f  these relationships 
groups or classes are generated (Wiley et al., 1991). In other words, entities are 
classified according to characteristics they share with other entities, using the relation 
with common ancestors as the basis for the creation of the groups
Henning first introduced the concept of phylogenetic systematics in his book 
“Phylogenetic Systematics" (Henning, 1966). The methodology he proposed is now 
called cladistics and the evolutionary diagrams that this methodology produces are 
called cladograms. This methodology was first developed by linguists to classify the 
evolution o f languages and it was later adopted in biological science. Nowadays, 
cladistics has emerged as a powerful analytical tool in comparative biology 
(McCarthy and Ridgway, 2000), that provides more information than any other set of 
biological observations and the results are displayed in a consistent test table and a 
reproducible framework.
For some researchers, cladistics is considered to be superior to other schools of 
classification (Ridley, 1996, Wiley et al., 1991 and Lipscomb, 1998). However, much 
debate accompanies the decision to use any classification methodology
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One of the most important advantages of cladism is that unlike other classification 
approaches, such as cluster analysis previously discussed, it does not rely on intuition 
to construct the classifications. This helps to avoid subjectivity when choosing the 
relevant characteristics for the classifications. Cladistics focuses on the phylogenetic 
or genealogical hierarchy, which exists independently of the methods used to discover 
it and is therefore relatively unique and unambiguous in form (Ridley, 1996). Hence, 
the main advantage of cladistics is the relative objectivity achieved through the 
empirical methodologies employed to reconstruct phylogenies (genealogical tables 
showing the racial evolution of a type of organisations).
There have been attempts to construct organisational classifications using cladistics 
(e g. Leseure, 1998 and McCarthy et al., 1997, Lord and Price, 2001), and the 
advantages claimed in these cases, indicate that cladistics is both appropriate and 
valuable as a methodology for creating classifications o f  drug discovery strategies to 
validate the four hypotheses presented in chapter 5. The following sections explain in 
detail the methodology used for constructing cladograms and how the resulting 
classification will be used in this thesis
6.2.6. The cladogram Explained
A cladistic classification is depicted using a tree like diagram, which is called a 
cladogram There are several possible ways of drawing a cladogram (each is 
topologically the same), the most popular o f which are shown in Figure 6-1 (trees 
with diagonal branches or trees with square branches (Maddison and Maddison, 
1992)). In Figure 6-1 the two cladograms represent exactly the same classification A 
cladogram consists of taxa (a group of individuals that is given a name (Wiley et al., 
1991)), branches (a line connecting a branch point to a terminal taxon),
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characteristics, (a feature or characteristic of an individual) and nodes (points where 
branches meet and represent speciation events i.e. the event during which a species 
splits into two (Ridley, 1996, p. 16) as shown in Figure 6-1.
Considering three taxa B and C are more closely related to each other than either is 
to taxa A. This is because B and C share a common ancestor ‘x’ (which lived at time 
t2) that is not shared with A or any other taxon. The group that consists of the taxa B 
and C is called the ingroup and refers to the group studied by the investigator (Wiley 
et al 1991, p. 4). Similarly taxon A is more closely related to the group B + C 
because A, B and C together share a unique common ancestor ‘y’ which lived at an 
earlier time (ti). The group B and C are called sister groups, while the A is the sister 
group of the combined group A+B+C. The aim o f cladistics is to establish sister 
group relationships and the concept of two taxa being more closely related to each 
other than either is to a third is fundamental to cladistics (Kitching et al., 1998) In 
Figure 6-1 taxon D is also called the outgroup and refers to any group used in an 
analysis, but not included in the taxon under study (Wiley et al., 1991, p 5). As will 
be explained later in this chapter, the outgroup is used for comparative purposes
Determining which type o f cladogram layout to use depends solely on practical 
issues, such as ease of drawing and visual interpretation. The layout adopted by this 
thesis is the tree with a square branching structure (shown on the right of Figure 6-1) 
because it is the easiest to draw using the cladistic software available (MacClade).
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Outgroup - The ancestral configuration used to help resolve the polanty of characters
Ingroup - A set of configurations considered to be more closely related to each other than any are to the outgroup 
Branch - A line connecting a branch point (node) to a terminal point 
Node - A branch point on a cladogram representing a spéciation event
Figure 6-1 Example of tree with diagonal branches and tree w ith square branches
6.2.7. Methodology fo r  constructing cladograms
Kitching el al (1998) suggest that cladistic analysis consists of three processes 
“inextricably interlinked” (pp 19): the identification of characteristics and entities; 
the characteristic coding; and the determination of the optimal cladograms (i.e. the 
cladogram that best explains the relation between characteristics and entities) 
Similarly, Lipscomb (1998) suggests a five-step methodology for constructing a 
cladogram The steps proposed are (i) selection of taxa, (ii) selection of 
characteristics, (iii) analysis of characteristics to reconstruct the relationship among 
the taxa, (iv) translation of the tree into a formal classification system, and (v) use of 
the tree to test various hypotheses about evolution in the group
McCarthy et al. (1997) and Leseure (1998) proposed a set of seven steps for 
constructing cladograms for the classification of manufacturing systems However, 
these steps do not coincide exactly (Fernandez, 2002) as shown in Figure 6-2.
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Figure 6-2 Methodologies for building cladograms
Fernandez (2002) in a study that explored the mass customisation strategies of 
electronics manufacturers proposed an alternative and hybrid methodology based on 
Lipscomb (1998), McCarthy et al (1997) and Leseure (1998) This methodology was 
used successfully to classify individual organisations (Fernandez, 2002). As will be 
explained later in this chapter, to meet the aims o f this research, it is proposed to 
construct a cladistic classification of drug discovery strategies o f pharmaceutical 
organisations Therefore, the methodology that will be used is the hybrid 
methodology developed by Fernandez (2002) as shown in Figure 6-3. This section
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introduces this methodology while it shifts the focus from manufacturing 
organisations to organisational strategies
Figure 6-3 Process of constructing cladograms
6.2.7.1. Step 1: Select a Clade
Wiley et al (1991) define a dade  as a monophylelic group, which is a group of 
entities discovered to be descendants of the same common ancestor Defining the 
clade establishes boundaries of the group that will be analysed and in a certain way, 
this step could be considered as a pre-classification since the selection is based on an 
a priori definition of the area of interest
6.2.7 2. Step 2: Collect data
When a clade (the monophyletic group) is selected the entities under study and the 
relationships between them are not known This step involves the collection of data 
that consists of the identification of the entities and the selection of the characteristics 
that will establish the relationships between them
When the entities under study have been identified it is recognised that they all share 
a common ancestor. This condition is known as a polylomy and is shown in Figure 
6-4. The aim of the cladistic classification is to transform the polytomy (Figure 
6-4(a)) into a phylogenetic model (Figure 6-4 (b)) i.e. to establish the ancestral 
relationships between entities. To achieve this, the characteristics o f each entity have 
to be explored.
(b) Phylogeny
Figure 6-4 Phylogeny and Polytomy
A characteristic is defined as an observable feature or characteristic o f an individual 
(Lipscomb, 1998 and Wiley et a l , 1991). Characteristics may be listed in the form of 
their presence or absence, as binary variables expressing different characteristic states 
or as multistate characteristics. The final result of a cladistic analysis depends on the
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selection of these characteristics. Therefore, the process by which characteristics are 
selected is one of the main concerns in cladistics.
Fernandez (2002) has suggested three features that any data has to embody to qualify 
as characteristics for cladistic analyses (Table 6-1).
Table 6-1 Characteristic features for cladistic analyses
Feature Explanation
D is c re te L o g ic a l  re p re s e n ta tio n  o f  th e  c h a ra c te r is t ic  w ith  in teg e r  
n u m b e r s
Q u a l i ta t iv e C h a ra c te r is t ic s  th a t  d o  n o t n eed  m a th e m a tic a l  e x p re ss io n s  o r  
q u a n t if ia b le  fe a tu re s  to  b e  e x p re s s e d
P r e s e n t  la rg e  
c h a r a c te r i s t ic  s ta te  
c h a n g e s
C h a ra c te r is t ic s  w h ic h  re p re se n t la rg e  c le a r  c u t  c h a n g e s  fro m  
o n e  s ta te  to  a n o th e r  s ta te .
In spite of these generic recommendations, selecting characteristics is a difficult and 
sometimes subjective task, since a good cladistic characteristic is a value judgement 
In addition to these recommendations, Leseure (1998) proposes a procedure to aid the 
process of selecting characteristics. This procedure is depicted in Figure 6-5 and it 
consists of the four following steps:
•  Identification of the characteristics that can potentially explain the 
differences and similarities between the species in the selected clade,
•  An informal search for characteristics i.e the collection o f data front sources 
like books and articles or the expert opinions,
• Decide whether the selected characteristics are analogies or homologies i.e 
decide whether these characteristics are shared between species, but were not 
present in their common ancestor (an analogy) or are shared between species
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that were also present in their common ancestor (an homology) (Ridley, 
1996), and
• Provide the final list o f characteristics relevant for the study.
M o d a l
Pro to typa
C ha racte r
search
C haracta r 
se le c tio n
Figure 6-5 Process for Selecting Characteristics (adapted from Lcscurc, 1998)
In addition to the methodology for selecting characteristics, Leseure (1998) 
suggested three guidelines for determining the required number of characteristics for a 
cladistic analysis. Although the number of characteristics selected does not play a 
crucial role in cladistic analysis, it is important to be aware of these guidelines:
• The number should not be less than the number of branches
• There should be at least three characteristics per branch to gain more 
confidence
• No theoretical maximum
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As McCarthy et al. (1997) stated, "characteristic selection is not a process o f  
choosing available characteristics from a reference list, it is a process o f  discovering 
which characteristics are responsible fo r  evolutionary change, the role o f  individual 
characteristics in the change” (pp. 278) The methodology and the recommendations 
described above should, however, make the work of the taxonomist more 
unambiguous.
6.2.7 3. Step 3: Setting Polarity
Once characteristics have been selected and their states defined, the next step in a 
cladistic analysis is to identify which characteristic states are derived (i.e apomorphic 
states) and which are ancestral (i.e. plesiomorphic). That is to say, to detect what is 
the direction of change o f  the characteristics’ states. The process of identifying the 
direction of a characteristic state change is called polarisation. Thus, a characteristic 
is considered polarised when its plesiomorphic state has been distinguished from its 
apomorphic state Polarisation consists o f determining the primitive and derived 
characteristics by comparing different groups.
To simplify the process of polarising the characteristics a hypothetical ancestor is 
attached to the tree, which is called, outgroup The outgroup is added to the 
cladogram as a new entity or taxon whose characteristic states are all zero (Kitching at 
al., 1998) The addition o f  the outgroup simplifies the polarisation process because it 
provides a taxon which is designed to be the ancestral Therefore, any comparisons 
between characteristics are made with the outgroup as the common reference
There are several methods for polarising characteristics. These can be classified 
according to the source of the data required for the study, into direct and indirect 
methods (Nelson, 1973). The direct methods are those that require data only from
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inside the taxa under study and the ontogenetic criterion holds as the principal direct 
method (Kitching et a l , 1998) Indirect methods are those that require data from a 
source external to the study and the outgroup comparison is the principal indirect 
method (Nelson, 1973).
6.2.7.3.1 The ontogenetic criterion
Ontogeny is defined as the development of an individual from its fertilisation to its 
adulthood. Nelson (1978) defines the ontogenetic criterion for determining polarity as 
follows: “Given an ontogenetic characteristic transformation, from  a  characteristic 
observed to be more general to a characteristic observed to be less general, the more 
general characteristic is primitive and the less general characteristic advanced' (pp 
327).
This approach is not generally accepted in the discipline of biology (Alberch, 1985; 
Kluge and, Farris, 1969, Kluge, 1985 and De Queiroz 1985) because of its over­
simplicity. Therefore, alternative methods have been recommended the most popular 
of which being the outgroup comarison.
6.2.7.3.2.The Outgroup Comparison
The outgroup criterion states that “For a given characteristic with two or more states 
within a group, the state occurring in related groups is assumed to be the 
plesiomorphic state” (Watrous and Wheeler, 1981, pp. 5) In other words, the 
outgroup criterion states that if one characteristic is found in both the ingroup and the 
outgroup, this characteristic is then postulated to be the ancestral state (plesiomorphic) 
(Fernandez, 2002).
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6.2.7.4. Step 4: Characteristic Coding
Once the characteristics, their states and their polarity have been defined, the next 
step involves their conversion into numerical or alphabetical symbols. These symbols 
are called the characteristic codes. The characteristic codes are inserted into a matrix, 
which also includes the classifying entities and the characteristics These matrices are 
used by the following step to construct the cladogram.
Various ways exist for carrying out this conversion However, detailed examination 
of these methods is not within the scope o f  this thesis and a description only o f the 
more widely used one is provided.
The method used in this thesis uses a binary approach to code the different states of 
the selected characteristics. The code ‘0’ represents the absence o f the characteristic, 
while ‘1’ represents its presence or otherwise plesiomorphic characteristic state is 
coded ‘0’ and the apomorphic characteristic state is coded ‘1’.
6.2.7.5. Step 5: Construct the Cladogram
Once the characteristics have been selected, polarised and coded, the next stage in 
the cladistic analysis process is to construct phylogenetic trees (i.e cladograms). 
There are several techniques for constructing cladograms including Wagner 
optimisation, Fitch optimisation, Dollo optimisation, and Camin-Sokal optimisation 
(Kitching et al. 1998). The differences between these techniques lie in the criteria 
imposed to find the optimum cladogram. For instance, the Wagner optimisation 
imposes minimal constraints upon permitted characteristic state changes, while it 
allows free reversibility of state changes i.e. from 0 to 1 and from 1 to 0. When the 
sets o f characteristic data are small and simple, a cladogram can be constructed 
manually using one of the methods mentioned However, when sets o f characteristic
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data are more complex, it is almost impossible to construct a cladogram manually and 
thus it is usually done through computer software specially designed for the cladistic 
analyses The following section explains how to manually construct a cladogram 
using the Wagner optimisation algorithm.
6.2.7.5.1. The Wagner Algorithm
The aim of this section is to explain how to manually build a cladogram using the 
Wagner optimisation algorithm. Although the construction of cladograms is usually 
achieved using computer software, it is important to explain the manual technique 
because it gives an insight into the nature of the data used and helps to understand the 
conclusions that may be drawn from a cladogram (Wiley et al , 1991).
To better explain the algorithm an example is also described The example uses the 
sample data matrix of Table 6-2
Table 6-2 Data matrix for calculating example cladogram
Taxon Characteristics
O u tg ro u p 0 0 0 0 0 0
A 1 1 0 0 0 0
B 1 0 1 0 1 0
C 1 0 1 1 0 1
Given a matrix of characteristics the Wagner Algorithm is implemented using the 
following algorithm:
1. An ancestor or outgroup is specified (as explained in section 6.2.7.3 of this 
chapter the outgroup may be a new hypothetical taxon).
2. Within the ingroup, the taxon that shows the least amount of difference from 
the ancestor/outgroup is found. To accomplish this, D for each taxon to the 
ancestor/outgroup has to be calculated The metric D is the difference
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between two taxa and is equal to the sum of the absolute differences their 
characteristics. For instance in the example of Table 6-2 the difference 
between A and the outgroup (D(A,outgroup)) is given by the formula::
D(A, outgroup) = £  |X(A, i) -  X (outgroup, /')|
Where X(A,i) is a particular characteristic (X) of a particular taxon (A) and / 
the /th characteristic in a vector of / characteristics. A vector of 
characteristics for a prticular taxon is defined as ^  X ( A j ) . For instance, 
the characteristic vector of A is:
^ A '( /4 ,/)  = 110000
The difference D(A,outgroup) is therefore calculated in the following 
manner:
D(A, outgroup) = 2 1 X ( A , i ) - X  (outgroup, ;')| =>
D(A , outgroup) = |l -  0| + |l -  0| + 10 -  0| + 10 -  0| + 10 -  0| + 10 -  0| =>
D(A, outgroup) = 2
Similarly:
D(B, outgroup) - 3
D(C, outgroup) = 4
3. An interval (INT) for the taxon that has the smallest D is created The 
interval of a taxon is the length of the line between that taxon and its 
ancestor For instance’ the interval of A (INT(A,outgroup) is:
INT (A,outgroup) = D(A,outgroup) = 2
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4. The next taxon that has the next smallest difference from the ancestor/sister
group is found This is done by inspecting the original D values calculated in 
the previous step. If two taxa or more have the same value of D, then one is 
arbitrarily selected. In the example that would be taxon B since 
D(B, outgroup) =3
5. The interval that has the smallest difference with the taxon selected in step 4 
has to be found i.e. taxon B The taxon is then attached to the selected 
interval by constructing a hypothetical ancestor of the two taxa The 
characteristic vector of the ancestor, and thus its position along the interval, 
is computed by taking the median value of the existing taxon, its ancestor, 
and the added taxon. Because there is only one interval, INT(A,outgroup) 
there is no choice, but to add B to this interval Therefore, D[B,INT(A)] does 
not have to be computed. Then B is connected to INT(A) by constructing a 
hypothetical ancestor (X) whose characteristics are the median of the 
characteristics outgroup, A, and B, the three taxa involved in the problem at 
this point (Table 6-3).
Tabic 6-3 Data matrix with a hypothetical ancestor (X)
Taxon Characteristics
O u tg ro u p 0 0 0 0 0 0
A 1 1 0 0 0 0
B 1 0 1 0 1 0
X (m c d ia n ) 1 0 0 0 0 0
The tree has now a branch, a new hypothetical ancestor, and, three 
intervals, INT(A), INT(B), and INT(X) (Figure 6-6)
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A(1 1 0 0 0 0 ) B(1 0 1 0 1 0)
INT(A)- INT(B)
X(1 0 0 0 0 0) 
◄---- INT(X)
outgroup(0 0 0 0 0 0)
Figure 6-6 A branched tree with a hypothetical ancestor X
6. For each remaining taxon steps 4 and 5 are repeated The taxon that shows 
the least difference from outgroup is C. To find the interval that has the 
smallest interval from C three interval difference values, one for each interval 
in the tree, have to be calculated. The formula for figuring the difference 
between a taxon and an interval requires finding the difference between the 
taxon added and the ancestor of the taxon already in the tree In this case 
there are two ancestors. The difference between C and the outgroup has 
already been calculated and equals to 4 Therefore, the next step is to 
calculate the differences between A, B, or C and the new ancestor X and the 
differences between C and A or C and B.
D(A, X)  = \X(A,i) -  X (X ,  /)| = 1 
B(B, X)  = |X(B,  /) -  X{X,  ;)| = 2 
D(C, ^ )  = |A '(C ,;) -^ (A ',/) | = 3 
£>(C, A) = |X(C,  i) -  X(A,  /)| = 4 
D(C,B) = \X(C,i) -  X(B,i)\ = 3 
D(X ,outgroup) = \X (C ,/) -  X (outgroup, /| = 1
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Therefore, the distances between the C and the intervals are
D\C, INT(A)] = * C , A )  + D<P^X)-D<A.X) = 4 + 3M  = 3 
D[C, INT(B)] = P(C,B) + D ^ X ) - D ( B , X )  = 3 + 3 -  2 = 2
D[c INT(X)]  = D<yC' + g (C ’ out^ rouP"> ~ D(A’ outgroup) = 3 + 4 - 1  _
Since the difference between C and INT(B) has the smallest value, another 
hypothetical ancestor (Y) is constructed and C is connected to the tree 
through this new ancestor to INT(B) as shown in Figure 6-7
C(1 0 1 1 0 0)
INT(C)
B(1 0 1 0 1 0)
Y(1 0 1 0 0 0)
◄---- INT(Y)
X
outgroup
Figure 6-7 Complete tree with two hypothetical ancestors
To calculate the characteristic vector for this new ancestor the median of 
the vectors of the three appropriate taxa, X, B, and C, have to be used as 
shown in Table 6-4
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T a b le  6-4  D a ta  m a tr ix  w ith  a  second  h y p o th e tic a l  a n c e s to r  (Y )
Taxon Characteristics
X 1 0 0 0 0 0
B 1 0 1 0 1 0
C 1 0 1 1 0 1
Y (m c d ia n ) 1 0 1 0 0 0
The construction of the tree is now complete
6.2.7.5.2.Cladistics software
Although the above section provides useful instructions on the manual construction 
of a cladogram, the sets o f characteristic data used in chapters 7 and 8 are too 
complex to be manipulated manually, and thus, computer software has to be used 
Two software packages were used for constructing the cladistic classifications in this 
research. These are called Phylip and Paup (a third software package called MacClade 
is also used to select the optimal cladogram as is explained in the next section) When 
constructing cladistic classifications with complex data sets (many taxa and 
characteristics) numerous possible cladograms may be constructed (Wiley et al 
1991). As it is explained in the next section several indices exist that aid the cladist to 
select the best tree by assessing on which proposed tree the characteristics and taxa fit 
better. The advantage of using two software packages is that more cladograms are 
developed and therefore it is more probable to find a better cladogram i.e a 
cladogram where the taxa and their characteristics fit better.
6.2.7.6. Selecting the optimal cladogram
The final step of the construction o f the cladogram involves the selection of the 
optimal cladogram. The methodology outlined above may result in multiple 
cladograms. This is because given a data matrix the taxa and their characteristics may
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be resolved to produce more than one cladogram in more than one ways. This 
occurrence is more frequent in situations where the number of taxa and characteristics 
is large Consequently, a best tree according to certain criteria is selected. When 
there are alternative solutions, i.e. multiple cladograms, then the simplest or most 
parsimonious cladogram is chosen (Kitching et al., 1996). The most parsimonious 
cladogram is referred to as the optimal cladogram and the other cladograms are 
considered suboptimal. The most parsimonious cladogram is the one where the 
characteristics and their states arise the least number of times (Kitching at al., 1996). 
To identify the most parsimonious tree from a technical perspective three descriptive 
statistics or indices have been developed. These are treelength, consistency index, 
and retention index In situations where the number of taxa and characteristics is 
large it is more practical to use computer software to carry out the calculations of 
these indices. The software package that is proposed is for this purpose called 
MacClade (Maddison and Maddison, 1992).
The following paragraphs discuss the descriptive indices used to select the optimal 
cladogram
6.2.7.6.1. Tree length
The length of the tree is the total number of characteristic state changes necessary to 
support the relationship of the configuration of a cladogram. If the state of a 
characteristic changes more than once on the cladogram then that characteristic may 
specify overlapping groups and is thus inconsistent. Thus the tree with the minimum 
length is considered to have less characteristics that specify different and overlapping 
groups of taxa from other characteristics i.e there are less inconsistencies in the
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selection of groups and thus is the optimal tree (for more information on the 
calculation of the tree length see Kitching et al., 1998 pp. 92-95).
6.2.7.6.2.Consistency Index
The second descriptive statistic of a cladogram is the consistency index (Cl). This 
assesses the level of difficulty in fitting a given data set to a given tree. The Cl serves 
as a measure o f the discordance of the characteristics with a particular cladogram 
The consistency index is calculated using the following formula:
Where:
• M is the total number of characteristic state changes expected given the data set. 
In this research each characteristic will have up to two states. It can be either 
absent (0) or present (1). Therefore, the total number of changes each 
characteristic could take is one (from absent to present or else from 0 to 1). Thus 
the value M of the cladogram will equal the number of characteristics of the data 
set.
• S is the actual number of characteristic changes that occur in the tree.
The best possible fit of a data set on a cladogram will be one where each 
characteristic arises only once on the cladogram. In such a case M and S would be 
equal and therefore the consistency index equals 1. In situations where the data 
matrices are composed of real and complex data (which, as will be shown in chapters 
7 and 8, is the case in this thesis) it is likely that the characteristics will appear more 
than once on a cladogram. Hence, the consistency index will be less than one, which 
suggests that the data are not 100% consistent with a cladogram.
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For more information on the calculation of the consistency index see Kitching et al., 
1998 p 95 or Wiley et al pp. 72-78).
6.2.7.6.3.Retention index
The last descriptive statistic of a cladogram is the retention index (RI). In contrast to 
the consistency index that measures discordance o f  the data set to the cladogram, the 
retention index is a measure of fit of the data set on a cladogram. The retention index 
is calculated using the following formula:
( G - M )
Where:
• G is the greatest number of steps characteristics can have on any cladogram
. M is the total number of changes expected given the data set and
• S is the actual number of changes that occur in the tree
Similar to the consistency index, the best possible fit of a data set to a cladogram will 
be when the retention index is equal to 1. The main benefit in using the retention 
index over the consistency index is that the value of the latter will decrease when the 
number o f taxa increases irrespective of any change in data content i.e. irrespective of 
the fit of the data set. As will be shown in chapter 8 the number of taxa used for the 
development of the cladogram of drug discovery strategies is large and thus it is more 
valuable to use the retention index for the selection and evaluation of the cladograms.
For more information on the calculation of the retention index see Kitching et al., 
1998 pp 97-99
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6.2.8. Using dadi sties fo r  this research
This chapter introduces cladistics as a methodology for processing and presenting 
data to validate the four hypotheses developed in chapter 5. This particular section 
reviews the decision to use cladistics by considering the nature of the four hypotheses 
and the theoretical assumptions adopted by this research.
In chapter 4 it was argued that the classifications presented (e g. Mintzberg and 
Waters, 1998, Whittington, 1993) do not allow comparison of organisational and 
more specifically drug discovery strategies, because they are not related to specific 
organisations. Also it was argued that a drug discovery strategy is a pattern of 
behaviour that changes over time and this change is influenced by knowledge, 
technology, organisation, and environment. As explained earlier in this chapter, 
cladistics classifies using phylogenetic relationships between entities, while considers 
observable characteristics. Therefore, a cladistic classification could provide a 
classification of drug discovery strategies where the phylogenetic relationships o f the 
strategies are established by considering the four factors, knowledge, technology, 
organisation (observable characteristics), and the environment of specific 
organisations.
As explained in chapter 2 a business history methodology (Hendry, 1992) will be 
used to combine the benefits of longitudinal analysis and case study research. In line 
with this approach it is proposed that two cladograms be constructed to achieve this 
aim. The unit of analysis of both cladograms will be drug discovery strategies i.e. 
patterns o f behaviour defined or adapted by the management o f pharmaceutical 
organisations The first will use historical secondary data derived from existing case 
studies and research programmes (e g Liebanau, 1987, Jones, 2001, Weatherall, 
1990, Mann, 1999) to classify types of drug discovery strategies i.e. classes of
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strategies that share a common profile along conceptually distinct characteristics. The 
drug discovery strategy types classified by this cladogram should correspond to drug 
discovery strategies adopted by one or more organisations i.e. each taxon shown on 
the cladogram should represent a population or cluster (Mintzberg, 1998) of 
organisations. Due to the nature of the taxa of this cladogram it will be referred to as 
the population cladogram
The second cladogram will use data collected from pharmaceutical organisations to 
classify drug discovery strategies of individual organisations. The difference between 
this and the population cladogram will be that the taxa on the branches of the former 
will be drug discovery strategy types while that of the latter will be organisational 
strategies. Therefore, the population cladogram will classify drug discovery strategies 
at a higher level than that of the organisation cladogram The two levels of analysis 
(population and organisation) are illustrated in Figure 6-8 Due to the nature of the 
taxa of this cladogram it will be referred to as the organisation cladogram.
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Kev:
Uppercase letters: Drug discovery 
strategy types
Lowercase letters: Drug discovery 
strategies of individual 
organisations
Figure 6-8 Levels of analysis of cladograms
This approach has two benefits. Firstly, the construction of the population 
cladogram provides a test bed for the validation of the hypotheses. It is anticipated 
that the construction o f the population cladogram will be relatively more 
straightforward than that o f the organisation. This is because the data used is derived 
from literature which has already been processed and aggregated and is therefore 
more robust and consistent. Thus, the population cladogram will assess and 
demonstrate how cladistics might help to reveal how an evolutionary and 
classification approach can be used to study drug discovery strategies, as per the third 
research question. Secondly, the construction o f the population cladogram will 
provide a provisional list of types of drug discovery strategies and characteristics that 
will aid the collection of data when constructing the organisation cladogram.
In summary, the construction of the population cladogram will provide the 
following:
a b c
JL
d e f g
JL
h
A B C D
Level of analysis of 
organisation cladogram
Level of analysis of 
population cladogram
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. A list of drug discovery strategy types and characteristics
• A provisional classification of these types
. A framework for assessing and demonstrating the four hypotheses might be 
validated.
The source of the data that will be used to construct the organisation cladogram is 
derived directly from the pharmaceutical industry. The entities that will be classified 
in this case will be drug discovery strategies of individual organisations.
The construction of the organisation cladogram has the following aims:
. Validate the types o f drug discovery strategies classified by the population 
cladogram. this will be achieved by identifying groups of pharmaceutical 
organisations that implement drug discovery strategies similar to the ones 
classified by the population cladogram. Therefore, the taxa classified by the 
population cladogram should be the populations of the taxa classified by the 
organisation cladogram. That is, the drug discovery strategy types classified by 
the population cladogram will correspond to a number of organisations that have 
adopted these strategies.
. Validate the four hypotheses the resulting classification should identify groups of 
organisational strategies. The investigation of these groups should help validate 
the four hypotheses. For instance, the formation of groups of strategies, which 
are characterised by the implementation of modern technologies, could denote the 
selection of technology dominated strategies
. Identify the most dominant characteristics i.e. fin d  the configuration o f  the fittest 
strategy. The fourth research question (What are the characteristics of the fittest 
drug discovery strategies?) requires the identification of the characteristics of the
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fittest strategies. It is anticipated that a selection of characteristics will be more 
decisive than others i.e. certain characteristics will have a stronger influence on 
the classification than others. These characteristics will be identified by 
observing the various cladograms constructed in step 5 of the construction of the 
cladogram. Therefore, these characteristics will be those that constitute the fittest 
strategies.
6.3. Conclusions
This chapter set out to explain and justify the use o f the cladistic classification 
methodology in this research. It explained how the four hypotheses developed in 
chapter 5 could be supported or rejected using a classification It then presented the 
key classifications used in biology and justifed cladistics as an appropriate 
methodology for this research. The chapter then described the methodology for 
constructing a cladistics classification (a cladogram) Finally, the chapter explained 
how this methodology will be used in the chapters 7 and 8 to construct a population 
and organisation cladogram that will address the third and fourth research questions
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7. CONSTRUCTION OF POPULATION CLADOGRAM
7 .1. Introduction
To address the third research question (How can an evolutionary and classification 
approach he used to study drug discovery strategies?) chapter 5 developed four 
hypotheses. In chapter 6 it was argued and proposed that to validate these hypotheses 
two cladistic classifications should be constructed. The unit of analysis of both 
cladograms will be drug discovery strategies as defined in chapter 4. The first 
(population cladogram) would use data from available historical secondary sources to 
identify and classify types or forms of drug discovery strategies. The second 
(organisation cladogram) would use data from the pharmaceutical industry to identify 
and classify drug discovery strategies found in individual organisations. As argued in 
chapter 6 the benefits o f this approach are that the population cladogram will provide 
a test bed for the validation of the hypotheses and that its construction will provide a 
provisional list and classification that will help the collection of data for the 
construction o f the organisation cladogram. Furthermore, chapter 6 explained the 
process for constructing a cladistic classification.
The aim of this chapter is to explain the process followed to construct the population 
cladogram. Also, the chapter will present and analyse the cladogram Accordingly, 
the structure o f the chapter is based on the process followed to construct a cladogram 
as explained in chapter 6.
Therefore, the objectives of this chapter are to provide:
. A list o f drug discovery strategy types and defining characteristics
• A provisional classification of these types
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A platform for demonstrating how the four hypotheses can be validated
7.2. Step 1: Select the clade
The definition of the clade establishes the boundaries o f the group that will be 
analysed. Hence, this step involves the definition of the study area of interest i.e. drug 
discovery strategy types. In chapter 6 a drug discovery strategy type was described as 
a class of strategies that share a common profile along conceptually distinct 
characteristics The concept o f  and a working definition for drug discovery strategy 
was presented in chapter 4 o f  this thesis as 'the pattern o f  behaviour defined or 
adapted by the management o f  a pharmaceutical organisation, within a certain 
environment, to effectively materialise the corporation’s goals and policies in order to 
achieve a competitive advantage through the application o f  knowledge and  
technology on the discovery o f  new drugs'. Consequently, the clade consists of types 
of strategies that fall under this definition. As argued in chapter 6 the taxa of this 
cladogram should correspond to drug discovery strategies adopted by one or more 
organisations i.e. each taxon shown on the cladogram should represent a population or 
cluster o f organisations For this reason, this cladogram will be referred to as the 
population cladogram
7.3. Step 2: Data collection
The second step of the cladistic classification involves collecting data that will 
establish the relationships between populations of drug discovery strategy types The 
source of the data used for the construction of the population cladogram is historical 
literature i.e. literature that reports the steps that people have taken to understand how 
diseases occur and how medicine, vaccines, dietary materials, anaesthetics, 
antiseptics, and other medical materials came to be invented and used (Weatherall,
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1990). The process that was followed to collect the characteristics and identify the 
drug discovery strategy types is shown in Figure 7-1.
Figure 7-1 Process followed to determine the characteristics of population cladogram
The first step consists of the collection and review of the literature that reports the 
history o f drug discovery. The literature used is listed in Table 7-1.
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Tabic 7-1 Sources used for the construction of the population cladogram
_____________________________________ Reference_____________________________________
A Danheiscr, S, 1997, Laboratory automation and robotics to play a major role in the drug 
discovery process, Genetic engineering news, Issue 10 
A Schneider, I., 1999, Robotic Systems: Adding speed and flexibility to the drug discovery 
process, Genetic engineering news, Issue 15
B Bogncr, W , Thomas, H ., 1996, Drugs to market: creating value and advantage in the 
pharmaceutical industry, Pergamon, NY
B Davcnport-Hines, R P.T., Slinn, J., 1992, Glaxo: A History to 1962, Cambridge 
University Press, Cambridge
B Gambardclla, A, 1995, Science and innovation the US pharmaceutical industry during 
the 1980s, Cambridge University press, Great Britain 
B Licbcnau, J., 1987, Medical science and medical industry, The John Hopkins university 
press, Hong Kong
B Loftus, P., Waldman, M , Hout, R., 1987, Computer-based approaches to drug design, 
Drug discovery and development, (cds) Williams, M., Malick, J B , pp. 37-96 
B Mann, J., 1999, The elusive magic bullet: the search for the perfect drug, Oxford 
university press, Oxford
B McKelvey, MD., 1996, Evolutionary innovations: the business o f biotechnology, Oxford 
university press, New York
B Wcathcrall, M., 1990, In search of a cure: A history of pharmaceutical discovery,
Oxford University Press, New York
OP Cardinal, F, 2002, Abe Lincoln's "Blue Mass" Pills: Was Lincoln a Victim of Mercury 
Poisoning?, Sleep disorders,
http://slcepdisordcrs.about.com/librarv/wceklv/aa072301a htm 
P Anderson, R.J., 1996, Managing the overall portfolio for Successful Discovery and 
development, Welling, P.G , Lasagna, L., Banakcr, UV, (eds) chapter 4, pp 79-115 
P Baba, Y ., 2001, Development of novel medicine based on genome science, European 
journal o f pharmaceutical sciences, Vol. 13, pp 3-47 
P Bcllott, E., M., Bondaryk, R., Luther, A.L., 1997, Combinatorial chemistry in the drug 
discovery process, Clinical research and regulatory affairs, Vol. 14, Nos 3&4, pp. 231 - 
241
P Deeds, D.L., DcCarolis, D., Coombs, J .E., 1997, The impact of firm-specific
capabilities on the amount of capital raised in an initial public offering: evidence from 
the biotechnology industry, Journal o f business venturing, Vol 12, pp 31-46 
P Frey, R., Lcsncy, M. S., 2000, Anodynes and Estrogens: The pharmaceutical decade.
The Pharmaceutical Century: Ten decades o f Drug Discovery Supplement to American 
Chemical Society, pp 92-109
P Koehler, C. S. W., 2000, Aids, Arteries and Engineering: Epidemics and Entrepreneurs, 
The Pharmaceutical Century: Ten decades o f Drug Discovery Supplement to American 
Chemical Society, pp. 130-147
P Lcsney, M. S., Frey, R., 2000, Chemistry, Cancer and Ecology: Environments of health, 
The Pharmaceutical Century: Ten decades o f Drug Discovery Supplement to American 
Chemical Society, pp. 110-129
P Lcsncy, M. S., Miller, J. B., 2000, Harnessing Genes, Recasting Flesh: Closing the
pharmaceutical century, The Pharmaceutical Century: Ten decades o f Drug Discovery 
Supplement to American Chemical Society, pp. 148-167 
P Lcsncy, M., 2000, Patents and Potions: Entering the Pharmaceutical Century, The 
Pharmaceutical Century: Ten decades o f  Drug Discovery Supplement to American 
Chemical Society, pp 18-31
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Tabic 7-1 Sources used for the construction of the population cladogram (continued from page 
_______________________________________ 195)_______________________________________
P Matraves, C., 1999, Market structure, R&D and advertising in the pharmaceutical 
industry, The journal o f industrial economics, Vol. XLVI1, No.2 pp. 169-194
P Miller, J. B , 2000, Antibiotics and Isotopes: Swigtime, The Pharmaceutical Century: 
Ten decades o f  Drug Discovery Supplement to American Chemical Society, pp. 52-72
P O’Reilly, B., 2001, There’s still gold in them thar pills, Fortune, Vol. 144, No. 2, pp 
78-85
P Pizzi, R., 2000, Salving with Science: The Roaring twenties and the Great Depression, 
The Pharmaceutical Century: Ten decades o f Drug Discovery Supplement to American 
Chemical Society, pp. 34-51
P Somberg, J. C., 1996, The Evolving Drug Discovery Process, The Drug Discovery
Process: Increasing Efficiency and Cost Effectiveness, eds. Welling, P G., Lasagna, L., 
Banakar, U. V., Marcel Dckkcr, New York
P Tweedy, B. D., Lesney, M. S., 2000, Prescriptions and Polio: Postwar progress, The 
Pharmaceutical Century: Ten decades o f Drug Discovery Supplement to American 
Chemical Society, pp 72-91
P U’Prichard, D C , Pullan, L.M., 1997, The future of drug industry research and the 
Zeneca response, Corporate strategy, Novcmbcr-Decembcr, pp. 35-39
P Williams, M., Giordano, T., Elder, R.A., Reiser, H.J., Neil, G.L, 1993, Biotechnology 
in the drug discovery process: strategic and management issues, Medicinal research 
reviews, Vol. 13, No. 4, pp 399-448
Key:
A: Industrial article
B: Book
OP: online publication
P: journal paper_____________________________________________________________
The historical literature used for the construction of the population cladogram and 
listed in Table 7-1 constitutes secondary data i.e. data that already exists (Hussey and 
Hussey, 1997). The benefit o f using secondary data is that it is published in a form 
that is easily accessible. Also, there is a huge saving in resources, in particular, time 
and expenditure. The drawbacks with the use of such data are related to the control of 
the researcher on the data. Secondary data is collected using a process that a 
researcher has no control over. This is because the form and the content of secondary 
data are shaped by the original institute/owner/researchers that gathered the data 
This feature can limit the overall scientific value of the secondary data However,
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secondary data can also provide data that might otherwise have been impossible to 
gather. Such is the case with the construction of the population cladogram. The 
construction of the organisation cladogram requires data that dates early in the 
pharmaceutical history and is therefore difficult to collect.
Zikmund (2000) presents a series of questions that should be asked when evaluating 
secondary data as shown in Figure 7-2. By following this evaluation the data listed in 
Table 7-1 was considered to be appropriate for the objectives of this research.
As will be explained in the next section, the history o f  drug discovery starts from 
very early in human history. However, it is only since the late 1800s when the 
developments in drug discovery have led to the establishment of the modern 
pharmaceutical industry. The second and third steps of the data collection involve the 
identification of the drug discovery strategy types and their characteristics. The final 
step involves the tabulation of the findings from the previous steps. The table that 
includes the drug discovery strategy types and the characteristics is Table 7-2 on page 
218.
7.3.1. History o f drug discovery strategies
The first step in determining the drug discovery strategy types and their 
characteristics, involves the identification and review o f  the relevant historical drug 
discovery literature Based on the literature sources listed in Table 7-1 the following 
paragraphs provide a description of the history of drug discovery from the age o f  
botanicals (1800s) up to today. This description is structured in chronological order 
The account of each period concludes with a discussion of each strategy that 
dominated that period
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Applicability 
to the Project 
Objectives
Accuracy of 
the Data
Figure 7-2 Evaluating Secondary Data (from Zikmund 2000 p. 127)
Chapter 4 presented and justified four factors that influence the configuration of 
drug discovery strategies. These are knowledge, technology, organisation, and
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environment. As it will be shown in the description of the history of drug discovery 
these factors have played a significant role in the evolution of drug discovery. In the 
next section (7.3.2) a table (Table 7-2) is presented that presents the drug discovery 
strategy types and their characteristics arranged according to these four factors.
7.3.11. The Pre 1800s
The pharmaceutical era prior to the 1800s is called ‘The age o f  botanicals’ 
(Somberg, 1996). Reports exist that prove that man has been making use of herbals 
from very early in human history. These could be used for foods, items of religious 
significance and also as medication. The Bible as well as early folklore relate stories 
o f use of medicinal plants and herbs. Also, ancient Greek and Egyptian proofs of 
pharmacopoeia have been found which include compounding and dosage 
requirements for various illnesses (Bogner and Thomas, 1996). For instance, the 
Ebers Papyrus lists 811 prescriptions used in Egypt in 550bc (Henderson et al., 1999).
Treatments of illnesses early in human history were inseparable from religious and 
magical practices. More coherent approaches to treatments have been found in the 
ancient Greece where Hippocrates (born 460 be) introduced a more rational outlook 
basing his practice on observation and experience (Weatherall, 1990). In the 
following centuries, many medicinal plants were discovered or recognised in the 
civilisations, which existed round the Mediterranean In the centuries that followed 
the decline of the Roman Empire, the study of medicine stagnated under the weight of 
authority and tradition (Weatherall, 1990). The Arabic speaking world and China also 
developed medicine independently.
In the 17th and 18th century medical treatment of diseases was based on reasoning 
However, such logic started from the dogmas of the time, which had little basis in fact
199
(Weatherall, 1990). For instance, the yellow colour of saffron showed that it was 
good for jaundice, the red colour of rust or wine showed that it was good for 
bloodlessness or anaemia, and the leaves of the plant lungwort, which had some 
resemblance to the appearance of the lungs, showed that the plant was good for lung 
disease (Weatherall, 1990). Therefore, any discoveries made during this period were 
random while there was no scientific justification.
Although the ‘age of botanicals’ and its unorthodox approach to drug discovery is 
now long gone, it provided the modern drug discovery era with a significant body of 
knowledge that led mainly to understanding the biological activity of certain 
substances found in nature. Even during the 20th century herbals were used during the 
botanical age were being investigated for their biological activities (Somberg, 1996).
7.3.12. The 1800s to 1910s
Early in the 19th century diseases were identified according to the symptom they 
produced Therefore, the road to health was to attack the symptom as vigorously as 
possible (Lesney, 2000). Fever was attacked by bloodletting (fever is hard to be 
sustained when there is no blood in the body), and stomach pains were attacked by 
violently cleaning the stomach from poisons (Lesney, 2000). Naturally, these 
approaches to curing diseases were not effective because attempting to cure people 
already weakened by a disease often meant that the cure had worse results than the 
disease itself. Reportedly, George Washington died from bloodletting, while 
Abraham Lincoln died from his constant doses of ‘blue mass’ (a medication common 
at that time for depression that was prescribed at a daily dose that contained over 9000 
times the amount of mercury that is considered safe by today's standards) (Cardinal, 
2002 ) .
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Later in the 19th century the patent remedies, usually used without a physician’s 
guidance (Liebenau, 1987), became popular. Homeopaths who developed interesting 
theories, which related the medicine used to the exact symptoms displayed by the 
individual patient (Weatherall, 1990), were common These non-effective, but 
harmless approaches to curing became the basis for a commodity based medicine 
industry that gave birth to the pharmaceutical industry. Among the drugs that were 
developed a few authentic ones were accidentally discovered like quinine, digitalis, 
and cocaine. These substances were a key part o f the modern era of pharmaceuticals 
(Lesney, 2000).
A significant development in the discovery o f new drugs during this decade was the 
synthesis o f the first coal tar dye in 1856. This discovery led to the development o f 
many synthetic dyes, but also to the realisation that some of these dyes had 
therapeutic effects (Lesney, 2000). Another significant discovery of this period was 
the microbial theory of disease i.e. the idea that infectious diseases were caused by 
microscopic living agents. Although initially this theory was not widely accepted 
(Lesney, 2000), it provided an understanding o f the causes and the potential cures for 
several diseases. The most significant outgrowth of the microbial theory, and one that 
created the greatest demand for new technologies, was the identification and 
production of vaccines (a safe source of active immunity) and antitoxins (antibodies 
isolated against disease organisms and their toxins from treated animals) (Lesney, 
2000).
Close to the end o f the century two synthesised drugs remarked the birth of the new 
era, aspirin in 1853 and antipyrine in 1883 (Weatherall, 1990). These two drugs 
together with the knowledge that was developed about vaccines and microbial 
pathogens set the scene for the following decades of pharmaceutical development
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Another significant development that took place during the last third of the 19th 
century was the gradual establishment of clinical tests. Horatio C. Wood a physician 
from Philadelphia was one of the first physicians that conducted experiments to 
establish the clinical effects of various drugs (Liebenau, 1987). This practice was 
further enhanced by the development o f new technologies such as bacterial cultures, 
chemical analysis, and clinical thermometers (Lesney, 2000).
One important development that occurred during the final decade of the 19th century 
is related to the change of the organisational structure of the pharmaceutical century. 
Up to then the typical structure of the pharmaceutical organisations consisted o f direct 
family control where the efforts o f individual scientists resulted in unplanned 
discoveries. In the course of the decade this changed dramatically with the 
development of physical departmentalisation and managerial hierarchies (Liebenau, 
1987). This development followed the acceptance by the physicians that the drugs 
produced by pharmaceutical organisations were generally of better quality and more 
standardised to those produced by individual pharmacists (Liebenau, 1987).
Finally, during the first decade o f the twentieth century the American government 
involved itself in the pharmaceutical industry for the first time. The form of its 
involvement was the 1902 and 1906 Acts for regulating drug production (Liebenau, 
1987). The 1902 Act aimed at controlling the sale and production of biological 
products and to regulate the sale o f  viruses, serums, toxins and analogous products. 
The 1906 Act aimed mainly at controlling the adulteration of food rather than the 
regulation of drugs (Liebenau, 1987).
The main characteristics and contributions o f the 19th century are the microbial 
theory of disease, the breakthroughs in organic chemistry and biochemistry and the 
development of new technology. The development of optics together with the
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development o f technologies such as sterilisation, media and methods for growing and 
staining microbes, X-Ray crystallography, chemical extraction, and the invention of 
the rotary tablet dominated the growth o f the new medical science Also the industrial 
revolution provided both the technical capability to respond to the technological 
challenges, but also a source of public hope for the decades to come.
7.3.13. The 1920s and 1930s
The key milestones of these two decades were the discovery of vitamins and the 
advances in chemistry (Pizzi, 2000). Although the discovery of the vitamins (a vital 
part of nutritional therapy) was made in 1912 by Casimir Funk (Davenport-Hines and 
Slinn, 1992) it was not until 1924 that the pharmaceutical organisation Glaxo 
marketed the vitamin extracts by developing vitamin D. Also, many new vaccines 
and drugs were discovered, most notable of which was penicillin that was accidentally 
discovered by Alexander Fleming in 1928.
Although this period was characterised by chemists trying to find chemical solutions 
to the diseases that plagued humankind one of the greater pharmaceutical discoveries 
of this period did not cure an infectious disease, but the physiological disorder 
diabetes mellitus. This disease is caused by a malfunction o f  the pancreas and nearly 
always resulted in death. In 1921 Frederick Banting, a Canadian physician, using the 
pancreas of a living dog managed to isolate an extract later called insulin and 
consequently created the first effective treatment of diabetes (Weatherall, 1990). 
However, insulin was not available until the pharmaceutical organisation's Eli Lilly 
technical development enabled its large-scale production in a state suitable for clinical 
use
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Infectious diseases however, were still responsible for the highest number of deaths 
in the 1920s and 1930s. Paul Ehrlich introduced the world to chemotherapy and 
successfully managed to treat syphilis (Mann, 1999). What was needed however was 
a drug that would fight pneumonia and septicaemia In the 1920s bacteriologists 
started experimenting with dyes that were used to stain bacteria and by the 1930s 
achieved a breakthrough. This involved injecting an orange-red azo dye called 
Prontosil. Using this technique Gerhard Farben managed to cure a group of mice 
infected with streptococcus. This discovery gave birth to a new series of drugs called 
sulfa drugs, which after further development had the ability to stop the growth and 
multiplication of the bacteria.
Assisting the quest to discover drugs was progress in the area o f scientific 
instrumentation that transformed R&D. The need to invent novel ways of developing 
new drugs brought for the first time together people from diverse disciplines into 
teams. Physical chemists and physicists collaborated with biochemists and biologists 
and instruments were invented such as the electron microscope (1931), the 
ultracentrifuge (1924), and the pH meter with a glass electrode (1921) (Pizzi, 2000)
Apart from drug discoveries, the main characteristic and contribution of this era was 
the interdisciplinary thinking that led to the development of new instruments and 
ultimately the creation of institutions for the regulation of drug discovery such as the 
USA’s Food and Drug Administration (FDA) established in 1927. For the first time 
knowledge acquired in physics and chemistry was combined to advance the field of 
pharmaceutical science.
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7.3.14. The 1940s
This era is more commonly known as the ‘antibiotic era’. As defined by Selman 
Waksman in 1941, an antibiotic is a chemical substance, produced by a 
microorganism which has the capacity to inhibit the growth and even destroy other 
microorganisms (Mann, 1999, p. 37). During this period drugs started to be 
discovered in a less serendipitous fashion Researchers began searching for specific 
drugs in response to a market need. This resulted in the discovery of numerous drugs, 
targeting various diseases. For instance, penicillin was developed into an antibiotic 
for fighting staphylococcal and streptococcal infections, quinine-a complex molecular 
structure and chloroquine were developed to cure malaria, vitamin Bn was developed 
to help cure pernicious anaemia (the name was inspired by the remorseless progress to 
a fatal outcome) (Weatherall, 1990).
World War II also played a very important role in the development of the 
pharmaceuticals. For example, the development and production of penicillin was 
accelerated by the need to cure infected soldiers. Also, new technology promoted by 
the war made the production of radioisotopes easy and these were then used for health 
research. Similarly, the need to fight malaria drove research towards the synthesis of 
quinine, which was achieved in 1994 when it was synthesised from coal tar
As a consequence of the cruel and inhuman experiments to the Jewish population by 
the Nazis during the Second World War, the Nuremberg Code was established in 
1949. This code requires that individuals enrolled in clinical research give voluntary 
consent. It also requires that research is undertaken for benefit of the society, must be 
performed by scientifically qualified persons, and be derived from research on 
animals that will suggest that anticipated outcome would justify human clinical 
experiments. By the end of the World War II the technology that was used was
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becoming routinely available for health research as computer aided drug discovery 
was introduced (Miller, 2000). In the UK the National Health Service, established in 
1946 by the labour government, stimulated the industry’s development (Davenport - 
Hines and Slinn, 1992 p. 167).
Another major breakthrough of the 1940s was the design and synthesis of 
antimetabolites that could destroy cancer cells In 1948, George Hitchings and 
Gertrude Elion synthesised and demonstrated the anticancer activity of 2,6 
diaminopurine. This development constitutes the foundations of rational drug design. 
(Matraves, 1999, Bogner and Thomas 1996)
In summary, the main characteristics and contribution of this period to the 
advancement of drug discovery include evidence o f a shift from serendipitous 
research motivated primarily by the academic and intellectual freedom to a less risky 
more disease focused one. Also World War II and the wartime need for antibiotics 
marked the industry’s transition to an R&D intensive business (Henderson et al., 
1999). Finally, the development of numerous antibiotics and their availability created 
a public expectation of health through drugs and medical intervention. Because of 
this expectation and the new possibilities, health became a political issue that led the 
way in the next decade
7.3.15. The 1950s
Following the end of World War II, drug discovery in the 1950s became highly 
influenced by other world events such as the Cold War, the Korean Conflict, the 
launch o f  the first orbital satellite in 1957, mass consumerism, etc Technologies 
previously used for pure scientific reasons or for war were now used for civilian life 
e g. silicone products, microwave ovens, radar, plastics, computing devices etc. In the
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USA a science and technology policy coupled with an anti-Soviet sentiment resulted 
in large sums of public money being allocated for the discovery and development of 
new drugs.
Improved mechanisation streamlined production in drug factories and the DNA 
(Deoxyribose Nucleic Acid) era was being born. Understanding of how the human 
body worked and the progress in computational power helped the development of new 
technology. The new technology and the understanding of DNA’s structure created 
new windows of opportunity for the development of new drugs. These breakthroughs 
led to the development of biotechnology. Biotechnology in a scientific sense may be 
viewed as the application of recombinant DNA technology to create new processes 
and products (Williams et al., 1993).
The main characteristics and contributions of this decade were the vast amount of 
knowledge discovered on human biology and chemistry as well as the development of 
instrumentation.
7.3.16. The 1960s
The 1960s was the pharmaceutical decade of the century (Frey and Lesney 2000) 
when consumers became conscious about drugs in all aspects o f their lives and led to 
the pill taking culture. There were pills for life, leisure, and for love. Prominent 
drugs for this decade include the pill for birth control, and Valium and Librium for 
soothing nerves. In terms of drug discovery, technological innovations led to its 
proliferation. New forms of chromatherapy became available, including HPLC (High 
Performance Liquid Chromatography), capillary GC (Gas Chromatography), GC/MS 
(Gas Chromatography to Mass Spectrometry) and the rapid expansion of thin-layer 
chromatography techniques By the end of the decade amino acid analysers were
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widely used and the centrifuge had become fully developed and integrated to 
biomedical sciences Also, analytical chemists and biologists collaborated as never 
before in the search for new drugs. New technologies were developed, while 
instruments that were previously designed were adapted to biomedical applications 
During this decade the development of new drugs was enhanced by new 
instrumentation, but also with the introduction of powerful computers that made 
laboratory automation a new trend.
One of the key developments in drug discovery that would mark the years to follow 
was the wider understanding of the structure of DNA and the acceptance that it was 
indeed genetic material (Frey and Lesney, 2000). During this decade the technology 
necessary for the development of biotechnology in the following decade also 
proliferated. For instance, in 1964 a simplified technique for protein and nucleic acid 
synthesis which was the basis for the first such machines, and in 1967 the first 
specific gene transfer was accomplished
Finally, breakthroughs in aetiology (the branch of medicine that deals with the 
causes or origins o f disease) strengthened the understanding of diseases and they 
helped in the development of more science driven strategies for the discoveries of 
new drugs.
7.3.17. The 1970s
During this decade the war against cancer began and the first biotechnology 
organisation was founded Treatments for various cancers appeared and 
chemotherapy joined the ranks of other routine treatments New drugs that reached 
the market included cyclosporin used for preventing rejection of organs transplants, 
rifampicin used for treating tuberculosis, and cimetidine used for treating peptic
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ulcers. An important discovery made during the early 1970s was that of reverse 
transcriptise which in the following decades became critical for the study of AIDS
Computational technology became further integrated with the life sciences and 
genetic engineering emerged. Genetic engineering allowed scientists to combine bits 
of DNA. In 1975 two different methods were developed that would allow DNA 
sequencing i.e the sequence of bases of DNA with relative ease and efficiency.
In 1976 Genentech (short for genetic engineering technology), the first dedicated 
biotechnology organisation, was founded by Herbert Boyer, a faculty member of the 
University o f  California, San Francisco and the venture capitalist Robert Swanson 
(McKelvey, 1996). This marked the birth of the biotechnology industry, which saw 
several entrepreneurs starting new organisations in an effort to capitalise on the new 
technology.
The 1970s also saw the dawning of a rapid development in information technology 
as computers started becoming faster, the first microprocessor was invented and 
Microsoft was founded. The coupling of life sciences with computers was marked by 
the development of the first microprocessor controlled HPLC by Hewlett-Packard
The main contributions and characteristics of this decade were associated with the 
introduction of computing technology into mainstream research and the formation of 
the biotechnology industry as a new type of drug discovery business. During the 
1970s knowledge and instrumentation were put in place that would lead to rational 
drug design in the 1980s and 1990s.
7.3.18. The 1980s
In addition to further advances in new drug discoveries and application of 
computational technology, new diseases also appeared during this decade The most
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significant was AIDS (Acquired Immune Deficiency Syndrome). Initially detected as 
a sexually transmitted disease between homosexual men, AIDS destroys the body’s 
own mechanisms for fighting off infection (Mann, 1999). Those affected by this 
syndrome die of a host of opportunistic infections such as rare viruses, fungal 
infection and cancers. The AIDS disease influenced the development of immunology 
i.e. the study o f  body resistance to infections (Koehler, 2000). Another phenomenon 
that triggered novel research was the rise of drug resistance. Diseases that were 
thought to have been eliminated in developed countries reappeared in the late 1980s, 
and showed a resistance to multiple drugs previously used for their elimination 
(Koehler, 2000).
In the area of drug discovery, the developments that marked this decade revolved 
around the application of computational technology to the design of new drugs and 
the strategic acquisition of small biotechnology organisations by larger 
pharmaceutical organisations. Molecular biology and the use of computers gave rise 
to a new approach to innovation. Before this decade the discovery of active 
compounds depended on a try and see empirical approach. From now on however, 
knowledge on body physiology and medical disorder coupled with knowledge on 
drugs would result in the conceptualisation of the right molecules. The result is ideal 
design specifications, which are presented to research chemists who search for a close 
match.
The increased use of computer modelling techniques was influenced by two major 
factors. The first of these was the availability of low cost, but powerful computer 
systems. This allowed researchers to perform fast and cost effective computations, 
which were previously only possible on large and expensive mainframe computer 
systems The second factor was the availability of high speed, high resolution,
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graphical display systems (Loftus et. al, 1987). The numeric and frequently complex 
input requirements of many theoretical chemistry programs had long been an obstacle 
to their acceptance by most chemists. By enabling researchers to build and 
manipulate chemical structures in a direct and simple manner and to transform the 
output o f  theoretical calculations into visual images, graphical display devices 
provided a powerful interface between the computer and the researcher. The ability to 
display theoretical results in a visual form, also provided a common means of 
communication between the fields of theoretical, physical, and synthetic chemistry, 
thus facilitating the development of effective multidisciplinary approaches to the area 
of drug design (Loftus et al, 1987).
Other developments and uses of the computational technology included genetic 
algorithms and fuzzy logic (Koehler, 2000). Genetic algorithms allow drug designers 
to evolve a best fit to a target sequence through successive generations until a fit or 
solution is found (Koehler, 2000). Fuzzy logic formalises imprecise concepts by 
defining degrees of truth and falsehood. Fuzzy logic has proved useful in modelling 
pharmacological action, protein structure and receptors (Koehler, 2000).
This decade also saw further commercialisation of drug discovery. Small 
entrepreneurial biotechnology organisations were founded primarily as a business 
venture that sought to discover active compounds. However, by the mid 1980s many 
of these organisations were struggling for survival. Most biotechnology organisations 
were pursuing a very limited number of potential drug treatments compared to that of 
pharmaceutical organisations. Also, the industry was based on highly complex and 
specific knowledge that was still emerging, unlike the mature knowledge structure of 
traditional pharmaceutical organisations. Therefore, the future of biotechnology 
organisations was more uncertain than that of large pharmaceutical organisations with
211
large pipelines (Deeds et al., 1997). This led to their acquisition by big 
pharmaceutical firms. The acquisition of smaller biotechnology firms a strategy that 
is still in use by big organisations. It is considered to be beneficial for both the 
acquired and the acquiring organisations as it provides stable source of funding for the 
former and expertise in a potentially successful area for the latter.
Finally, another very significant step in the progress of discovery was made in the 
1980s and that was the development of combinatorial chemistry. This is the 
simultaneous use of large sets o f  chemically similar agents to produce thousands of 
organic compounds, which are then screened for biological activity. One of the 
factors that led to the development of this technology was the rise of drug resistance, 
discussed earlier Diseases that had learnt to resist drugs needed to be confronted 
with more powerful complex drugs (Bellott et al., 1997).
This decade contributed to the science of drug discovery by further integrating and 
adapting of computing technology into research, which has since completely changed 
the environment of pharmaceutical research. The biotechnology sector also 
flourished with numerous entrepreneurs establishing small dedicated drug discovery 
businesses across the globe, but most notably in areas such as San Francisco, 
Maryland, San Diego, Boston, Seattle and North Carolina.
7.3.1 9. 1990s-current
Following computational technology advances made in the 1970s and 1980s and 
their use in health sciences, the 1990s saw the development and application of 
robotics and automation to drug discovery (Schneider, 1999, 2000, Danheiser, 1997). 
Apart from these rapid advances in drug discovery technology, again primarily due to
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the computational technology, this decade was also characterised by the reappearance 
of diseases previously treated.
Continuing the problems that were first observed in the 1980s, old and new diseases 
were increasingly resistant to the array of drugs fabricated against them As the 
decade progressed the number of diseases resisting the treatment increased 
Consequently, the researchers had to keep up with the race against bacterial resistance 
to traditional antibiotics. Bacteria that were previously treatable, but were now 
resistant include various streptococcal infections, strains o f tuberculosis, pathogenic 
E coli, and gonorrhoea.
Another front that the pharmaceutical industry had to  fight was that of AIDS 
Despite the advances in understanding its biology, technology still was unable to 
master the disease The viral strains proved to be resistant to any drug or drug- 
cocktail thrown at them. The drugs available to date can only prolong the lives of 
patients, while the death rate in Western countries where the expensive drugs were 
available dropped precipitously (Lesney and Miller, 2000).
For drug discovery the main technological advances that enhanced the process 
during this decade were combinatorial chemistry, rational drug design, genomics, 
proteomics and pharmacogenomics. A short description o f  each of these technologies 
is provided in chapter 4. The combinatorial methods resulted in an increase in the 
number of potential drugs. This in turn created a bottleneck in the number of 
candidates that could be screened for biological activity. To conduct high throughput 
screening new processes and techniques were developed Finally, bioinformatics was 
developed to achieve computerised storage and analysis o f  biological data
During this decade the management aspect of drug discovery also developed Large 
amounts of information and scientists from various disciplines had to be effectively 
managed to increase the efficiency of the drug discovery process and reduce its lead- 
time. This led to the division labour.
Also the pharmaceutical industry saw the institunalisation of mergers, and 
acquisitions, and the outsourcing of research to medium sized organisations (Lesney 
and Miller, 2000). This led to the development of large multinational organisations. 
Another factor that transformed the business during this decade was the Internet, 
which firstly facilitated the purchase of medicines, and secondly, it allowed to drug 
producers access to wider range of raw materials.
Another trend popularised during the 1990s was the competition to  introduce 
generic drugs (Anderson, 1996) and the improvement o f old drugs (Gambardella, 
1995). This trend was the result o f the increasing cost and difficulty o f  finding new 
blockbuster drugs (O’Reilly, 2001).
The main contributions and characteristics of this final decade of the century are 
associated with the rationalisation (i.e. more focused, targeted and business like) of 
the drug discovery process. Also, the biotechnology industry established itself as the 
discovery arm of the pharmaceutical industry (Baba, 2001). The competitive pressures 
and the direct link between the number of discoveries and the financial performance 
of organisations further enforced the quest to discover effective drugs. In addition, 
new technologies like combinatorial chemistry and high throughput screening helped 
to create libraries of compounds that would aid scientists with drug design
The 20th century has seen tremendous advances in the medical sciences resulting in 
the presence of a multimillion-dollar industry. Particularly during the last two
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decades the combination of the advances in computers and the knowledge in human 
biology has created a wealth of knowledge and resources. Therefore, effective 
utilisation o f  these resources became a major issue for pharmaceutical organisations 
In the 21st century the technological and knowledge advances coupled with increased 
cost pressures, more informative, and expensive clinical data require flexible and 
innovative research (U’Prichard, 1997).
7.3.2. Tabulating the drug discovery strategy types and their characteristics
The previous paragraphs provided a description of the history of drug discovery that 
aimed at determining the drug discovery strategy types and their characteristics. This 
section presents a table (Table 7-2) that summarises the drug discovery strategy types 
(taxa) and their characteristics based on the data gathered, analysed and presented in 
the previous section. As explained in chapter 6 the strategy types and characteristics 
included in Table 7-2 will also be used in the second step of the construction o f  the 
organisation cladogram, data collection
As explained in chapter 4 a drug discovery strategy is a pattern of behaviour defined 
or adapted by the management of a pharmaceutical organisation while a strategy type 
is a class of strategies that share a common profile along conceptually distinct 
characteristics. From the historical account of the previous section several such types 
may be identified that populations of organisations have adapted to improve their drug 
discovery process. Early in the pharmaceutical history (age of botanicals) this pattern 
was characterised by unconventional or unorthodox techniques, such as use of 
herbals, which lacked any scientific justification. As knowledge and technology 
progressed the pattern changed to one where pharmaceutical organisations focused on 
the development of drugs for specific diseases For instance, in the 1960s the
215
breakthroughs in disease aetiology, the enhancement of biomedical instrumentation, 
and the use of powerful computers assisted organisations to adapt to a more science 
driven drug discovery strategy. To list the drug discovery strategy types in a table, 
classes of patterns were identified that were adapted by the management of 
pharmaceutical organisations over the last century.
The names given to these strategy types depend on the manner by which knowledge, 
technology, organisation, and environment (the four factors identified and justified in 
chapter 4) were employed. For instance, the strategy that used herbals with no 
scientific justification has been named unorthodox, while the one that was using 
science based techniques such as disease aetiology and biomedical instrumentation 
has been named science driven. This process of taxa nomenclature is inline with 
McCarthy and Ridgway (2000) who argue that the name given to a taxon should act 
as a vehicle for communication, be unambiguous, and indicate the position of the taxa 
within the classification.
Chapter 4 presented and justified four factors that influence the configuration of 
drug discovery strategies These are knowledge, technology, organisation, and 
environment. To show that these four factors played a significant role in the 
evolution of drug discovery strategies Table 7-2 is arranged according to these 
factors. Also the table sorts the characteristics according to the year o f their 
appearance. A description of each strategy is included in section 7.6 4. In total 15 
drug discovery strategy types and 57 characteristics are identified. The numbering of 
the characters shown in Table 7-2 is the one given to the table of the matrix of the 
Appendix A.
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Steps 1 and 2 defined the area of interest and identified potential drug discovery 
strategy types and their characteristics. The third step involves setting the polarity for 
each characteristic, to define which state is derived (apomorphic state) and which is 
ancestral (plesiomorphic state). That is to say, to detect the direction of change of the 
characteristics presented in Table 7-2. As explained in chapter 6 a new taxon called 
the outgroup (a hypothetical ancestral taxon added to the classification to help resolve 
any polarity issues) is added at this stage to simplify the process of polarisation. 
Hence the total number of taxa (strategy types) is now 16.
Chapter 6 explained two methods for polarising the characteristics, the ontogenic 
criterion and the outgroup comparison. In the case o f  the construction of the 
population cladogram these two methods were not used, because the data presented in 
Table 7-2 has an obvious and self-determined polarity. This is because for each 
characteristic shown in Table 7-2 there are two possible states, present or absent. The 
presence of a characteristic could denote any of the following, the development of a 
new technology (e g. computers), a key discovery (e g. DNA understanding), a new 
way of thinking (e g. interdisciplinary), or a change in the environment (e g World 
War II, new regulation). Since the presence of a characteristic is associated with 
something new it is considered to have a derived state (apomorphic). In line with this 
argument the absence of characteristic indicates an ancestral state (plesiomorphic).
7.4. S tep 3: Setting the polarity
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When classifying biological organisms this step (setting the polarity) is important 
and often assumptions are made about the polarity of the characteristics. As 
explained in the previous paragraph however, this is not the case when classifying 
organisational strategies at the population level This is because the absence of a 
characteristic is an ancestral state, while the presence is a derived state Yet, due to 
the importance of this step in the cladistic methodology was explained in this section
7.5. Step 4: Characteristic coding
So far the characteristics, their states and the direction of change o f  these states have 
been defined. Step four involves the conversion of the characteristic states into 
numerical symbols. The purpose of this step is to construct a matrix, which includes 
all the identified drug discovery strategy types (taxa), their characteristics and their 
states. As explained in chapter 6 this matrix is used for the construction of the 
cladogram.
As described in chapter 6 the method used by this research to code the characteristics 
is a binary approach with ‘0 ’ representing an absence (plesiomorphic state) of the 
characteristic and ‘ 1 ’ representing its presence (apomorphic state).
The full matrix listing the drug discovery strategy types, the characteristics, the 
characteristics’ states and codes is presented in Appendix A The first column of the 
matrix lists the strategy types that were identified in the historical account. The first 
row of the matrix of Appendix A lists the characteristic names and numbers When 
the value of a cell is 1 then the characteristic shown at the top of the column is present 
in the strategic configuration shown on the left of that row. When it is 0 the 
characteristic is not present
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7.6. S tep  5: Construct the cladogram
Steps one to four identified and defined strategy types, their characteristics, their 
states, polarity and codes. The fifth step of the construction o f the cladogram involves 
its actual construction. As opposed to the example given in chapter 6, the large 
number o f characteristics in this study make the construction o f  the cladogram too 
complex for the manual method described in section 6.2 7.5.1. Therefore, two 
computer software packages specially designed for cladistic analyses were used, 
PAUP and Phylip. Both packages process the data using a variety of algorithms to 
produce numerous potential cladograms. The key is to select the best fit cladogram 
by calculating and comparing three indices for each cladogram (treelength, 
consistency index, and retention index). The computation o f  these indices was 
undertaken using a software package called MacClade The primary functionality of 
this software is the comparison o f various cladograms (Maddison and Maddison, 
1992). The following sections present the application of these software packages to 
construct and select a population cladogram.
7.6.1. Phylip
Phylip stands for ‘Phylogeny Inference Package’ and the version used by this 
research is 3.57c. It is a DOS-based software and therefore all the data in the matrix 
(produced using Microsoft Excel format) needed to be transferred into a text only 
table (input file). Phylip consists of twenty-eight different algorithms to produce 
cladograms. These algorithms vary in their abilities, to handle different types of 
characteristics, to manipulate complex input files, and to compare cladograms The 
algorithm used to construct the cladograms for the drug discovery strategies (both 
population and organisation) is called ‘MIX’. As per the discussion in chapter 6, MIX
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is a general parsimony algorithm, which performs the Wagner and the Camin-Sokal 
parsimony methods The reason for using MIX is that it estimates phylogenies for 
discrete characteristics with two states (0 and 1).
The results of the program are automatically written to a file called the treefile. The 
treefile includes data about the best cladograms produced by the algorithm (Camin- 
Sokal or Wagner). The application o f  MIX provided two different treefiles one for 
each parsimony principle used (Camin-Sokal, and Wagner). Each treefile contains a 
set of very similar cladograms The treefile produced by the Camin-Sokal parsimony 
method included three cladograms, while the treefile produced by the Wagner 
parsimony method included five. The cladograms provided by each method are 
shown in figures Figure 7-3, Figure 7-4, and Figure 7-5. Characteristics 1 and 2 are 
not drawn on the cladograms because they are the characteristics distinguishing the 
outgroup branch from the unorthodox branch and are the same for all cladograms
7.6.2. PAUP
The second software used to construct cladograms was PAUP, which stands for 
Phylogenetic Analysis Using Parsimony, and is Macintosh based The main 
difference between the PAUP and Phylip is that the former allows the user to enter 
how many different cladogram combinations the program should test. Therefore, a 
large number could potentially result in the discovery of a better cladogram The use 
of this software should validate the cladogram obtained by Phylip by producing a 
similar branching arrangement The input file developed for Phylip was inserted in 
this software. The algorithm that this software uses to develop the cladogram is based 
on the Wagner method, also used by Phylip
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After running the program three cladograms were saved in the treefile. The 
cladograms are shown in Figure 7-6.
7.6.3. Selecting the optimal cladogram
So far three sets of cladograms have been constructed (11 cladograms). This stage 
involves analysing and testing these cladograms to select the optimal one. The 
optimal cladogram selected from this stage will provide the test bed for the validation 
of the hypotheses. Also this cladogram will provide a provisional list and 
classification that will help the collection of data for the construction o f the 
organisation cladogram in chapter 8.
Cladistic software utilises a number o f  different statistics to assess the quality o f the 
cladograms. The standard measures and the ones used in this thesis are the treelength, 
the consistency index (Cl) and the retention index (Rl) (see section 6 2.7 6). This 
section calculates and compares the three measures for each cladogram. A Cl equal 
to 1 indicates a perfect fit between the characteristics, the taxa, and a cladogram 
structure where there is no conflict at all Similarly, cladograms with higher retention 
indices are preferred, as this metric indicates more evidential support for the resulting 
groups.
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This comparison was conducted by the software package MacClade MacClade is a 
Macintosh based program that provides an interactive environment for exploring 
phylogeny (Maddison and Maddison, 1992). The benefit of using MacClade is that 
the cladograms may be manipulated by moving the branches and automatically 
searching for more parsimonious cladograms As the cladograms are manipulated 
MacClade calculates the cladogram statistics It also allows the automatic comparison 
of two treefiles
The three treefiles previously constructed were inserted into MacClade and the 
average indices are shown in Table 7-3.
Tabic 7-3 Statistical indices of cladograms
Index Wagner (Phyiip) Camin-Sokal (Phyiip) PALP
Consistency Index 0.79 0.79 0 79
Retention Index 0.92 0.92 0 92
Cladogram length 71 71 71
The optimal cladogram is the one with the highest consistency and retention indices, 
and the lowest cladogram length. The first conclusion that may be drawn by 
comparing the indices of the cladograms shown in Table 7-3 is that their values are 
identical for all cladograms. This suggests that the data set fits equally for all the 
cladograms constructed and that the data set is relatively stable The most 
parsimonious cladogram would represent the best summary of the data to hand and 
would thus be the preferred hypothesis of relationships among the study of taxa 
(Kitching et a l , 1998) (in this case drug discovery strategy types) Therefore, the fact 
that the data fits equally on all the cladograms implies that all the hypothetical 
relationships depicted on the cladograms of Figure 7-4, Figure 7-5, and Figure 7-6 
have equal probability of being correct. However, special care should be taken, as
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this could lead to conflicting results since more than one arrangement could be 
correct.
Before considering further why all indices have the same value, it is important to 
review the confidence of the data set. In fact, one of the reasons for the equal values 
of the different cladograms presented above could be the lack of significant cladistic 
structure (Kitching et al., 1998 p. 118). A cladistic analysis with significant cladistic 
structure is one where there is confidence that its results are not the by-product of 
chance. As argued by Archie and Felsenstein (1993), for a given data set, as the 
length of the most parsimonious cladogram increases, the confidence that one has in 
both the data and the cladogram decreases To address this confidence issue Archie 
and Felsenstein (1993) suggest using the length of random cladograms as an index to 
make comparisons with the most parsimonious cladograms already constructed They 
argue that if the length of the most parsimonious cladogram is significantly smaller 
than the mean value of the random cladograms then there is confidence in the data set.
The software package MacClade used for the calculation of the cladogram indices 
also allows construction of random cladograms. Ten cladograms were constructed 
randomly and their mean treelength (along with the retention and consistency indices) 
is shown in Table 7-4.
Tabic 7-4 Mean statistics for random cladograms
Treelength Consistency Index Retention Index
204 0.3 0.234__________________
The mean treelength of the random cladograms is 204 (Table 7-4) and is 
significantly higher than that of the cladograms constructed in the previous section 
(71 in Table 7-3). Similarly, the values of Cl (consistency index) and RI (retention
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index) o f the random cladograms are lower Therefore, it can be concluded that there 
is confidence in the data set and that the cladograms produced are not the product of 
chance. In summary, it can be argued that the data set contains significant cladistic 
structure.
Having addressed data confidence, the issue of the equal values of the statistical 
indices must be considered The cladograms depicted in Figure 7-4, Figure 7-5, and 
Figure 7-6 are very similar The difference between them is the arrangement of those 
drug discovery strategy types (taxa) at the top of the cladogram (see Table 7-5).
Table 7-5 Taxa that create different arrangements
Computer driven II
Partnerships and acquisitions
R&D concentration for niche markets (R&D niche
R&D concentration for innovation and competition
Outsourcing
Me-too _____
As explained in section 6.2.8, the aim of the construction of the population 
cladogram is to provide the following:
• A list of drug discovery strategy types and characteristics
. A provisional classification of these types
. A framework for assessing and demonstrating how the four hypotheses might be 
validated.
The process followed to construct the population cladogram has provided 15 strategy 
types and 57 characteristics as shown in Table 7-2 (page 218) and therefore the first 
aim has been met.
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With regard to the second and third aims of the construction of the population 
cladogram, a comparison of the structure of the cladograms reveals that the 
dissimilarities between the different arrangements are very small For instance, the 
taxon outsourcing in figure Figure 7-5 (b) (cladogram (e)) is shown as an ancestor of 
taxa R&D concentration fo r  innovation and competition, R&D concentration for  
niche markets, and Partnerships and acquisitions, while on the cladogram of Figure 
7-6 (b) is shown as an ancestor of R&D concentration fo r  innovation and competition, 
and Partnerships and acquisitions only. Such differences could be significant when 
studying biological organisms as they could trigger philosophical arguments about 
evolution. Ffowever, in the case of this research, where the cladogram is used to 
classify drug discovery strategy types and not to explore their order of evolution, such 
small differences are insignificant Therefore, any of the cladograms shown in Figure
7-4, Figure 7-5, and Figure 7-6 could provide a provisional classification of the drug 
discovery strategy types and characteristics (second aim), and could provide a 
framework for assessing how the four hypotheses might be validated (third aim).
To conclude this line o f  argument any cladogram from those shown in Figure 7-4, 
Figure 7-5, and Figure 7-6 is considered valid and appropriate within the scope of this 
research. As it is unpractical to refer to more than one cladogram, the one shown in 
Figure 7-6 (b) has been arbitrarily chosen and is shown enlarged in Figure 7-7.
One reason for the presence of such differences however, could be the fact that 
reports for the early evolution of the pharmaceutical industry are concise and 
consistent and thus, there are no conflicts on the order o f  appearance o f the drug 
discovery strategy types. However, such is not the case for the more recent periods 
Data sources are not yet as clear and sometimes are conflicting It is therefore likely
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that arrangements and hypotheses about the evolution of drug discovery strategy (i.e. 
the information contained in a cladogram) will also be vague
Another point to be addressed, is the fact that the consistency and retention indices 
are less than one. This is because characteristics 24, 47, 48, 49, 54, and 56 appear 
more than once on the cladogram i.e. their states change more than once As 
explained in section 6.2.7.6, in situations where the matrix is complex it is likely that 
some characteristics will arise more than once on a cladogram. This indicates that the 
data set is not 100% consistent with the proposed cladogram. In this case, although 
the multiple appearances of the characteristics reduce the cladogram’s technical 
consistency, it does not necessarily affect its theoretical validity. For instance, the 
presence of characteristic 47 (combinatorial chemistry) on the Science driven and the 
R&D concentration fo r  innovation and competition branches is meaningful 
Combinatorial chemistry has been a critical characteristic in the formation of both 
strategy types (Lesney and Miller, 2000). Therefore, as long as the researcher is 
aware of this, the cladogram may provide a useful framework for testing and 
validating hypotheses.
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Furthermore, comparing the indices calculated for the population cladogram with 
indices of other cladograms (see Table 7-6) it may be concluded that the cladogram is 
relatively consistent. That is, there is not significant difference between other 
cladograms and the one constructed in this chapter. A more detailed comparison of 
the cladograms is presented in section 9.4.1.
The following section describes each of the strategy types classified by the 
cladogram.
Tabic 7-6 Indices found in the literature
Source Reference Consistency index Retention index
The automotive Leseure, 1999 0.89 (not calculated)
cladogram 
The hand tool Leseure, 1999 1.0 (not calculated)
industry
cladogram
Electronics Fernandez, 2002 0.1 0.48
industry 
cladogram 
The population 
cladogram
0.79 0.92
7.6.4. Description o f  the population cladogram
The aim of the population cladogram is to classify drug discovery types. The drug 
discovery strategy types classified should correspond to drug discovery strategies 
adopted by one or more organisations i.e. each taxon shown on the cladogram should 
represent a population of organisations (hence the label population cladogram). The 
classification provided by the population cladogram will provide a test bed for the 
validation of the four hypotheses developed in chapter 5. Also, the drug discovery 
strategy types and their characteristics identified during the construction of the 
population cladogram provides a provisional list and classification that will help the 
collection of data for the construction of the organisation cladogram in chapter 8.
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7 6 .4  1. U n o rth o d o x  (U northodox)
Unorthodox drug discovery strategies are those that had no scientific reasoning The 
main characteristics of these strategies are 1 and 2 (herbals’ use and random 
discoveries with no scientific justification). These two characteristics are not drawn 
on the cladograms because they are the characteristics distinguishing the outgroup 
branch from the unorthodox branch and are the same for all cladograms Particularly 
present during the age of botanicals (pre 1800s) the unorthodox drug discovery 
strategies employed little or no scientific knowledge or technology The methods to 
discover new drugs included prayers, and beliefs in tradition. Any successful curing 
attempts had no scientific justification and were entirely coincidental. Naturally, 
there was a high degree of emergence present in this strategic type.
7.6.4.2. Individual efforts (Ind effort)
This type of strategy focused on the efforts of an individual A main characteristic in 
the formation of this type of strategy is the attack of the symptom (characteristic 3) 
Researchers did not understand disease aetiology, but began to focus their strategies 
on phenomena that accompanied disease. Although in this case scientific knowledge 
and technology are still absent this strategy type is less random than the unorthodox as 
the researchers were striving for some form of scientific breakthrough (Cause and 
effect) to cure the disease.
7.6.4 3. Technology dominated (Tech domin)
This strategy type was present when relevant technology was advancing and 
represents a significant change in type It is defined by eight new characteristics The 
industrial revolution (characteristic 4) and the microbial theory (characteristic 7) of 
disease are the principal characteristics of this taxon Microbial theory provided the
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scientists with a fundamental understanding o f  the diseases The strategies started to 
become more focused in that scientists attempted to attack the microbes rather than 
simply the symptoms.
The industrial revolution and its accompanying innovations in technology led to the 
development of sophisticated instrumentation, which indicated the path that drug 
discovery, would follow in the future. Another important characteristic o f this 
strategy was the introduction of government legislation (characteristic 10), which 
regulated the process of drug discovery. The other defining characteristics, are 5 
(homeopathy), 6 (chemical extraction), 8 (infectious diseases/vaccines), 9 (synthetic 
dyes), and 11 (organic chemistry and biochemistry)
7.6.4.4. Multi-disciplinary (Multidisc)
Scientific knowledge is often divided into subject areas, which can then be 
composed in a modular fashion to define larger pieces o f knowledge (Valle and 
Gambardella, 1993). The need to combine the various subject areas for the 
development of new drugs encouraged management of pharmaceutical organisations 
towards division of labour (characteristic 56) amongst individuals into specialised 
segments of the drug discovery process. A critical characteristic of this branch is the 
interdisciplinary thinking (characteristic 14) when for the first time disciplines such as 
physical chemists and physicists collaborated with biochemists and biologists to 
explore solutions. The other defining characteristics of the multi-disciplinary drug 
discovery strategy are the discovery of insulin (characteristic 12), the development of 
antibacterial (characteristic 13), the introduction of federal regulation (characteristic 
15), and instrumentation development (characteristic 16).
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7 .6 .4  5. D isease  fo cu sed  (D iseasefoc)
This is one of the first strategic types where the discovery of a new drug is clearly 
influenced by non-planned environmental conditions such as the World Wars 
(characteristic 18) and the fight against malaria (characteristic 19). Characteristics 
such as these have driven the management of pharmaceutical organisations to seek 
research patterns that focus on specific diseases Also, this strategy type encompasses 
the introduction of computer-aided design (characteristic 21), while the large-scale 
production of vitamins (characteristic 18) and antibiotics (characteristic 17), mainly to 
satisfy the needs of the wars, also began
7.6.4 6. Knowledge and instrumentation focused (K & 1 focu)
Further understanding of human biology together with the discovery of DNA 
(characteristic 25) and the progress in computing technology (characteristic 24) are 
the main characteristics of this strategy type. Another key characteristic o f  this 
strategy is the instrumentation wave (characteristic 23) where a range of instruments 
became available to scientists to carry out more effective research
The implementation of this type of strategy was enhanced by funding for drug 
discovery provided by the government (characteristic 22) and again by the world wars 
(characteristic 18) Government funding provided academia with the resources for 
carrying out basic research (i.e. research that identifies chemical and/or biological 
properties of a newly synthesised or previously known substance). This research 
became applied when a pharmaceutical organisation identifies a therapeutic use for 
the new substance The two world wars exerted pressure on pharmaceutical 
organisations to tackle the diseases that affected the soldiers
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7 .6 .4 .7 . Science driven (Science d r)
The science driven drug discovery strategies are those strategies that combine the 
characteristics o f  the previous strategies with biomedical instrumentation 
(characteristic 27) and powerful computers (characteristic 28). In addition, 
breakthroughs in disease aetiology (characteristic 29) meant that scientists were able 
to conduct research that focused directly on the disease rather than on the symptom
7.6.4 8 Biotechnology (Biotechnol)
The biotechnology drug discovery strategy type applies the technology 
characteristics genetic engineering (characteristic 30), and the introduction of 
computing technology (characteristic 24) supported by DNA sequencing 
(characteristic 32). Naturally, these strategies are primarily employed by 
biotechnology organisations This is also one of the first strategic types where drug 
discovery is seen as a commercially valuable process. Small entrepreneurial 
biotechnology organisations (characteristic 31) such as Genentech, were founded that 
aimed solely at the discovery of active compounds
7.6.4.9. Computer driven I (Computer I)
The computer driven drug discovery strategy types developed in two phases This 
type refers to the first phase that was triggered by the affordability of information 
technology and the increase in computational performance (characteristic 35). 
Information technology is used in mainstream research, as most of the drug discovery 
laboratories are equipped with fast computers This technology enabled researchers to 
perform complex computations and to build and to manipulate chemical structures in 
a direct and simple manner
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Also, during the development of this strategy chemotherapy joined the ranks of other 
routine treatments (characteristic 33) and reverse transcriptise was also developed 
(characteristic 34) a technique which would prove useful in the understanding of 
AIDS
7.6.4.10. Computer driven II (Computerll)
The second computer driven drug discovery strategy type is differentiated from the 
first, with the automation of the laboratories and the use of robotics. Following the 
widespread implementation of this strategy type by pharmaceutical organisations, 
computers became an integrated part of drug discovery research (characteristic 42) 
The computational power now available to scientists helped the development of 
techniques and technologies such as rational drug design (characteristic 47), genetic 
algorithms (characteristic 39), fuzzy logic (characteristic 40), combinatorial chemistry 
(characteristic 48), high throughput screening and robotics (characteristic 49).
7.6.4.11. Partnerships and acquisitions (Part/Acq)
Partnerships and acquisitions is a strategy employed by the management of 
pharmaceutical organisations to enhance the discovery of new drugs by sharing 
knowledge and technology with other organisations Acquisitions imply the take-over 
of one organisation by another Partnerships on the other hand are focused on the 
sharing of knowledge and technology In fact partnerships could exist both between 
two competing organisations, but also between organisations and organisations such 
as research associations and academic institutions. A key characteristic of this 
strategy is limited discovery (characteristic 41). Most biotechnology organisations 
were pursuing a very limited number of potential drug treatments compared to that of 
pharmaceutical organisations. This reduced the probabilities of the discovery of new
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drugs and forced several small biotechnology organisations to seek funds from larger 
corporations to help them to survive which in turn encouraged the trend for formation 
of multinational organisations (characteristic 53). The global nature o f  this strategy 
has been strengthened by division of labour (characteristic 56).
7.6.4.12. R&D concentration for innovation and competition (R&D 
in&com)
The characteristic that primarily differentiates this strategy from previous ones is the 
trend for the formation of multinational pharmaceutical organisations (characteristic 
53). Large pharmaceutical organisations spend large amount of effort and resources 
to develop the ability to innovate and achieve a sustainable competitive advantage 
The introduction of a blockbuster drug could provide such an advantage 
Technologies such as rational drug design (characteristic 47) and combinatorial 
chemistry (characteristic 48) allow the management of pharmaceutical organisations 
to better guide their drug discovery process. The degree of randomness that this 
strategy encompasses is further reduced as the failure to deliver new products 
translates into high costs. Therefore, pharmaceutical organisations cannot afford to 
rely on serendipity as much as they used to
7.6.4.13. Me-too (Me-too)
Me-too strategies are employed by organisations whose research has not been as 
effective as their competitors’. In situations like these, organisations imitate their 
competitors’ products, whilst avoiding infringement of patents The imitation o f these 
drugs can take several forms. Patent laws protect a new product for 17 years 
Therefore, the first form of imitation is the production of a drug once its patent has 
expired These types of drugs are known as generics (characteristic 52). The second
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form o f  imitation is through the reformation of other organisations’ rejected research 
One organisation’s rejected research could be another’s success. Several 
organisations look for opportunities such as these The third form of imitation is 
through the production of a drug, which is similar to the drug of another organisation 
This form is associated with the development of those new drugs, which in reality are 
modified versions of existing drugs containing the same active ingredients as those 
already in the market. In fact, according to a survey conducted by USA’s National 
Institute for Health Care Management (NIHCM) nearly two-thirds of prescription 
drugs approved in the 1990s belonged to this category
7.6.4.14. Outsourcing (Outsourcin)
High specialisation in technology fields such as genomics (characteristic 46) and 
proteomics (characteristic 50) has forced those organisations that cannot cope with the 
demand of research to outsource all or parts of it The strategy of partnerships and 
acquisitions previously discussed focuses on the acquisition of technology and 
knowledge of other organisations. Outsourcing still focuses on the utilisation of 
another organisation’s capabilities, and high specialisation (characteristic 43), but the 
difference is that the motivation for using another organisation’s capabilities is that 
the outsourced tasks require less specialisation, but more time and resource.
7.6 4.15. R&D concentration for niche markets (R&D niche)
This type o f strategy is adopted primarily by medium sized organisations 
(characteristic 54) These organisations identify a niche in the market and focus their 
research and capabilities towards this niche (e g Syntex Corporation) This strategy 
type also applies to those organisations pursuing a generics strategy where they 
develop a competitive advantage by being the first to introduce to the market a drug
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form of imitation is through the reformation of other organisations’ rejected research 
One organisation’s rejected research could be another’s success. Several 
organisations look for opportunities such as these The third form of imitation is 
through the production of a drug, which is similar to the drug of another organisation 
This form is associated with the development of those new drugs, which in reality are 
modified versions of existing drugs containing the same active ingredients as those 
already in the market. In fact, according to a survey conducted by USA’s National 
Institute for Health Care Management (NIHCM) nearly two-thirds of prescription 
drugs approved in the 1990s belonged to this category.
7.6.4.14. Outsourcing (Outsourcin)
High specialisation in technology fields such as genomics (characteristic 46) and 
proteomics (characteristic 50) has forced those organisations that cannot cope with the 
demand of research to outsource all or parts of it. The strategy of partnerships and 
acquisitions previously discussed focuses on the acquisition of technology and 
knowledge of other organisations. Outsourcing still focuses on the utilisation of 
another organisation’s capabilities, and high specialisation (characteristic 43), but the 
difference is that the motivation for using another organisation’s capabilities is that 
the outsourced tasks require less specialisation, but more time and resource
7.6.4 15. R&D concentration for niche markets (R&D niche)
This type o f  strategy is adopted primarily by medium sized organisations 
(characteristic 54). These organisations identify a niche in the market and focus their 
research and capabilities towards this niche (e g Syntex Corporation) This strategy 
type also applies to those organisations pursuing a generics strategy where they 
develop a competitive advantage by being the first to introduce to the market a drug
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whose patent has expired (characteristic 55). The degree of emergence o f this type of 
strategy is further reduced as the organisation focuses on a specific aspect of the 
research.
7.7. Review o f  data and results
This section considers the validity of the data and the resulting cladogram. It is 
important to note that the construction of the population cladogram (Figure 7-7) has 
the following potential limitations.
D ata exhaustiveness To construct the population cladogram the chapter explored 
the factors that have affected the change of drug discovery strategy types and 
categorised them under the four headings that were identified and justified in chapter 
4. These are technology, knowledge, organisation, and environment (see Table 7-2). 
As argued earlier in this chapter, the complete history of the pharmaceutical industry 
is long and thus, innumerable characteristics may exist. Although every effort has 
been made to include the defining characteristics, it is unavoidable that some 
characteristics will have been omitted The collection of data for the construction of 
the organisation cladogram in chapter 8 partly addresses this limitation.
Data collection valid ity . As explained in chapter 6, the collection o f data for the 
construction of a cladogram is subject to a number of criteria. These criteria should 
ensure that the collection process is both consistent and objective. These criteria 
however are not foolproof. Chapter 6 described how the selection o f a good cladistic 
characteristic is often a value judgement guided by research design and objectivity. 
Therefore, it is expected that the construction of the cladogram is subject to a degree 
of subjectivity. If however, all or some of the groupings identified on the population 
cladogram are also present in the organisation cladogram, then the confidence in the
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selection process will be increased This is because any implicit assumptions taken 
during the data collection process will be validated
Classification robustness The consistency and retention indices of a perfect 
cladogram would have a value of one. This is not the case with the population 
cladogram Nevertheless, as explained in section 7.6.3, this imperfection does not 
affect the theoretical validity of the cladogram.
7.8. Conclusions
The construction of the population cladogram had three aims. The first was to 
provide a list o f drug discovery strategy types and their defining characteristics In 
total 15 strategy types and 57 characteristics were identified as shown in Table 7-2 
(page 218). These strategy types and characteristics will be used in chapter 8 to help 
the collection o f data for the construction of the organisation cladogram. The second 
aim was to provide a provisional classification of these populations to assess and 
demonstrate how cladistics might help to reveal how an evolutionary and 
classification approach can be used to study drug discovery strategies. The cladogram 
shown in Figure 7-7 (page 233) provides such classification The third aim of the 
cladogram was to provide a framework to demonstrate how the four hypotheses 
(developed in chapter 5 to address the third research question) could be validated 
The discussion provided in this section explains how the population cladogram 
advances this research towards validating the four hypotheses.
Similar to the classification provided by Mintzberg and Waters (1998) and discussed 
in chapter 4, it is argued that the strategy types classified by the population cladogram 
vary along the spectrum emergent to focused. Emergent strategies are those patterns 
realised despite, or in the absence, o f  intentions (Mintzberg and Waters, 1998 p 20).
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Therefore, within this context, the emergent drug discovery strategies are those that 
were practiced before and during the early years of the 20th century and shown on the 
left hand side of the cladogram (e g. unorthodox and individual efforts). As available 
knowledge and technology increased, drug discovery strategies became more focused 
as shown in Figure 7-8 (e g. science driven and me-too)
Evolution of Strategies
• Unorthodox
• Individual 
efforts
Technology dominated 
Multidisciplinary research 
Disease focused 
Knowledge and 
instrumentation focused 
Science driven 
Biotechnology 
Computer driven I 
Computer driven II
R&D concentration for niche
markets
Me-too
Partnerships/Acquisitions 
Outsourcing 
R&D concentration for 
innovation and competition
Figure 7-8 Evolution of strategics for drug discovery
It would be delusive to argue that the more focused strategic types discussed above 
have eliminated any emergence. Although drug discovery strategies still encompass a 
degree of emergence, advances in technology and knowledge aid scientists to better 
understand their target and consequently, are better equipped to guide their research 
In addition, the escalating costs o f  research means that pharmaceutical organisations 
cannot afford to leave their research to chance and continuously seek less emergent 
strategies.
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7.8.1. Hypotheses validation
The first hypothesis states that there are similar drug discovery strategies employed 
by different pharmaceutical organisations to form  populations whose (the 
population’s) size follows a concave pattern o f growth and decline. The population 
cladogram is not organisational specific and therefore, it is not possible at this stage to 
draw conclusions about the drug discovery strategies o f individual organisations (this 
issue is tackled in chapter 8) However, as explained in chapter 6 the drug discovery 
strategy types classified by this cladogram correspond to drug discovery strategies 
adopted by one or more organisations and thus, the population cladogram represents 
populations of drug discovery strategies. Therefore, each drug discovery strategy 
branch should represent one or more organisations that have implemented that 
strategy into their system Consequently, the construction of the organisation 
cladogram in the next chapter (whose aim is to be organisation specific) should 
identify groupings of strategies that match all or some of the branches of the 
population cladogram If this is true then the first part of the hypothesis (there are 
similar drug discovery strategies employed by different pharmaceutical organisations 
to form populations) will be validated. The size of these groupings or populations 
will be the number of organisations that are included in each branch. If the size of the 
population is small when the population emerges, then rapidly increases in size and 
then stabilises or declines, then the second part of the hypothesis will be validated (the 
population ’.v size follows a concave pattern o f  growth and decline)
The second hypothesis suggests that within a drug discovery population, there are 
strategies that differ to each other in terms o f  their characteristics and their fitness. 
As discussed above the population cladogram is not organisation specific and 
therefore, it is not possible at this stage to compare the configurations of drug
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discovery strategies of individual organisations as required by this hypothesis 
However, each drug discovery branch on the cladogram should represent one or more 
organisations that have implemented that strategy into their system As explained in 
chapter 4 ultimately, each organisation is unique and thus has a unique configuration 
of characteristics. The construction of an organisation cladogram should allow the 
comparison of these organisations and conclusions to  be drawn about the differences 
and similarities o f  their drug discovery strategies and their fitness (i.e the condition 
where the configuration of an organisational strategy matches that of the environment 
and the frequency of its characteristics appearing in future strategies is potentially 
high).
The third hypothesis suggests that those characteristics o f  drug discovery strategies 
credited with successful drug discovery performance are likely to appear in future 
strategic configurations, while those characteristics that are not are likely to be 
absent. The data collected for the construction o f  the population cladogram has been 
arranged in chronological order as shown in Table 7-2. Therefore, it is possible to 
observe from the cladogram how the third hypothesis could be validated by 
identifying the presence of characteristics in past and future strategic configurations. 
For instance, characteristic 14 (first interdisciplinary thinking) first appeared in the 
1920s and 1930s. As explained in section 7.6.4.4 the progress of scientific knowledge 
forced pharmaceutical organisations to think multidisciplinary i.e to combine 
scientists from disciplines such as physical chemistry, biochemistry, and biology to 
collaborate for the discovery and development of new drugs. Since then, 
interdisciplinary thinking has increased the performance of drug discovery (Harvey, 
1995) and is thus present in future strategic configurations such as biotechnology and 
science driven. In the contrary characteristic 2, random discoveries/no scientific
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justification, which belongs at the unorthodox branch, is not present in future strategic 
configurations. Drug discovery strategies based on dogmas and religious beliefs did 
not advance the practice of drug discovery. In fact, as explained in section 7.3.1.1, on 
many occasions this acted as a barrier. Therefore, this characteristic is absent from 
the future strategic configurations shown on the right hand side o f the cladogram
The fourth hypothesis suggests that with a change in the environmental conditions 
those drug discovery strategies that remain are the ones whose strategic 
characteristics are favoured by the environment The proposed way of validating this 
hypothesis is by examining the response of drug discovery strategies following a 
significant environmental change. The history of drug discovery offers two obvious 
and distinct events. The first is the two world wars (characteristic 18) and the second 
is the introduction of drug regulation (characteristic 15). The groupings of the 
population cladogram do not show any particular change with the appearance of these 
characteristics. This may be due to the fact that the population cladogram does not 
group drug discovery strategies of individual organisations. However, this is not the 
case with the organisation cladogram (presented in chapter 8) that uses data from 
pharmaceutical organisations to classify their drug discovery strategies. As will be 
shown on the organisation cladogram these two characteristics do affect the formation 
of populations of drug discovery strategies.
To conclude, in addition to the first two aims, the population cladogram partly 
addresses the third aim by providing a framework for demonstrating how the four 
hypotheses for the evolution of drug discovery strategies developed in chapter 5 could 
be validated. To complete this aim chapter 8 presents the construction of the 
organisation cladogram that will identify groups o f pharmaceutical organisations that
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8. C O N S T R U C T IO N  O F  O R G A N IS A T IO N A L  C L A D O G R A M
8.1. Introduction
To address the third research question (How can an evolutionary and classification 
approach be used to study drug discovery strategies?) chapter 5 developed four 
hypotheses about the evolution of drug discovery strategies Chapter 6 explained how 
cladistics would be used to validate these hypotheses It was argued that two cladistic 
classifications (cladograms) would be constructed. The unit of analysis of both would 
be drug discovery strategies as defined in chapter 4. The first (population cladogram) 
was constructed in chapter 7 and used data from available historical secondary 
sources to identify and classify types or forms o f drug discovery strategies The 
second (organisation cladogram) is constructed in this chapter and uses data from the 
pharmaceutical industry to identify and classify drug discovery strategies found in 
individual organisations. As explained in section 6.2.8 the difference between this 
and the population cladogram is the level of analysis. The taxa on the branches of the 
former will be drug discovery strategy types (classes of strategies that share a 
common profile along conceptually distinct characteristics), while that of the latter 
will be organisational strategies As argued in chapter 6, which explained the process 
for constructing cladograms, the benefits of this approach are that the population 
cladogram will provide a test bed for the validation of the hypotheses and that its 
construction will provide a provisional list and classification that will help the 
collection o f data for the construction of the organisation cladogram. In addition, as 
explained in section 7.8.1, the construction of the organisation cladogram will address 
the following issues that the population cladogram did not Firstly, the organisation 
cladogram will allow the comparison of drug discovery strategies and their fitness of
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individual organisations and thus, advance the research towards validating the first 
and second hypotheses. Secondly, it will allow examining the characteristics that are 
favoured by the environment and thus advance the research towards validating the 
fourth hypothesis.
The aim o f this chapter is to explain the construction of the organisation cladogram. 
Similar to chapter 7 the structure of the chapter is based on the process followed to 
construct a cladogram as explained in chapter 6 (see Figure 6-3).
The fourth research question (What are the characteristics of the fittest drug 
discovery strategies?) requires the identification of the characteristics of the fittest 
drug discovery strategies i.e. those drug discovery strategies whose configuration 
matches that o f the environment and the frequency o f their characteristics appearing 
in future strategies is potentially high As explained in chapter 6 the process of 
constructing the organisation cladogram will also address this research question.
Therefore the objectives of this chapter are:
• To validate the drug discovery strategy types classified by the population 
cladogram
• To validate the four hypotheses, and
• To identify the most dominant characteristics i.e. identify the configuration 
of the fittest strategy.
8.2. Step 1: Select a clade
As explained in chapter 7 this step involves defining the area of interest and unit of 
analysis. Similar to the construction of the population cladogram the unit o f  analysis 
for the organisation cladogram is drug discovery strategies as defined in chapter 4
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However, whereas the population cladogram classified drug discovery strategy types 
(i.e. classes o f  strategies that share a common profile along conceptually distinct 
characteristics) the organisation cladogram classifies drug discovery strategies of 
individual organisations. Therefore, the clade in this case consists o f the drug 
discovery strategies of individual organisations. The construction of the population 
cladogram has provided a list o f drug discovery strategies types. As argued in chapter
6 the taxa of the population cladogram (constructed in chapter 7) should correspond to 
drug discovery strategies adopted by one or more organisations i.e each taxon shown 
on that cladogram should represent a population or cluster of organisations. The 
construction o f  the population cladogram (chapter 7), focused on the drug discovery 
strategy types o f  the last two centuries. To maintain consistency between the two 
cladograms, the construction o f the organisation cladogram will focus on individual 
pharmaceutical organisations that have existed (but do not necessarily exist today) 
over the last tw o centuries.
8.3. Step 2: Data collection
This step involves the collection of data that will establish the relationships between 
drug discovery strategies of organisations and the characteristics identified in chapter
7 and listed in Table 7-2. Although the unit o f analysis for the construction of the two 
cladograms (population and organisation) are the same (drug discovery strategies), 
the type of data and the collection process are not. The data collected in this case 
focuses on individual organisations as per the aims and objectives o f the organisation 
cladogram.
An exhaustive classification o f drug discovery strategies of individual organisations 
would require the inclusion of all pharmaceutical organisations that have existed
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during the last two centuries. However, equally valuable results may be deducted 
from a well designed sample (Czaja and Blair, 1996, Thompson, 2002). Also, a 
sample could be more efficient and less expensive than a census i.e. an exercise that 
attempts to include every element or member of a population (Czaja and Blair, 1996). 
Therefore, to construct the organisation cladogram the data collection process uses 
random sampling.
Sampling consists of selecting some part of a population to observe or to classify. 
This permits estimation about something for the whole population (Thompson, 2002) 
In this case the term population refers to all organisations that have existed in the 
pharmaceutical industry over the last two centuries
The size of a sample depends on a number of things such as the research design 
being used, if hypotheses are being tested, and the size o f  the differences between two 
variables. With simple random sampling (as is the case with the construction of the 
organisation cladogram) an approximate size of the sample n is given by the 
following equation (Thompson, 2002):
Equation 8-1
Where:
N  is the size of the population
d 2 is the confidence interval and refers to the margin of error that is tolerated 
The only way to avoid a sampling error is by including all the members of the 
population (i.e. n=N).
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<t 2 is an approximation of the population variance i.e. the standard deviation 
of the population and is usually provided by previous data
z 1 is the square value of the standard deviation score that refers to the area 
under a normal distribution of variables. The value o f z is set by the researcher and 
expresses the probability level of the sample results i.e. in how many repeated 
samples of 100 that total the same size as the sample n, the population value is likely 
to fall within the specified confidence interval d. One standard deviation includes 
about 68% of the sample value and its score is 1.0, two standard deviations include 
about 90% of the sample values and its score is 1 64, and three standard deviations 
include about 99% of the sampled values and its score is 2.58 (Blank, 1980).
When N  is large relative to the sample size, the finite population correction f 1 -  j  
is close to 1 and thus the sample size is given by:
Equation 8-2
This research is not limited to a geographical area nor to a certain moment in time 
and therefore it could be assumed that the size of the population is large relative to the 
size of the sample. Therefore, the size of the sample will be calculated by Equation 
8- 2 .
The values of the variables of Equation 8-2 are estimated as follows
8.3.1. Confidence interval: d
The only way to estimate a population value without a sampling error (i.e d= l) is to 
include every element of the population (Czaja and Blair, 1996). As was argued due
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to limited time and resources, this is not possible and thus a margin o f error to be 
tolerated has to be defined. As argued by (Czaja an Blair, 1996) this value is set by 
the researcher. A reasonable confidence interval is 0.1 (Czaja and Blair, 1996). This 
means that margin o f error tolerates is set at ±10% .
Therefore,
d  = 0.1
8.3.2. Population variance: cr1
This value is the standard deviation of the population and is usually provided by 
previous data when available (Thompson, 2002). Due to the originality of this 
research no such data is available in the literature other than that used of the 
construction of the population cladogram and presented in chapter 7 of this thesis 
Therefore, to obtain an approximation of this value the standard deviation of the 
matrix constructed for the population cladogram (included in Appendix A) will be 
calculated
The standard deviation a  is given by:
l » Z * 2 - ( Z * ) 2
Equation 8-3
Therefore, the standard deviation o  of the values included in the data matrix of 
Appendix A is:
a  * 0.499
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8.3.3. Probability level: z 2
As argued by Czaja and Blair (1996) the values of z is also set by the researcher To 
ensure that the population values are included in the sample, the probability level is 
set at 90% (which is also a reasonable probability level as argued by Czaja and Blair, 
1996). That is to include the population value in 90 out of every group of 100 
samples o f  the same size. Thus,
Therefore, the required size of the sample is 67 organisations.
8.3.4. Selection o f  organisations
As explained earlier the organisations which are eligible for this research are not 
limited to one geographical area nor to a moment in time. Therefore, there is a 
plethora of organisations to choose from The only limitations for the inclusion of an 
organisation in this research were that they should carry out research in the area of 
drug discovery.
The next task in the selection of organisation is to find the sampling frame i .e. the 
lists of resources that contain the elements of the defined population (Czaja and Blair, 
1996). Three pharmaceutical specific directories were used for this purpose and listed 
in Table 8-1. The reason why three directories were used was to overcome the 
following problems arisen when the frame is a list as reported by Czaja and Blair 
(1996).
z = 1.96
Therefore, the sample size is:
(l.64)2(0.499)2
(o i)2
=> n  = 66.9 =>
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• The list could contain units that are not members o f  the defined population. 
The use of multiple directories allows the cross reference of information
• Information about individuals or units on the list may not be accurate. The 
use of multiple directories allows the validation of the information.
• Information about individuals or units on the list could be missing. Missing 
information of one directory may be filled in with information from another 
directory.
Table 8-1 Pharmaceutical directories
Directory name Web address Description
Drug Info Net w w w .d rua in fone t.com Drug InfoNet contains 
information to healthcare and
pharmaceutical topics on the 
Internet. It provides a wide 
range of healthcare 
information. It is a free 
service that aims at providing 
education as consumers and 
healthcare professionals
InPharm w w w .D ha rm w eb .ne t Pharmvvcb is an online 
community of pharmaceutical 
and healthcare-related
professionals with 
approximately 25,000 self- 
registered users.
Pharmaceutical and w w w .D ha rm a -lex icon .com T h is  d ire c to ry  p ro v id e s
medical abbreviation m e d ica l s e a rch  too ls  n ee de d
directory to  find  in fo rm a tion  on the 
Internet.
2 5 6
T he se lec ted  o rg an isa tio n s  a re  listed in Table 8-2.
Tabic 8-2 List of organisations
Abbot Laboratories Advanced biotechnology ltd
American Home Products Amgen
AstraZeneca Bayer
Aventis Schwarz pharma
Baxter International Bene-Arzneimttel
Bristol Myers Squibb Biogen
Ciba Geigy Datex-Ohmeda
Eli Lilly Vertex Pharmaceuitcals
Fujisawa Britannia pharmaceuticals
Genentech Celltech
Genetics Institute ICN pharmaceuticals
Glaxo Glaxo Holdings
GlaxoSmithkline Glaxo Wellcome
Marion Astra
Merck Zeneca
Miles Laboratories Johnson & Johnson
Mylan Laboratories Tanox
Novartis Aegis pharmaceuticals
Novo Alliance pharmaceutical
Pfizer SmithKline Beecham
Pharmacia Wellcome
R P Scherer Upjohn
Roche Takeda
Rorer Group Menarini
Roussel Uclaf Orion Pharma
Sandoz Zila Pharmaceuticals
Sankyo Remington
Sanofi-Synthelabo King pharmaceuticals
Schering-Plough Gate pharmaceuticals
Searle Ferring pharmaceuticals
SmithKline Beckman Drogsan
Sterling Drug Inc. Cadila pharmaceuticals
Syntex corporation Dimethaid
Axcan Scandipharm
The process followed to collect the data for the construction of the organisation 
cladogram is outlined in the flowchart of Figure 8-1
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Figure 8-1 Process for determining characteristics
All surveys are limited by time and resource constraints and thus consistent data for 
36 organisations were found This means that the margin of error increases If all the 
variables are left constant in Equation 8-2 the margin of error for a sample of 36 
organisations becomes:
n  = ■ >d = ■ d  =
f(l.96)2(0 499)2 
36
■ d  = 0 16
Therefore, the confidence interval now becomes ±16%
258
T he o rg an isa tio n s  th a t d a ta  w a s  co llec ted  from  a re  show n in table T a b le  8-3
Tabic 8-3 Revised list of organisations
A b b o t L a b o ra to r ie s M ylan L aboratories
A m erican  H om e P roduc ts Pfizer
A straZ eneca U pjohn
A ventis Bristol M yers Squibb
B ax te r In te rna tiona l Searle
C iba Geigy Sanofi-Synthelabo
E li L illy W ellcom e
F ujisaw a Sankyo
G cnentech Sm ithk linc  Beckm an
G enetics Institu te P harm acia
M arion T akeda
M erck M iles L aboratories
N ovartis Schering-P lough
Roche G laxoS m ithk linc
R orer G roup R.P. S cherer
R oussel U claf Novo
S andoz Sterling  D ru g  Inc.
Syntcx corpora tion G laxo
8.3.5. Selection o f  characteristics
The process of constructing the cladogram in chapter 7, allowed the working 
definition of drug discovery strategy (presented in chapter 4) to be developed into a 
classification of strategy types and the relationship between the types, and their 
defining characteristics. To ensure research consistency, the characteristics used to 
construct the population cladogram form the basis of the data collection for the 
organisation cladogram. As discussed in sections 8.1 and 8 2 the unit of analysis is 
the same for both cladograms, the difference is the source of data and the level of 
analysis. The population cladogram (chapter 7) used historical literature (i.e. 
literature that reports the steps that people and organisations have taken to understand 
how diseases occur and how medicine, vaccines, dietary materials, anaesthetics, 
antiseptics, and other medical materials came to be invented and used (Weatherall, 
1990)) to classify drug discovery strategy types. As will be explained the
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organisation cladogram uses data about pharmaceutical organisations to classify drug 
discovery strategies of individual organisations.
The construction of the population cladogram in chapter 7 provided 57 
characteristics of 15 drug discovery strategy types. The manner by which the 
characteristics are used for the construction of the organisation cladogram is by 
linking them with organisations during the data collection process (outlined in Figure
8-1). This means that the collection of data for each organisation will focus on 
identifying whether an organisation has acquired the characteristics used for the 
construction of the population cladogram and listed in Table 7-2, or not.
Although the above process should reveal the drug discovery strategies of the 
organisations within the context defined in this thesis, it is anticipated that the 
collection process will identify several more characteristics. This is due to two 
reasons. As explained in chapter 4, each organisation tries to achieve competitive 
advantage by developing idiosyncratic capabilities (Barney, 1991, Porter, 1980). 
Therefore, characteristics unique to each organisation should exist which are not 
necessarily included in the list of characteristics of the drug discovery population 
cladogram. The second reason is that, as explained in chapter 7, the list of 
characteristics is not exhaustive. Therefore, the collection o f data about individual 
organisations should reveal more characteristics. This is also supported by McCarthy 
et al (1997) who argue that characteristic selection is not a process of choosing 
available characteristics from a reference list, it is a process o f discovering which 
characteristics are responsible for evolutionary change, and the role of individual 
characteristics in the change. Hence, the list o f characteristics in Table 7-2 will serve 
as a very good starting point for the collection of data for the construction of the 
organisation cladogram.
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A note should be made at this stage with regard to the point in time when the data 
was collected for the drug discovery strategy o f each organisation As explained in 
chapter 4, this thesis adopts an evolutionary perspective for examining strategic 
change In accordance with this perspective a strategic configuration at any point in 
time depends on the evolutionary and co-evolutionary paths an organisation has 
followed throughout its history (Teece et al. 1997, Eisenhardt and Martin, 2000, 
Spanons and Lioukas, 2001). As will be explained the data included for each 
organisation spans from the moment it was introduced until either the date of its death 
(usually due to a merger or acquisition) or the date the data collection took place 
Therefore, the configuration of the organisations’ drug discovery strategies included 
on the cladogram should take account of the organisations’ evolutionary and co- 
evolutionary paths and the point in time when the data was collected should not affect 
the research
The data collected was principally from two publicly available sources, historical 
archives (Kepos, 1995), and organisation annual reports The historical archives 
provided data about the main milestones on the history of organisations. The 
organisation annual reports provided information only on the therapeutic areas 
organisations are undertaking research on In addition, several other sources were 
obtained including the history of Glaxo reported in two books by Davenport-Hines 
and Slinn (1992) and by Jones (2001), and the history of Pfizer reported in a book by 
Rodengen (1999). A list of the organisation literature used is shown in Table 8-4
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Tabic 8-4 List of organisation literature
Organisation Name Name of literature Contacted during 
validation
AstraZeneca A-Z: evolution of a medicine 
Annual report, 2001
Yes
Glaxowellcome Key Facts, 1999 
Annual report, 2000 
Jones, E., 2001, The business o f  
medicine: the extraordinary history o f 
Glaxo, a baby food producer that 
became one o f the world's most 
successful pharmaceutical 
organisations, Profile books, London 
Davcnport-Hines, R.P.T., Slinn, J., 
1992, Glaxo: A History to 1962, 
Cambridge University Press,
Cambridge
Yes
Novo Group Charter, 2001 
Annual report, 2000
No (Group of 
organisations)
Roche Roche in brief, 2001 
Annual report, 2000
Yes
Schering Plough Product pipeline, 2002 Yes
Abbott Laboratories Annual report, 2001 Yes
Wyeth (AHP) Annual report, 2001 Yes
Aventis Annual report, 2000 Yes
Baxter Annual reports, 1996-2000 Yes
Bristol Myers Squibb Annual report, 1999 No
Gencntech Annual report, 2000 No (biotechnology)
GSK Product development pipeline, 2001 Yes
Elli Lilly Annual report, 2000 Yes
Merck Annual report, 1999 Yes
Mylan Annual report, 2001 Yes
Novartis Annual report, 2001 Yes
Pfizer Annual report, 2001
Rodcngcn, 1999 (ISBN: 0945903375)
Yes
Pharmacia Annual report, 1998 Yes
Sankyo Flistory, 2001
Innovative new drugs, 2001 
Review of operations, 2001
Yes
Sanofi-Synthclabo Annual report, 2000 Yes
Takcda Annual report, 2001 Yes
Fujisawa Annual report, 2001 Yes
Miles laboratories Annual report, 2001 No (Generics)
The International directory of histories (Kepos, 1995) was also used for the construction 
of the organisation cladogram
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To ensure that there were limited inconsistencies, (e g. omitting therapeutic areas) in 
the selection of the characteristics from these sources, the following criteria were 
imposed in addition to the criteria suggested by Leseure (1998) and Fernandez (2002) 
and presented in chapter 6:
1 Drug discovery strategies were described in chapter 4 as business strategies 
Therefore the selected characteristics must be such that have a direct effect on 
the business level of strategy. This criterion was imposed, because on many 
occasions the future of pharmaceutical organisations has been influenced by 
factors such as political occurrences and strategic financial investments by 
senior management in areas such as manufacturing and marketing. Unless 
these factors have influenced the drug discovery process of an organisation 
they were not included in the cladogram. For instance, the world wars have 
been a crucial factor in the formation of drug discovery strategies (a detailed 
description of the effect of the wars on drug discovery is included in section 
8 8.1.1). Therefore, the wars have been included as a characteristic where 
appropriate.
2 Their effect must influence the evolutionary paths of drug discovery strategy 
That is, the characteristics must have altered the way drug discovery strategy 
in a particular organisation is being employed i.e. it does not only have short­
term effects, but also long term.
3 They must fall under the four categories: knowledge, technology, organisation, 
and environment as discussed and justified in chapter 4
As explained in chapter 7 the construction of the population cladogram provided a 
list and classification of strategies and characteristics, which helps specify the
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collection of data for the construction of the organisation cladogram. Therefore, the 
next task in the selection of characteristics is the identification o f individual 
organisation specific characteristics and determining how they relate to the 
characteristics in the population cladogram. A review of the historical archives for 
each organisation identified a list o f  key milestones that were included in the study as 
characteristics. Several characteristics were present in more than one organisation, 
several were found solely in one organisation. This latter point was expected, as it is 
known that each organisation tries to achieve competitive advantage by developing 
idiosyncratic capabilities (e g. Barney, 1991, Porter, 1980).
As per chapter 7, the characteristics identified have been classified according to the 
four factors that shape the drug discovery strategy. These factors are btowledge, 
technology, organisation, and environment. The following sections present, discuss, 
and justify the reasoning for each characteristic category. The full list of 
characteristics is shown in Table 8-5.
8.3.6. Technology
There is plenty of evidence to  suggest that the pharmaceutical industry is a 
technology-dominated sector (Deeds et al., 1997, Ratti and Trist, 2001). The scope of 
this thesis is to identify the key factors that influence the change of the drug discovery 
strategies. The construction o f the population cladogram, and more specifically the 
historical account provided in chapter 7, has demonstrated that there are some 
technologies that have affected the drug discovery process more than others, e g 
combinatorial chemistry and genomics. Therefore, it is within the scope o f this thesis 
to identify the most influential technologies, which are at the disposal o f the drug 
discovery scientists
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Chapter 4 identified five key enabling technologies. These are genomics, 
proteomics, high throughput screening, combinatorial chemistry, and 
pharmacogenomics. Since these technologies have been credited with driving the 
pharmaceutical drug discovery process (Reuters, 2000), they are included as 
technology characteristics in Table 8-5. Additional technologies that are selected 
include fermentation technology, procaine development, blood collection etc.
8.3. 7. Knowledge
Chapter 4 argued that the scientific knowledge acquired by an organisation, is a 
resource critical to the success of the discovery of new drugs Such knowledge is 
generated tacitly, but is then codified and combined with other existing knowledge 
Accordingly, the characteristics that fall under the category knowledge have been 
divided into two subsections; tacit and codified Tacit knowledge is intangible 
knowledge that may include personal insights, intuition, hunches and  is acquired 
through informal processes o f learning rather than through manuals and procedures. 
It includes the mechanisms that an organisation may use to acquire and/or manage the 
codified knowledge. The acquisitions of these mechanisms by an organisation denote 
the ability o f  an organisation either to acquire external knowledge or develop new 
knowledge internally. For instance, characteristic 25 of Table 8-5, acquisitions, 
denotes that an organisation has acquired another organisation and that it has 
developed the ability to acquire knowledge Naturally, the fact that an organisation 
has gone through an acquisition or even a merger (characteristic 24) does not on its 
own imply that an organisation has developed the ability to acquire external 
knowledge. If however, an organisation has acquired more than one characteristic 
from the list it is reasonable to deduce that such ability has been developed
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The second area of knowledge, codified, is the scientific or technological knowledge 
that is at the heart o f  and forms the foundation fo r  a product or service. In drug 
discovery, core knowledge is associated with the areas o f research that develop new 
products i.e. new drugs Therefore, codified knowledge in a pharmaceutical 
organisation is linked with therapeutic areas o f  interest e g. cardiovascular, oncology, 
immunology.
Research within a certain therapeutic area requires a pharmaceutical organisation to 
acquire a degree of expertise within that area (Henderson and Cockburn, 1994). As 
noted a number of times in this thesis, the discovery o f new drugs is a process that 
requires time, resources, and the dedication of a number of people from diverse 
disciplines. Therefore, the fact that an organisation is conducting research within a 
certain therapeutic area means that they have developed a capability within that area 
This argument is supported by Henderson and Cockburn (1994) who argue that drug 
discovery productivity is an increasing function of component competence, i.e. 
knowledge and skills, in particular disease areas.
There are two means by which an organisation may acquire a capability within a 
therapeutic area. The first one is through the acquisition of another organisation that 
may already be expert in the field. The second is by slowly acquiring the necessary 
knowledge. Thus, the importance of the therapeutic areas is such that they have been 
identified and listed as characteristics for this study.
The therapeutic areas were identified from the annual reports o f the sample 
organisations (Table 8-3). To ensure that the data collected was reliable the data was 
cross-referenced with related commercial publications (e g Financial Times, Drug 
Discovery and Development Magazine, American Chemical Society Publications).
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To achieve data compatibility and consistency, the diversity of the report formats is 
considered Due to variations in both the organisations’ locations and the principles 
used to construct such a report, the data was not in the same format. The required 
data existed in the following formats:
• Therapeutic areas This was the simplest form to handle as the therapeutic area 
was explicitly stated e g. infectious diseases, cardiovascular etc.
• Diseases. The name of the disease was stated instead of the therapeutic area This 
was less straightforward to handle, as most o f the diseases (e g. Alzheimer’s 
disease, AIDS, angina, hyperlipenia) specified were not known to the author and 
thus could not be categorised under therapeutic areas.
. Name o f  drug This was the most difficult format to translate to a therapeutic area 
as only the name of the drug under development was stated eg . Pfizer’s Cardura.
To achieve data compatibility, the following format was adopted For the diseases, 
they were compiled into a list, which was in turn forwarded to a medical practitioner 
The medical practitioner then identified the therapeutic area where each disease 
belongs (e g. Alzheimer's disease belongs to the therapeutic area neurology) For the 
drugs, the British National Formulary of the Royal Pharmaceutical Society o f  Great 
Britain (Mehta, 2001) was used. This publication is used by doctors, pharmacists and 
other healthcare professionals to  provide sound, up to date data about the use of 
medicines. It includes key data on the selection, prescribing, dispensing and 
administration of medicines. It is considered a valuable and reliable source for 
obtaining descriptions and data about drugs Each drug was found in the formulary 
(which sorts drugs in both alphabetical order and according to the therapeutic area
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they treat) and then from the data provided the therapeutic area was identified (e g 
Pfizer’s Cardura belongs to the cardiovascular therapeutic area)
8.3.8. Organisation structure and process
Chapter 4 discussed and justified organisation structure and process as the second 
factor that influences the change of drug discovery strategies. This factor includes the 
structure and process related with the management of the diverse scientific disciplines 
required for the development of new drugs.
As argued in chapter 4 the advances in scientific knowledge and technology have 
created the need for specialisation of individuals in different sections of the drug 
discovery. This in turn has created the need for communication interfaces between 
these individuals and the teams they are part of. Also the challenge faced by project 
management techniques is to exercise control without influencing creativity. Over the 
last century, these techniques together with advances in scientific knowledge and 
technology have played an important role in the formation of drug discovery 
strategies.
The characteristics listed in Table 8-5 under the heading organisation include those 
practices that are associated with the management and coordination of these 
individuals such as division of labour and centralised management. The historical 
archives used to obtain data about the organisations of Table 8-3 provided information 
about this category.
8.3.9. Environment
This factor consists of those elements that are directly associated with the 
competitive advantage of a pharmaceutical organisation i.e. the drug discovery 
process. The environment of the drug discovery process was described as consisting
of the technology and knowledge of other organisations, the legislation and political 
situation that directly influences the drug discovery process, and the diseases that are 
targeted. The diseases targeted by organisations depend on the therapeutic area in 
which they have developed an expertise on. Therefore, data about the diseases that 
each organisation is targeting, is included in the list of characteristics under the 
heading codified knowledge For instance, an organisation that undertakes research 
on endocrinology may be targeting diseases such as diabetes, acromegaly, etc.
A detailed description of all characteristics is included in the Appendix B of this 
thesis.
As explained earlier the starting point for the development o f  Table 8-5 is Table 7-2. 
An examination of the two tables reveals that there are a number of differences. 
Firstly, Table 7-2 lists 57 characteristics, while Table 8-5 lists 77. This is expected 
because the level o f analysis and the process of collecting data for organisations 
revealed more detailed characteristics several o f which were unique to individual 
organisations. Secondly, several characteristics, such as herbal's use, included in 
Table 7-2, are not included in Table 8-5. This is because these characteristics 
correspond to strategies that were present at the beginning of the pharmaceutical 
history and thus, they are not found in the strategic configurations of the organisations 
included in this chapter. Also, the characteristics of Table 7-1 correspond to generic 
strategy types. For instance, the characteristic introduction o f  computer aided drug 
design (included in Table7-2) represents a technology that influenced the formation 
o f  populations of drug discovery strategy and not simply one single organisation. 
Finally, the numbers given to the characteristics of the two tables are different. In 
both cases the numbers are the ones used in the tables of the Appendix.
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8.3.10. Validation o f  data
To increase the confidence of the collected data, those organisations from Table 8-3 
that are still in existence today were surveyed to validate the characteristics listed in 
Table 8-5.
The survey used a structured questionnaire and was distributed by email, telephone 
interviews, and post mail The questionnaire was directed to the research and 
development departments o f the surveyed organisations. The contact person within 
the departments was identified through the company website or the business 
directories
Once a contact with each organisation was established, the aims and scope of this 
study were explained and the characteristics identified for each organisation were 
confirmed As shown in Table 8-4 nineteen pharmaceutical organisations were 
contacted
The characteristics shown in Table 8-5 is the final validated list The characteristics 
not validated, were omitted. The final data matrix (organisations V characteristics) 
for building the organisation cladogram is presented in Appendix C.
8.4. Step 3: Setting polarity
The polarity of the characteristics (in most cases) was derived by observing the 
sequence of appearance of the characteristic states in history. For instance, 
characteristic 13, Diversification, has two states. The first, is that of the absence of 
diversification, i.e an organisation focuses on its original line o f research The 
second, is that of the presence of diversification i.e an organisation attempts to enrich 
its research portfolio by developing new lines o f research Historically, organisations
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diversified when their own line of research brought no results or was considered 
obsolete. Therefore, the absence of diversification precedes its presence Thus, the 
absence of diversification is considered a plesiomorphic or ancestral state, while the 
presence of diversification is considered an apomorphic or derived state
Similarly, the characteristics representing the codified knowledge may only be 
present or absent. That is an organisation is either undertaking research in a certain 
therapeutic area or it is not Therefore, the absence of the characteristic will be the 
plesiomorphic (ancestral) state while the presence will be its apomorphic (derived).
Although this rule was applied to most characteristics, it cannot be generalised to all 
the characteristics of the cladogram. This is because there are some characteristics, 
where it is not possible to distinguish which characteristic states came first 
historically. One such example is characteristic 23, Reformation o f others' 
rejected/unfmished research
8.5. Step 4: Characteristic coding
So far the characteristics, their states and the direction of change of these states have 
been defined. This step involves the conversion of the characteristic states into 
numerical symbols. The purpose of this step is to construct a matrix, which includes 
all the studied organisations, their characteristics and their states. This matrix is used 
in the next step for the construction of the organisation cladogram.
The matrix summarising the data and used for the next step of the construction of the 
cladogram is shown in the table of the Appendix C. The first column of that matrix 
includes the names o f  the organisations that were included in the study. The names of 
the organisations denote the drug discovery strategy of that organisation i.e. it is not 
the organisation that is classified, but the configuration o f its drug discovery strategy
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The first row includes the characteristics. Similar to the matrix constructed for the
population cladogram, the boxes that include the number 1 denote that the 
characteristic that is shown at the top o f the column where the box is included is 
present in the drug discovery strategy o f  the organisation shown in the first box of the 
row Similarly, the boxes that include the number 0 denote that the characteristic that 
is shown at the top of the column where the box is included is not present in the drug 
discovery strategy of the organisation shown in the first box of the row.
8.6. Step 5: Construct the cladogram
So far the characteristics, their states, polarity and codes have been defined and all 
the acquired data has been summarised in a matrix shown in Appendix C. The final 
step o f  the construction of the cladogram involves its actual construction. Similar to 
the construction of the population cladogram the software packages Phylip, Paup and 
MacClade were used.
8.6.1. Phylip
The treefile produced by the Wagner parsimony method included forty cladograms 
while the Camin-Sokal provided forty-nine different cladograms.
Figure 8-2 and Figure 8-3 each show the three most parsimonious (i.e. the ones with 
the shortest treelength and highest values of consistency and retention indices) 
cladograms found in the Wagner and Camin-Sokal treefiles respectively
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Figure 8-3 Cumin Sokal sample eladograms
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8.6.1. l.l.PAUP
The number of cladograms produced by PAUP was eighty-four. Figure 8-4 includes 
the three most parsimonious cladograms. The + sign included in the statistics of 
Figure 8-4(c) implies that the cladogram includes an unresolved polytomy (for an 
explanation of the polytomy see section 6.2.7.2 o f chapter 6). The unresolved 
polytomy is encircled
8.7. Determining the optimal cladogram
The three treefiles previously constructed were processed using MacClade and the 
average indices are shown in Table 8-6.
Table 8-6 Indices of organisation cladograms
Index Wagner (Phylip) Camin-Sokal (Phylip) PAUP
Consistency Index 0.26 0.25 0.26
Retention Index 0.49 0.46 0.50
Tree length 296 311.67 296
The optimal cladogram is the one with the highest consistency and retention indices 
and the lowest tree length. The first conclusion is that the three sets of cladograms are 
relatively similar, but not as similar as these listed in Table 7-3 for the population 
cladogram. The second conclusion is that the longest cladograms (least 
parsimonious) are the ones provided by the Camin-Sokal method. Similarly, the 
shortest cladograms and the ones with the highest consitency indices were provided 
by PAUP. Consequently, the optimal cladogram should be one of the 84 cladograms 
provided by PAUP.
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(b)
(c)
Figure 8-4 PAUP cladograms with best indices
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The selection of the best cladogram was carried out in two stages. First the three tree 
statistics (treelength, consistency index, and retention index) were used Three o f the 
84 cladograms produced by PAUP had slightly higher consistency and retention 
indices (0.26, and 0.51 respectively). The three cladograms are shown in Figure 8-4 
A comparison of the branching arrangement o f  the three cladograms reveals that all 
three of them group the drug discovery strategies in 2 groups and 5 subgroups (these 
groups will be presented and explained in detail in the following section) The 
differences between the cladograms are in the order of the drug discovery strategies 
within each group To illustrate this, these differences have been encircled on Figure 
8-4 From the comparison of the encircled parts of Figure 8-4 it may be concluded 
that the only difference between them is indeed the order by which the drug discovery 
strategies appear in each grouping
As explained in section 7.6.3 such differences could be significant when studying 
biological organisms as they could trigger philosophical arguments about evolution 
However, in the case of this research, where the cladogram is used to classify drug 
discovery strategy types and not to explore their order of evolution, such small 
differences are insignificant Also, as explained in section 6 2 8, the aim of the 
construction of this cladogram is the identification of such groupings (populations) 
while the order that the taxa appear within each grouping is not important for this 
research Therefore, any of the cladograms shown in Figure 8-4 are correct within the 
scope of this thesis However, as it is not practical to refer to more than one 
cladogram, cladogram (a) o f Figure 8-4 has been selected and will be used for further 
discussion and testing of the four hypotheses developed in chapter 5
Similar to the construction of the population cladogram, the confidence o f the data 
set should be considered i.e. to establish the significance o f  the dadistic structure
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(Kitching et al., 1998 p. 118). To address this confidence issue the process proposed 
by Archie and Felsenstein (1993) and explained in chapter 7 is followed
MacClade was used to construct random cladograms and calculate their mean 
statistics (see Table 7-4).
Tabic 8-7 Mean statistics for random cladograms
Treelength Consistency Index Retention Index
456 0.17 0.15____________________
The mean treelength of the random cladograms is 456 (Table 7-4) and is 
significantly higher than that o f the cladograms constructed in the previous section 
(292 in Table 8-6). Therefore, it can be concluded that there is confidence in the data 
set and that the results o f the cladistic analysis presented above are not the product of 
chance and it can be said that the data set contains significant cladistic structure
8.8. A nalysis o f  the cladogram
In this section the selected cladogram (Figure 8-5) is analysed. The section presents, 
explains and labels the major groups identified on the organisation cladogram Also, 
an aggregated version (Figure 8-6 Aggregated organisation cladogram) of the 
organisation cladogram is presented The aims of the aggregated organisation 
cladogram is to demonstrate the groupings identified in this section along with the 
defining characteristics, and to bring the organisation cladogram to the same level as 
the population cladogram. As explained in section 6.2.8 the drug discovery strategy 
types classified by the population cladogram correspond to a number of organisations 
that have adopted these strategies Therefore, by identifying classes of organisations 
that have adopted such strategies, the organisation cladogram can be elevated to the 
level of the population cladogram. This will help compare the two cladograms
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As explained in the previous section 2 groups and 5 subgroups o f  organisations were 
the same in all 84 cladograms constructed by Phylip. These groupings are shown on 
the aggregated organisation cladogram of Figure 8-6.
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Two major groups o f drug discovery strategies were identified at the same level 
The first is defined by characters 16 and 28 and the second by characters 6, 7, 8, 9, 10, 
16, 25, 27, and 28. These have been named the technology driven, and the alternative 
strategies respectively. The two groups can be divided into five subgroups, which 
have been named knowledge and instrumentation focus, externally enforced 
management pattern, me-too, biotechnology, and partnerships and acquisitions The 
names given to these branches are in line with the names of the population cladogram 
and they depend on their defining characteristics.
The following sections describe each branch.
8.8.1. Technology driven
The main characteristics of the first group are 6 7 8 9 and 10. These characteristics 
are combinatorial chemistry (6), rational drug design (7), high throughput screening 
(8), proteomics (9), and genomics (10). These characteristics were considered and 
discussed in chapter 4. Most of the drug discovery strategies that are present in this 
branch belong to those organisations that are still in existence today and have 
therefore adopted the new technologies to remain competitive. In line with this 
argument the name given to this branch is technology driven
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Another important characteristic present in the drug discovery strategies of this 
branch is the characteristic collaboration and jo in t ventures (27). An analysis of the 
cladogram reveals that drug discovery strategies that do not belong to  the technology 
driven branch have also implemented this characteristic. The need for collaboration 
and joint ventures was identified in chapter 5 as an important aspect o f the 
development o f new knowledge. It is therefore anticipated that this characteristic will 
be present in more than one branch. Finally, the characteristics R&D focus (16), 
acquisitions (25), and marketing (28), are also present in most of the drug discovery 
strategies of the technology driven branch.
The technology driven branch is split into two sub-branches. The first one is that of 
the drug discovery strategies that have acquired the characteristic world wars (39) and 
the second is that of the drug discovery strategies that have acquired characteristics 
instrumentation development (2), and diversification (13) as explained in the 
following sections.
8.8.11. Externally enforced management pattern
This branch was not present on the population cladogram. This strategy type is 
traced back in the 1940s and is associated with the political control enforced to 
pharmaceutical organisations during the world wars (39).
The strategic configurations that have been affected by the wars revolve around three 
issues. The first is associated with the transfer o f the research of German 
organisations to their American competitors after the Second World War (e g Abbott 
Laboratories, Schering-Plough, Sterling Drug Inc ). The second is associated with the 
wartime restrictions on imports and the boycott of German products The restrictions 
on imports meant that many pharmaceutical organisations faced shortages of
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ingredients (eg. Ciba Geigy was unable to secure raw materials and chemical 
intermediaries for the production of dyes from German suppliers in 1914). These 
shortages upset the equilibrium that had existed before the wars between German and 
other pharmaceutical organisations. The boycott o f the German pharmaceutical 
products had a twofold result. Firstly, the German organisations had to organise 
themselves for anti-German sentiments both during and after the war (e g. Merck 
turned over a sizable portion of its stock to the Alien Property Custodian of the United 
States). Secondly, the European organisations that had either established research 
plants in Germany or were supplying drugs to Germany also had to be prepared for a 
change in the political structure. The final issue is associated with the increasing 
necessity of certain therapeutic products for the war like blood collection, antibiotics, 
anaesthetics, and vitamin supplements.
The rest o f the drug discovery strategies included in these branches are differentiated 
by the type of codified knowledge organisations have acquired an expertise on
8 8.1.2. Knowledge and instrumentation focus
This strategy type is present on the population cladogram. The characteristics that 
differentiate this branch to the externally enforced management pattern branch 
previously discussed are instrumentation development (2), and diversification (13). 
Instrumentation development is a technology characteristic, while diversification is a 
tacit knowledge characteristic.
The acquisition of the instrumentation development characteristic implies that a drug 
discovery strategy does not only focus on the discovery and development of new 
drugs, but also on the development of medical instruments. As explained in chapter 7 
the emergence of this branch was enabled with the development of computing
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technology, when large computers became widely used in pharmaceutical 
laboratories, and the understanding of DNA, hence its name.
The acquisition of the diversification characteristic on the other hand implies that an 
organisation has entered new market segments by introducing new products The 
decision for a diversification strategy is usually coupled with a merger with or an 
acquisition o f another organisation
These two characteristics are usually triggered by the need of an organisation to 
increase their product portfolio. Both the development of instruments, and 
diversification have a similar aim, the introduction to the market of new drugs.
8.8.2. Alternative strategies
The second main group o f the cladogram is the one whose main characteristics are 
R&D focus (16) and Marketing (28). Although these characteristics are important and 
are possessed by most o f  the drug discovery strategies in that branch, they are also 
present in the first branch. Therefore, the main difference between the two branches 
(technology driven and alternative strategies) is the lack of the technologies 
(characteristics 6, 7, 8, 9, and 10). Most of the drug discovery strategies which are 
included in this branch belong to organisations that do not exist any more mainly 
because they have merged or been acquired by other organisations. Hence, they have 
not adopted these technologies into their drug discovery process
8.8.3. Partnerships/Acquisitions, biotechnology, and me-too
Within the alternative strategies branch three smaller groups were identified The 
first is the partnerships and acquisitions branch and is differentiated by characteristics, 
diversification (13), merger (24), and acquisitions (25). Within this branch several 
smaller groups of drug discovery strategies may be identified. The principal
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differentiation of these groups is the core knowledge that they possess i.e. the 
therapeutic areas. The second is the biotechnology and is differentiated by 
characteristics computational power (1), biotechnology (4), and DNA marketing. The 
third is the me-too branch and is differentiated by characteristics limited discovery 
(21), and dependence on strangers ' research (22).
Diversification is a characteristic that was acquired by many organisations 
particularly during the 1960s and 1970s and it was a result of the lack of major 
breakthroughs in drug discovery (e g Marion Laboratories spent little on original 
research while they invested on reformulating and developing products discovered, 
but rejected by other companies) and the establishment of an organisation in a foreign 
country (e g Roussel-Uclaf was established following a merger between a French and 
a German organisation). Mergers and acquisitions are tw o characteristics that have 
been present in strategic configurations throughout the pharmaceutical history. 
However, their popularity has significantly increased during the 1980s and 1990s as 
explained in chapter 7. This was the direct result of the escalating costs of drug 
discovery. Smaller research organisations needed the financial support of larger 
organisations while larger organisations needed the flexibility and technology 
breakthroughs of smaller organisations.
The drug discovery strategies that belong to the second branch, biotechnology, are 
associated to those entrepreneurial organisations that were established following the 
development of technology that allowed scientists to combine bits of DNA in the 
1970s.
The drug discovery strategies that are included in the third branch, me-too, are the 
ones that belong to organisations that belong in the generics industry. Limited 
discovery and the escalating costs of drug discovery forced several organisations to
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pursue different approaches to survive in the market. As it was previously discussed 
one of those approaches was diversification. Another less popular approach was that 
o f the manufacturing of generics (e g. Mylan Laboratories). Generics are those drugs 
that are manufactured once their original patent has expired The difficulty associated 
with this approach is that as drugs come off the patent, competing organisations 
quickly manufacture their own generic versions. Due to the nature of the strategies 
grouped in this branch that advocates imitation of drugs o f other pharmaceutical 
organisations the branch has been named Me-too.
8.9. Discussion on the four hypotheses
This section of this chapter discusses how the population cladogram, constructed in 
chapter 7 (Figure 7-7), and the organisation cladogram (Figure 8-5) address the four 
hypotheses developed in chapter 6.
8.9.1. 1st hypothesis
There are similar drug discovery strategies employed by different pharmaceutical 
organisations to form  populations whose (the population’s) size follows a concave 
pattern o f  growth and decline.
As explained in the previous section of this chapter the organisation cladogram 
classified drug discovery strategies into five groups, me-too, biotechnology, 
partnerships and acquisitions, knowledge and instrumentation focus, and externally 
enforced management pattern, as shown in the aggregated organisation cladogram of 
Figure 8-6. With these branches there are variations o f drug discovery strategies 
implemented by different organisations Four of these groups match four of the 
groups of the population cladogram. Therefore, it may be argued that the first part of
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the hypothesis that requires the drug discovery strategies to form populations is 
validated
As explained in section 5.2.1.1 the size o f a population is the number of entities that 
exist within that population. Therefore, the size of each population aggregated on the 
cladogram of Figure 8-6 is the number of the organisations included in the 
corresponding groups of the cladogram o f Figure 8-5. For instance, the population 
externally enforced management pattern includes the organisations (1) AbbotLabs, 
(2) Wyeth, (3) ScheringPlough, (4) Novo, (5) Sankyo, (6) AstraZeneca, (7) Merck, (8) 
BMS, (9) Baxter International, (10) Fujisawa, and (11) Sanofi Synthelabo Therefore, 
the size of that population is 11.
Table 8-8 summarises the sizes of the 5 populations of drug discovery strategies 
identified in the cladogram of Figure 8-6.
Table 8-8 Size of populations
Drug discovery strategy Number of drug discovery strategies in 
population
Me-too 3
Biotechnology 2
Partnerships and acquisitions 9
Knowledge and instrumentation focus 8
World wars 11
Although four o f the branches of the population cladogram match the branches of the 
organisation (me-too, biotechnology, partnerships and acquisitions, and knowledge 
and instrumentation focus), constructed and explained in chapter 7, there are another 
11 (one of the taxa is the outgroup which was included only for simplifying the 
polarisation process, as explained in chapter 6) that do not. There are two possible 
reasons for this The first is that in line with the second part of the hypotheses two of 
the drug discovery strategies found early in the pharmaceutical history, unorthodox
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and individual efforts, do not exist anymore Unorthodox strategies are not pursued 
anymore due to their inefficiency and thus this population could be extinct. Also the 
need for combining knowledge from different disciplines could have also eliminated 
the population o f  individual effort strategies The elimination of this strategy type 
shows that populations of drug discovery strategies may follow a concave pattern of 
growth and decline as suggested by the second part of the 1st hypothesis If this line 
of argument is correct then the second part o f the hypothesis is also validated, since 
the size of these older strategies reduces, while the size of the newer increases i.e. the 
size of the population follows a concave pattern o f  growth and decline. However, the 
cladogram does not provide strong evidence to support this argument This is because 
patterns of change for population size are not clearly depicted on the cladogram
The second possible reason for the smaller number of branches on the organisation 
cladogram, is that both the number of organisations and the process of collecting the 
characteristics has not covered the complete spectrum of the drug discovery strategies 
classified by the population cladogram Although this may be considered a limitation 
of the methodology, it does not affect the overall conclusions and findings of the 
cladogram constructed in this chapter The aim of the population cladogram was to 
provide a platform for demonstrating how the four hypotheses could be validated and 
not an exact match with the organisation cladogram.
H. 9.2. 2nd hypothesis
Within a drug discovery population, there are strategies that differ to each other in 
terms o f  their characteristics and their fitness.
The organisation cladogram (Figure 8-5) classifies drug discovery strategies that 
individual organisations implement The configuration of an organisation’s drug
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discovery strategy can be different to that of another’s because, as explained in 
chapter 4, it is a function o f its idiosyncratic processes such as, strategic decision­
making, creating alliances, and its interpretative flexibility (the degree to which users 
of a technology are engaged in its constitution during development and use 
(Dougherty et al. 1998)). In addition, competitive advantage depends on the 
organisational processes, shaped by an organisation’s asset positions (Helfat, 1997) 
and moulded by its evolutionary and co-evolutionary paths. The branches of the 
organisation cladogram (Figure 8-5) show the characteristics that differentiate one 
drug discovery strategy from another. The main difference between the implemented 
drug discovery strategies o f  individual organisations is the core knowledge they have 
acquired, i.e. the therapeutic areas. Consequently, the cladogram clearly demonstrates 
that there is difference in the characteristics of their drug discovery strategies and thus 
validates the first part o f the hypothesis.
The second part of the hypothesis requires the strategy o f each branch to demonstrate 
variation in their fitness. Fitness was defined in chapter 5 as:
The condition where the configuration o f  an organisational strategy 
matches that o f  the environment and the frequency o f  its characteristics 
appearing in future strategies is high.
The fitness of organisations may be demonstrated on a cladogram by observing the 
response o f drug discovery strategies to a change in an element of the environment 
such as the world wars (which could be classified as a political situation). The branch 
externally enforced management pattern includes the drug discovery strategies of 
organisations that were present during the world wars. Therefore, these strategies 
have been successful in curing diseases to a degree that have managed to make the 
organisations successful and present up to the end o f the 20th century.
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The organisation cladogram (Figure 8-5) provides evidence for the fitness of drug 
discovery strategies following a change in the environmental conditions However, 
such evidence is not present for the fitness of these strategies in the market i.e. the 
degree to which these strategies help the organisations achieve their market 
objectives. Evidence for this requires detailed market analysis and comparison with 
the performance of the pharmaceutical organisation where each strategy is 
implemented The use of the cladogram is limited to the classification of strategies 
within a population and does not provide any data about the market conditions One 
suggestion however, may be made from the cladogram with regard to the market 
performance of organisations. The sustainability of organisations could imply that the 
implemented strategies have been successful. Although the success of a 
pharmaceutical organisation heavily relies on the discovery of new drugs, other issues 
like marketing, diversification, mergers and acquisitions play an important role 
Therefore, difference in the financial performance of an organisation could imply 
difference in the implementation o f  strategies The cladogram does not provide 
enough supporting evidence for this argument, but it is an interesting issue to examine 
in future work.
Therefore, the organisation cladogram provides appropriate evidence to support the 
2nd hypothesis. It has demonstrated that within the classified populations of drug 
discovery strategies, there are strategies that differ to each other in terms of their 
characteristics such as the therapeutic areas and fitness such as the survival of the 
organisations following the world wars. However, the cladogram does not provide 
enough evidence for the fitness of drug discovery strategies in the market
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8 9.3. 3rd hypothesis
1'hose characteristics o f  drug discovery strategies credited with successful drug 
discovery performance are likely to he present in future strategic configurations, 
while those characteristics that are not are likely to be absent.
This hypothesis is validated by the organisation cladogram (Figure 8-5), because the 
characteristics of the early strategies are also present in the later ones. For instance, 
characteristics 4, 6, and 7 (industrial revolution, chemical extraction, and microbial 
theory of disease) are also present in later strategies, while characteristics such as the 
therapeutic areas, which only depend on the specialisation of each organisation, are 
not. The mechanisms by which the characteristic transfer takes place could be 
explained by the three types o f isomorphic change discussed in detail in chapter 5; 
coercive isomorphism; mimetic processes, and normative isomorphism.
An additional mechanism that enhances the transfer of characteristics is that of 
collaboration between two organisations. As it was also explained in chapter 5 this 
collaboration might take several forms e g mergers, acquisitions, and research 
agreements. When the result of the collaboration is the formation of a new 
organisation, as is usually the case with mergers and acquisitions, then the newly 
founded organisation acquires the majority of the characteristics o f the previous 
organisations. Naturally, through the reorganisation and restructuring that usually 
follows such an action, the characteristics change. On the other hand when the 
collaboration is the result of a research agreement between two organisations then the 
diffusion of characteristics could be more selective and is usually focused on the core 
knowledge that is being acquired.
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The occurrence of characteristics’ transfer is also present on the population 
cladogram (Figure 7-7). Those characteristics that have proved to be successful have 
been transferred to later drug discovery strategies This is clearly illustrated by 
characteristics 16 and 28 (R&D focus and marketing). These characteristics were 
considered vital for the sustainability of a pharmaceutical organisation 
Consequently, these characteristics are present in both main branches of the 
organisation cladogram (alternative strategies and technology driven)
The second part of the hypothesis suggests that those characteristics that have not 
been credited with the success of strategy will be absent from future strategic 
configurations This part is demonstrated by the fact that early characteristics such as 
herbals ’ use (1) and random discoveries with no scientific justification (2) that were 
present on the population cladogram (Figure 7-7) have not been included in the 
organisation one (Figure 8-5). As it was discussed earlier strategies such as 
unorthodox are not pursued anymore and thus their characteristics have not been 
transferred in later strategic configurations.
Therefore, the organisation (Figure 8-5) and population (Figure 7-7) cladograms 
provide enough evidence to support the third hypothesis. They demonstrate that those 
characteristics of the drug discovery strategies, such as chemical extraction that have 
been credited for the success of a strategy in the past, are present in future strategic 
configurations, while those characteristics that are not, such as herbals’ use, are 
absent.
8 9.4. 4lh hypothesis
With a change in environmental conditions those drug discovery strategies that 
remain are the ones, whose strategic characteristics are favoured by the environment.
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As it was discussed earlier, the organisation cladogram (Figure 8-5) does not provide 
clear information about the market conditions surrounding the drug discovery 
strategies. However, it provides information about significant events that have 
influenced the drug discovery strategies (shown in Table 8-5) with the most 
significant of those being the world wars The world wars have provided significant 
changes in the environmental conditions of the drug discovery strategies. The way 
that strategic configurations were affected by the wars was discussed in section
8 . 8 . 1. 1.
The organisation cladogram (Figure 8-5) has grouped the drug discovery strategies 
of organisations affected by the wars together (externally enforced management 
pattern in Figure 8-6). It could therefore be argued that these strategic configurations 
were the ones that had the capability to withstand the pressures exerted by the war. 
Those strategies that were present prior to the wars, but were not favoured by the 
changes are not included in this branch and may thus be assumed that they do not 
exist anymore Such an assumption, however, is not directly supported by the 
cladogram since some of the strategic configurations of the remaining branches 
correspond to drug discovery strategies that were founded after the war e g 
biotechnology. However, the drug discovery strategies that belong to the externally 
enforced management pattern were sustained after the war was ended The fact that 
they have been grouped together by the cladogram demonstrates the importance of 
knowledge as a core competency in pharmaceutical organisations. As explained in 
chapter 4 the ability of this industry to quickly recover technological and business 
momentum after the war’s restrictions and destructions suggests that the core 
competencies of the organisations were not in their physical plant and technology 
They were in the collective knowledge they possessed about organic chemistry and
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the associated techniques of their research laboratories’ personnel, (Bogner and 
Thomas, 1996).
In summary, the cladogram provides support for the validation of the fourth 
hypothesis. It demonstrates that following a change in the environmental conditions 
the drug discovery strategies that were sustained are the ones whose strategic 
characteristics such as the collective knowledge are favoured by the environment.
8.10. Fittest strategies
The fourth research question seeks to identify the fittest drug discovery strategies. 
This section attempts to address this question by identifying the key characteristics 
that have been revealed on the organisation cladogram Figure 8-5.
Similar to the construction of the population in chapter 7, the construction of the 
organisation cladogram used three different algorithms (Wagner, Camin-Sokal and 
Paup). This resulted in the construction of a number of different cladograms To 
select the optimal cladogram the statistics of each cladogram were used. One 
important observation of this process is that a number of characteristics are more 
decisive than others i.e. they have a stronger influence on the classification than 
others.
Regardless of the different arrangements of the cladograms, several characteristics 
have been consistently selected as the most decisive i.e. the ones that are responsible 
for the formation o f the main branches. These characteristics are shown in Table 8-9.
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Tabic 8-9 Decisive characteristics of conglomeration cladogram
C haracteristic number
2
6
7
8
9
10 
13 
16 
21 
22
24
25 
28 
39
Characteristic name
Instrumentation development
Combinatorial chemistry
Rational drug design
High throughput screening
Protcomics
Genomics
Diversification
R&D focus
Limited discovery
Dependence on strangers' research (generics)
Merger
Acquisitions
Marketing
World Wars
Instrumentation development is a key characteristic in the history of drug discovery 
since its acquisition enabled organisations to increase their efficiency. Characteristics 
6, 7, 8, 9, and 10 constitute the key enabling technologies, which have been discussed 
in chapter 4. Diversification (13) is an approach that has been used by many 
organisations as a result either o f limited discovery or in an effort to increase market 
share RAD focu s (16) is a characteristic that has been identified in the literature as a 
source of competitive advantage Limited discovery (21) has forced organisations to 
seek alternative strategies in the endeavour to survive and be successful 
Characteristic 22, dependence on strangers' research, is a decisive characteristic as it 
defines the generics industry Mergers and acquisitions have been changing the 
pharmaceutical industry especially over the last two decades and have therefore a 
significant effect on the drug discovery process Finally, the world wars (39) have 
also been a significant parameter in the formation of the drug discovery strategies
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All characteristics of Table 8-9, but 9 and 14 (World wars and limited discovery) are 
controlled by organisations and therefore can be included in strategic planning 
Therefore, the fittest strategy as this has been identified by this study is one that 
includes the twelve characteristics included in Table 8-9. It is important to note that 
successful strategies heavily rely on good planning and good execution of this 
planning. The strategic configuration that is being selected in by the environment is 
the one that reduces the degree of randomness. Using the terminology from the fourth 
chapter it is the less emergent strategies that are being favoured. These are the 
strategies that highly utilise knowledge and technology to plan their strategy. This 
point comes as no surprise to those who employ the latest knowledge and technology 
to achieve their targets. It is however, o f significant importance from a strategic 
management point of view. This point supports the argument that the less emergent 
and the more planned strategies equip organisations with the competitive advantage, 
in this case the discovery o f new drugs.
Finally, a note has to me made about the lack of characteristics from the codified 
knowledge category. The selection o f a therapeutic area depends on idiosyncratic 
parameters such as the research interests o f the founder or the geographical area were 
an organisation was first established. Therefore, although the development of a 
specialisation in a therapeutic area is considered key for the success of the 
development of a pharmaceutical organisation, there is not one single therapeutic area 
that appears to be more significant.
8.11. Conclusions
The aim o f this chapter was to construct a cladogram of drug discovery strategies of 
individual organisations. The chapter explained in detail the methodology followed to
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construct the cladogram, and how the data was collected. Using this cladogram 
(Figure 8-5), the chapter also discussed the validity of the four hypotheses developed 
in chapter 5 and thus addressed the third research question of this thesis (How can an 
evolutionary and classification approach he used to study drug discovery strategies?).
Similar to the population cladogram (Figure 7-7), the unit of analysis of the 
organisation cladogram, shown in Figure 8-5, is drug discovery strategies as these 
were defined in section 4 8 and not organisations If the unit of analysis was 
organisations then the resulting treelike structure shown in Figure 8-5 would be a 
phenogram  i.e. a branching diagram (dendrogram) that represents phenetic 
relationships (i.e the arrangements by overall similarity based on the available 
characters without any weighting (Cain and Harrison, 1960 in Sneath and Sokal, 
1973)). This is because organisations selected and used in the organisation 
cladogram, were not done so according to phylogentic principles The organizations 
were used for collecting data about the evolving entity and unit o f analysis (i.e drug 
discovery strategy). The organizations shown in Figure 8-5 do not have ancestors in 
the conventional use of the term and therefore, the classification would be based only 
on the organisations’ phenetic relationships Drug discovery strategies on the other 
hand, could have ancestors, which would be older patterns of behaviour adopted by 
the management o f one or more pharmaceutical organisations
The cladogram showed that there is evidence to support the first part of the first 
hypothesis. That is, the organisation cladogram showed that there are similar drug 
discovery strategies employed by different organisations to form populations 
However, such is not the case for the second part of the hypothesis, which requires the 
population’s size to follow a concave pattern of growth and decline As explained in
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this chapter, patterns of change of the population size are not depicted on the 
organisation cladogram (Figure 8-5).
Similar to the first hypothesis, the organisation cladogram (Figure 8-5) provides 
evidence to support the first part of the hypothesis, but not the second The 
cladogram shows that within a drug discovery population, there are strategies that 
differ to each other in terms o f their characteristics, which is the first part of the 
hypothesis. The cladogram also provides support about the variation of the fitness of 
the drug discovery strategies following a change in the environmental conditions 
However, the cladogram does not provide any evidence about the fitness of the drug 
discovery strategies in the market
The third hypothesis required the characteristics o f  drug discovery strategies credited 
with successful drug discovery performance to be present in future strategic 
configurations, while those characteristics that are not to be absent The population 
(Figure 7-7) and organisation (Figure 8-5) cladograms provide evidence to support 
this hypothesis Characteristics such as R&D focus (16) and marketing (28) are 
present in later strategic configurations, while characteristics such as herbals ' use and 
random discoveries with no scientific justification (characteristic 2 of the populastion 
cladogram) are absent.
Finally, the fourth hypothesis is also validated by the organisation cladogram 
Following a change in the environmental conditions such as the world wars the drug 
discovery strategies that were sustained are the ones whose strategic characteristics 
such as the collective knowledge are favoured by the environment
The chapter also addressed the fourth research question of this thesis, which requires 
the examination of the characteristics of the fittest strategies The process followed
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for the construction o f  the organisation cladogram used three different algorithms 
(Camin-Sokal, Wagner, and PAUP). This resulted in the construction o f several 
cladograms Although the cladograms were different in terms of both the statistic 
indices (see chapter 6) and the arrangement of the drug discovery strategies there 
were 14 characteristics (Table 8-9) that were decisive in all the arrangements The 
chapter argued that these characteristics constitute elements o f the fittest strategy.
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9. C O N C L U S IO N S
9.1. Introduction
Throughout this thesis, each chapter has an aim and resulting conclusion that 
contributes to or advances this research towards addressing the research questions 
listed in chapter 1 and justified in chapter 3. This final chapter presents an overview 
o f the research questions and how they were addressed, and summarises the 
contribution made to knowledge.
The process followed to address the research questions of this thesis is summarised 
in Figure 9-1. It begins with the definition of the research problem, and the 
formulation o f the research questions. Following a literature review o f drug discovery 
strategy, strategic management, and evolution, the research questions were 
reformulated to reflect the findings from the literature, and four hypotheses were 
developed as part of the third research question. To validate these hypotheses, a 
business historical study was conducted and two cladistic classifications (cladograms) 
were constructed, a population cladogram and an organisation cladogram. The black 
boxes of Figure 9-1 illustrate the process followed to construct the population 
cladogram while the grey boxes illustrate the process followed to construct the 
organisation cladogram. The former classified drug discovery types identified from 
historical and generic industry data collected (e g Liebanau, 1987, Jones, 2001, 
Weatherhall, 1990, Mann, 1999). The characteristics and types identified were used 
to  design the data collection methods for the classification of drug discovery strategies 
o f  individual organisations (organisation cladogram). The data collected was found 
from i) histories of companies, and ii) annual reports. To demonstrate the groupings 
identified on the organisation cladogram and to bring the organisation cladogram to
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the same level as the population cladogram, an aggregated organisation cladogram 
was also constructed and presented in chapter 8 together with a discussion on the 
validation of the four hypotheses. This chapter presents the overall research 
conclusions (answers to research questions), discusses the limitations of the research, 
and suggests directions for future work.
9.2. Research Questions
1. How does the discipline o f  strategic management relate to the process o f  drug 
discovery and what is the definition o f  a drug discovery strategy?
2. What are the factors (internal and external) that influence and define different 
drug discovery strategies?
The first two research questions explore the nature o f  the concept of drug discovery 
strategy. Due to the strong link between the two questions, they are addressed 
together
Chapter 4 reviewed, developed, and integrated the literature of strategic management 
to i) identify and justify the factors that influence drug discovery strategies, and ii) 
provide a working definition of the term drug discovery.
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The four factors identified are:
•  K now ledge Scientific knowledge acquired by an organisation is a resource 
critical for discovering new drugs Such knowledge is generated tacitly, but 
is then codified and combined with other existing knowledge. The resulting 
knowledge is then communicated both within an organisation and with other 
organisations and institutions The absorptive capacity of an organisation is 
also critical in the formation of drug discovery strategies as it reflects the 
ability o f an organisation to use the external knowledge and convert it into 
new drugs.
•  Technology Advances in technology have altered the pattern by which new 
drugs are discovered. This alteration has influenced both the success rates of 
drug discovery and the structure of pharmaceutical organisations since new 
capabilities are now required. Consequently, technology is similar to 
scientific knowledge in that it constitutes an important asset of a 
pharmaceutical organisation, and is critical to any drug discovery strategy.
•  O rganisation . The advances in scientific knowledge and technology created
the need for worker job specialisation in different sections o f the drug 
discovery process. This in turn created the need for communication
interfaces between these individuals and their teams. Management 
techniques evolved to address the challenge o f exercising control without 
influencing creativity. Over the last century, these techniques together with 
the scientific knowledge and technology have played an important role in the 
formation of drug discovery strategies.
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•  Environm ent. The elements o f the environment that affect the formation of
drug discovery strategies are those that are directly associated with the 
competitive advantage of an organisation, i.e. the drug discovery process. 
The environment of the drug discovery process is described as consisting of 
the technology and knowledge of other organisations, the legislation and 
political situation that directly influence the drug discovery process, and the 
diseases that are targeted.
The key points that underpin the definition developed in chapter 4 are as follows:
• Drug discovery strategy is seen as a pattern of behaviour rather than a 
predetermined plan
• Drug discovery strategy is considered a business strategy, rather than a 
corporate or a functional strategy
• The formation of a drug discovery strategy is determined by using the four 
strategic factors: knowledge, technology, organisation, and environment.
Therefore, the working definition of drug discovery strategy created in chapter 4 is:
'The pattern o f behaviour defined or adapted by the management o f  a 
pharmaceutical organisation, within a certain environment, to effectively materialise 
the corporation's goals and policies in order to achieve a competitive advantage 
through the application o f  knowledge and technology on the discovery o f  new drugs. '
The manner by which the four factors influence drug discovery strategies and each 
other is outlined in Figure 9-2.
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Figure 9-2 Factors influencing the drug discovery strategy
3. How can an evolutionary and classification approach he used to study drug 
discovery strategies?
To address this research question, chapter 5 identified four requirements that systems 
should meet for evolution to explain their change These requirements were 
developed into four hypotheses for the evolution of drug discovery strategies (Table
9-1).
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T ab ic  9-1 H y po theses
Requirement Hypothesis
1. E x is ten ce  in 
p o p u la tio n s
There are similar drug discovery strategies employed by different 
pharmaceutical organisations to form populations whose (the 
population’s) size follows a concave pattern o f growth and decline
2 .  V a ria tio n Within a drug discovery population, there are strategies that differ to 
each other in terms o f their characteristics and their fitness.
3 . H ered ity Those characteristics o f drug discovery strategies credited with 
successful drug discovery performance are likely to be present in future 
strategic configurations, while those characteristics that are not are 
likely to be absent.
4  S e lec tio n With a change in the environmental conditions those drug discovery 
strategies that remain are the ones whose strategic characteristics are 
favoured by the environment.
To validate these hypotheses, chapter 6 justified the use of classification and 
cladistics Chapter 7 constructed a cladogram of populations of drug discovery 
strategy, and chapter 8 constructed a cladogram o f drug discovery strategies of 
individual organisations. The unit of analysis of both cladograms are drug discovery 
strategies as defined in section 4 8 The differences between the two cladograms are 
the level of analysis and the sources of data
The conclusions of the analysis of these classifications are as follows:
1. The two cladograms constructed in chapter 8 (organisation (Figure 8-5) and 
aggregated organisation (Figure 8-6) cladograms) classified the drug 
discovery strategies of individual organisations into five groups. Within 
these groups there are variations of drug discovery strategies implemented by 
different organisations Therefore, the first part of the hypothesis is validated 
(There are similar drug discovery strategies employed by different 
pharmaceutical organisations to form populations).
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The second part of the hypothesis has not been validated by either o f  the two 
cladograms because patterns of change of the population size cannot be 
depicted on a cladogram. However, as argued in chapter 8, the fact that the 
branches o f the population cladogram (Figure 7-7) do not match all the 
branches of the organisation cladogram could provide some information with 
regard to the change of the populations’ sizes Early drug discovery strategy 
types, such as unorthodox, and use o f  herhals, are not pursued anymore due 
to their inefficiency and thus they could be extinct. The elimination o f these 
strategy types shows that populations of drug discovery strategies may follow 
a concave pattern of growth and decline as suggested by the second part of 
the 1st hypothesis. Yet, there is not enough evidence on the cladogram to 
validate this argument.
2. The branches of the organisation cladogram (Figure 8-5) show the 
characteristics that differentiate one drug discovery strategy from another. 
The drug discovery strategies are differentiated by characteristics that belong 
to each o f the four categories, technology, knowledge, organisation, and 
environment identified and justified in chapter 4 However, the main 
difference between the implemented drug discovery strategies o f  individual 
organisations is the core knowledge they have acquired, i.e the therapeutic 
areas. Therefore, the cladogram clearly demonstrates that there is difference 
in the characteristics of their drug discovery strategies and, thus, validates the 
first part o f the hypothesis (Within a drug discovery population, there are 
strategies that differ to each other in terms of their characteristics).
The second part of the second hypothesis requires the strategy of each branch 
to demonstrate variation in their fitness. In chapter 8 it was argued that the
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organisation cladogram provides evidence for the fitness of drug discovery 
strategies following a change in the environmental conditions The branch 
externally enforced management pattern includes the drug discovery 
strategies o f organisations that were present during the world wars. As 
argued in chapter 8, these strategies have been successful in curing diseases 
to a degree that they have managed to make the organisations successful and 
present up to the end of the 20th century. However, the cladogram does not 
provide any evidence about the fitness of the drug discovery strategies in the 
market.
3. The organisation (Figure 8-5) and population (Figure 7-7) cladograms 
demonstrated that characteristics of early strategies are also present in later 
ones. As argued in chapters 4 and 8, the mechanisms by which the 
characteristic transfer takes place could be explained by the three types of 
isomorphic change, namely, coercive isomorphism; mimetic processes, and 
normative isomorphism.
Also, the organisation and population cladograms provide evidence to 
support the second part of the hypothesis (...those characteristics that are not 
are likely to be absent). Characteristics of earlier drug discovery strategy 
present on the population cladogram are not included in the organisation one.
4 Finally, the organisation cladogram (Figure 8-5) has grouped the drug 
discovery strategies of the organisations affected by the world wars together 
(enforced management pattern branch). As explained in chapter 8, the world 
wars have provided significant changes in the environmental conditions of 
drug discovery strategies. The fact that they have been grouped together 
demonstrates the importance of knowledge as a core competency in
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pharmaceutical organisations Therefore, the drug discovery strategies that 
remaine are the ones that had acquired before the war the knowledge 
characteristics favoured by the environment Thus, the fourth hypothesis is 
also validated.
4. What are the characteristics o f  the fittest drug discovery strategies?
To address this research question, chapter 8 identified 12 key characteristics in the 
formation of the fittest strategies. These are listed in Table 9-2.
Tabic 9-2 Decisive characteristics of conglomeration cladogram
C haracteristic num ber Characteristic name
2 Instrumentation development
6 Combinatorial chemistry
7 Rational drug design
8 High throughput screening
9 Protcomics
10 Genomics
13 Diversification
16 R&D focus
22 Dependence on strangers' research (generics)
24 Merger
25 Acquisitions
28 Marketing
Chapter 8 categorised the characteristics according to the factors that influence drug 
discovery strategies (Table 8-5). According to this categorisation, characteristics 2, 6, 
7, 8, 9, and 10 belong to the technology category, characteristics 13, 22, 24, 25, and 
28 belong to the tacit knowledge category, and characteristic 16 belongs to the 
organisation category The characteristics that belong to the category environment 
are omitted because they are outside the control o f a pharmaceutical organisation and
thus cannot be included in strategic planning Finally, as explained in chapter 8,
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(section 8.10) none of the characteristics that fall under the certified knowledge 
category are included in Table 9-2.
9.3. Contribution to knowledge
The contribution to the body of knowledge of this thesis is summarised in the 
following points:
. The creation of a definition of drug discovery strategy.
• The identification o f  the factors that influence the change of drug discovery 
strategies
. The creation of an evolutionary classification that identifies and arranges different 
types of drug discovery strategy, and reveals the characteristics of the fittest
• The validation of evolution as a process for understanding change as a process for 
understanding change in drug discovery strategies.
9.4. Limitations o f this research
As with all research projects, the limiting aspects of the work are often associated 
with the tools and methods used Regardless of the method or tool, they all provide a 
partial representation o f reality. The following discussion considers the limitations of 
the resulting cladograms and the data collection method.
9.4.1. Low indices
As discussed in chapter 6, the theoretically perfect cladogram would be the one 
where the consistency and retention indices are equal to one. Lower values suggest 
low performance of the data set, i.e. there are characters that appear on the cladogram
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more than once. Some indices of cladograms found in the literature are shown in 
Table 9-3.
Tabic 9-3 Indices found in the literature
Source Reference Consistency index Retention index
T h e  a u to m o tiv e  
c la d o g ra m
L e se u rc , 1999 0 .8 9 (n o t  c a lc u la te d )
T h e  h a n d  to o l
in d u s try
c la d o g ra m
L c se u rc , 1999 1.0 (n o t c a lc u la te d )
E le c tro n ic s
in d u s try
c la d o g ra m
F e rn a n d e z , 2 0 0 2 0.1 0 .4 8
The population 
cladogram
0.79 0.92
The organisation 
cladogram
0.26 0.50
Although the consistency and retention indices calculated for the population 
cladogram are high, the ones calculated for the organisation cladogram (Figure 8-5) 
are relatively low. This implies that the data set does not fit well to the proposed 
cladogram. The following discussion provides reasons for the low indices and 
compares them with the other indices shown in Table 9-3.
One possible reason is the large number of taxa Kitching et al (1998) argue that as 
the number of taxa increases, values of Cl tend to decrease. In fact, they argue that 
when the number taxa increases, the consistency index will decrease irrespective of 
any change in the information content The number o f taxa o f the automotive 
cladogram (Leseure, 1999) is 16 while its consistency index is high (0.89). In the 
case o f this research, the number o f taxa is 36. Such a number is considerably high 
and therefore a low consistency index is expected and should not undermine the 
structure of the cladogram.
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Organisations could implement more than one strategy at any given time. Therefore, 
an organisation could belong in more than one branch at any given moment. As the 
structure of the cladogram does not allow the strategic configuration of an 
organisation to appear more than once on the cladogram, the characteristics of a 
strategy may appear a number of times on the cladogram. Although this is the main 
reason why the consistency and retention indices are low, it does not reduce the value 
of the analysis. This is because the analyst is aware o f the multiple appearances of the 
characteristics on the organisation cladogram and they are taken under consideration.
Although the branches are different, the organisation cladogram has classified the 
drug discovery strategies according to most dominant characteristics (the selection of 
the dominant characters depend on the algorithm used). The fact that most of the 
cladograms are similar means that the selection o f  the characteristics for the 
development has been consistent However, a researcher using cladistics must be 
careful when conclusions are drawn as a characteristic, which has been considered 
important for one branch, may not be so for another. Although this could be true 
within the scope of the cladogram, it may not be so in reality. Therefore, a researcher 
has to check that the characteristics have been selected realistically.
Comparing the values of the indices shown in Table 9-3, it may be concluded that 
the indices of the population cladogram are closer to those of the automotive 
cladogram (Leseure, 1999) while those o f the organisation are closer to the electronics 
industry cladogram (Fernandez, 2002). As explained in chapter 6, the level of 
analysis of the population cladogram (Figure 7-7) is that of drug discovery strategy 
types (classes of strategies that share a common profile along conceptually distinct 
characteristics) while that of the organisation cladogram is drug discovery strategies 
of individual organisations (see Figure 9-3). The automotive cladogram classified
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automotive manufacturing systems, i.e. those technologies and processes used for 
assembling cars (Leseure, 1999) These systems may have been adopted by classes of 
organisations. Therefore, the level of analysis of the automotive cladogram is 
consistent with that o f the population cladogram constructed in this thesis, hence, the 
similar values. The fact that the values of the automotive cladogram are higher is due 
to the condition of its data set Compared to the pharmaceutical, the automotive 
industry is widely documented and it is far easier to collect and process relevant data
On the other hand, the electronics industry cladogram classified manufacturing 
systems of individual organisations. Therefore, the level o f analysis o f the electronics 
industry is consistent to that of the organisation cladogram. Again, the values o f the 
indices of the two cladograms (organisation and electronics industry) are close. 
Similar to the previous cases, the fact that the values o f  the indices o f the organisation 
cladogram are higher is due to the condition of the data set. The electronics industry 
cladogram collected data from a very large set o f individual organisations. This 
resulted in a large number of taxa and characteristics, which, as argued before, affects 
negatively the indices.
To conclude this line o f  argument, the levels of analysis for the organisation and 
population cladograms lie between the levels of analysis for the automotive and 
electronics industry cladograms.
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Figure 9-3 Levels of analysis of cladograms
9.4.2. Relative subjectivity in the selection o f  the best cladogram
As argued in chapter 6, one of the strengths o f  cladistics is that the resulting 
classifications are objective. They should represent real, unambiguous and natural 
properties of the entities (evolutionary relationships) and, thus, different rational 
people, working independently should be able to  agree on these classifications 
However, two stages in the construction of the cladogram required judgement from 
the researcher. The first involved the selection of the characteristics The history of 
drug discovery is long and the characteristics that have influenced its development are 
numerous. Therefore, the selection of all the characteristics is an unrealistic option 
and a selection procedure is conducted Although several rules (identified and 
described in sections 6.2 7.2, 7.3, and 8.3) have been employed to ensure the 
consistency and objectivity of this selection process, a degree of subjectivity is 
unavoidable.
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The second area o f subjectivity is that of the selection of the optimal cladogram 
Step 5 in the construction of the population and organisation cladograms provides the 
user with a big number of possible cladograms. The first filtering of the cladograms 
is done through the use of the treelength, retention and consistency indices. Although 
the selection of the cladograms up to this stage is objective, it provides the researcher 
with more than one possible cladograms with equal statistics. Therefore, the 
researcher is left to decide which cladogram is best for his study Unfortunately, the 
method of selection at this stage is subjective as it depends on the researcher’s 
judgement.
However, as argued in chapter 8, all cladograms produced were very similar, and 
changes between them were insignificant. Therefore, this limitation should not 
considerably affect the conclusions drawn from the cladogram.
9.4.3. Limitations in the collection o f  data
The main limitations associated with the collection of the data are its exhaustiveness 
and reliability in the construction of the organisation cladogram The quality of the 
research results depends on the exhaustiveness of the collection of data. This is 
because the pattern of change of the organisational strategies may have been affected 
by innumerable factors. However, the collection o f all the possible data is not feasible 
because there is limited access to data The required information is not limited to one 
department of one organisation or indeed to one organisation. Exhaustive collection 
of data would require the careful examination o f  all the pharmaceutical organisations 
garound the world. As explained in chapter 8 the margin o f error for the sample was 
16%.
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9.5. Further Work
There are many stimuli for further work originating from this thesis. In chapter 8 it 
was argued that the constructed cladograms do not present sufficient evidence to fully 
support the first and second hypotheses. Therefore, the first area for future 
investigation is associated with collecting further evidence to validate or refute the 
hypotheses.
With regard to the validation o f the first hypothesis, future research efforts should be 
directed towards an examination o f the sizes (number of drug discovery strategies) of 
populations over time For example, if the size of one or more o f  the populations, 
depicted on the aggregated organisation cladogram of Figure 8-6, were measured at 
various moments in time over the last century, then its pattern o f  change would be 
revealed If the pattern were cyclical, i.e. if the size of the population follows a 
concave pattern of growth and decline, the first hypothesis would be fully validated.
With regard to the validation o f the second hypothesis, future research should be 
directed towards the examination of the financial performance o f  the organisations 
included in the population If a correlation between the financial performance of the 
organisations within the population and the size of the population were found, then it 
could be argued that there is variation in terms of the fitness o f  the drug discovery 
strategies
A second area of future investigation is associated with the development of 
management tools and techniques that will use the knowledge developed in this 
thesis. The creation of the working definition of drug discovery strategy along with 
its defining factors could provide a new perspective for understanding and planning 
strategy within a pharmaceutical organisation. In addition, the population and
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organisation cladograms could provide the basis for constructing road maps for 
strategic change. The two cladograms provide a list o f characteristics that could be 
adopted to move from one strategic configuration to another.
Finally, the research conducted here cannot claim that it has covered all the aspects 
o f drug discovery strategy. However, as argued in chapter 3, there is no existing 
introductory account, definition and classification to drug discovery strategy. This 
research has made a contribution towards providing a rigorous and systematic 
approach in this area Also, from a methodological standpoint, this study has 
advanced the development and application of evolutionary classifications to an area of 
strategic management. Yet, more research is required to fully understand both the 
area of drug discovery strategy and the mechanisms by which it changes over time.
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Appendix B: Description of characteristics
Tacit knowledge
13. Diversification
This characteristic means that an organisation pursued a diversification approach for 
bringing new products to the market. This approach could be either product or market 
diversification. It is considered as characteristic because it influences the approach of an 
organisation to drug discovery. Diversification usually happens through mergers, 
acquisitions or building of new capabilities
0. The company has not pursued a diversification strategy
1. The company has pursued a diversification strategy
14. Reduction o f  diversification
Throughout the history of the pharmaceuticals there are examples of organisations that 
realised that extreme diversification caused losses either in terms of profits or in terms of 
expertise. This characteristic means that organisations after realising that this strategy 
was not beneficial for the company they abandoned it and focused on the discovery and 
development of a smaller number of drugs. This realisation usually follows a change in 
an organisation’s status such as change of management or acquisition. The methods 
followed to reduce diversification include direct termination of the non-profitable 
projects and selling of the non-efficient divisions.
0. An organisation has not gone through a reduction of diversification exercise
1. A n o rgan isation  has no t red u ced  its diversification
15. Focus on pharmaceuticals
This characteristic means that the management of organisations has decided to focus on 
the manufacturing and development of pharmaceutical products. Many pharmaceutical 
organisations develop products such as diagnostic equipment, nutritional tablets etc. The 
acquisition of this characteristic means that an organisation has focused only on the 
development of pharmaceutical products. The difference between this characteristic and 
the reduction of diversification is that this one is more focused i.e. reduction of 
diversification does not necessarily mean focus on a certain type of product
0. An organisation does not focus only of pharmaceuticals
1. An organisation focuses only on pharmaceuticals
16. RAD focus
Research and development focus is a characteristic that means that an organisation that 
has acquired it focuses on the development of new drugs This means that they see R&D 
as a major function for the acquisition of a competitive advantage In addition 
organisations that have acquired this characteristic are usually the ones that bring new 
drugs to market and are consequently the market leaders
0. An organisation does not focus on R&D
1. An organisation focuses on R&D
17. Increase in RAD expenditure
The acquisition of this characteristic means that an organisation has gone a step further 
in focusing on R&D by devoting more resources to it It has been considered as an 
important characteristic because its acquisition implies that an organisation has changed 
its approach towards R&D and has consequently affected its drug discovery strategy
0. An organisation has not decided at any point in time to increase its R&D spending
1 An organisation has at least once decided to significantly increase its R&D spending
18. Cost culling RAD
This characteristic has the opposite effect to the previous one Its acquisition means that 
the capital spending on R&D has been reduced This is usually the direct result of the 
financial state of the company and it is usually a condition enforced to the company
0. An organisation has never been forced to cut its R&D expenditure
1. An organisation has been forced to cut its R&D expenditure
19. RAJ)  performance
The acquisition of this characteristic means that an organisation has combined the 
research and development goals with performance objectives
0. An organisation has not explicitly combined the R&D goals with performance
objectives
1 A n  organ isation  has explicitly  com bined th e  R & D  goals w ith perform ance
objectives
20. R&D concentration
The acquisition of this characteristic means that an organisation limits its R&D efforts to 
the most promising efforts. Usually this happens when organisations weigh their 
portfolio of projects and conclude that some of their projects do not have a market 
potential.
0. An organisation has not concentrated its research efforts
1. An organisation has concentrated its research efforts
21. Limited discovery
The acquisition of this characteristic means that an organisation has not managed to 
achieve any breakthroughs for a considerable amount of time. The importance of this 
characteristic is that limited discovery for a considerable amount of time may result in 
organisational changes and restructuring of an organisation.
0. An organisation makes discoveries at frequent intervals
1. At least once in the lifetime of an organisation there has a been a significantly long 
period when no discoveries were made
22. Dependence on strangers' research (generics)
This characteristic means that an organisation focuses on developing drugs that have 
been discovered by other institutions (usually competitors). Pharmaceutical companies
have exclusive rights to their discovery for seventeen years after which other companies 
may also produce the same drug Several companies are pursuing this tactic to survive 
and be profitable.
0. An organisation focuses on its own research
1. An organisation produces generic drugs
23. Reformation o f others' rejected/unfinished research
Due to reasons like reduction of diversification, review of portfolio and concentration of 
research and development the management of an organisation may reject a project. This 
research however, may be potentially beneficial for other organisations competing in 
different environment and aiming on different goals. The acquisition of this 
characteristic means that an organisation is pursuing this type of strategy.
0. An organisation focuses on its own research
1. An organisation seeks the development of others’ reearch
24. Merger
This characteristic means that two organisations have combined their efforts for the 
discovery of new drugs. The merger of two organisations may result in the acquisition of 
several other characteristics like diversification and increase in R&D expenditure
0. An organisation has not merged
1. An organisation has merged
25. Acquisitions
This characteristic means that an organisation has acquired one or more smaller 
organisations to expand its research capabilities The acquisition of other organisations 
results in product and market diversification. In addition, acquisitions may result in 
access to knowledge and technology that was previously impossible.
0. An organisation has not pursued an acquisition strategy
1. An organisation has pursued an acquisition strategy
26. Collaboration with academia
The research capabilities of a single organisation are in many occasions not enough to 
achieve the goals. Therefore, organisations have sought collaborations with academic 
institutions. The advantage of collaborating with such institutions is that knowledge that 
has been acquired by them may be available to the companies. The acquisition of this 
characteristic implies that such collaboration has taken place.
0. An organisation has not collaborated with academic institutions
1. An organisation has established collaborations with academic organisations
27. Collaboration/joint ventures
Due to similar reasons to the ones that led organisations to seek collaborations with the 
academia, organisations have collaborated with each other. This has taken the form of 
exchange of information or joint ventures where jointly funded research develops
products beneficial to both companies. The acquisition of this characteristic means that 
an organisation has experienced such collaborations.
0 An organisation has not collaborated with academic institutions
1. An organisation has established collaborations with academic organisations
28. Marketing
Marketing has always been a decisive factor in the pharmaceutical industry. The 
acquisition of this characteristic within the scope of this thesis means that an 
organisation’s marketing has affected the way drugs are being discovered for example by 
understanding the market needs better.
0. Marketing has affected the discovery of new drugs
1. Marketing has mot affected the discovery o f new drugs
29. Focus on effective analysis and treatment
This characteristic means that an organisation is undertaking research to satisfy the need 
for cost effective analysis and treatment in health care For instance, the development of 
comprehensive nutritional therapy programmes to speed the recovery o f  health patients 
and thereby reduce medical costs.
0. An organisation is not undertaking such research
1. An organisation is undertaking research.
30. Centralised management
The acquisition of this characteristic means that an organisation has adopted a top-down 
approach to management. Pharmaceutical organisations being traditional and old 
organisations have been in most cases formed by an individual Usually, organisations 
that are formed in such way, adopt a centralised approach to management, which may be 
sustained for a few generations. This may affect the strategies for drug discovery and this 
is when this characteristic is included in the cladogram.
0. Centralised management has not directly affected drug discovery
1. Centralised had an influence in drug discovery
33. Reorganisation (restructuring)
The acquisition of this characteristic means that an organisation has gone through an 
organisational restructuring which has affected the way research and development is 
carried out. This may include an organisation o f the research based on therapeutic areas. 
Whenever organisations go through mergers organisations go through such restructuring 
This characteristic is present only when the reorganisation has not been the result o f a 
merger and has a direct impact on drug discovery.
0 An organisation has not restructured itself
1. An organisation has restructured itself
3 %
35. Management innovations
This characteristic denotes the attempt of the management to encourage research by 
trying new management methods. For instance, a management innovation would be the 
achievement of working welfare and the division of labour.
0. No management innovations have been recorded
1. An organisation has attempted the application of management innovations
36. DNA marketing
This acquisition o f this characteristic means that an organisation is in the biotechnology 
business and markets research. The biotechnology industry has made it possible to 
market research rather than final products.
0. An organisation is not in the biotechnology industry
1. An organisation markets is in the biotechnology industry
37. Niche Market establishment
The acquisition o f this characteristic means an organisation has managed, through its 
research activities, to produce a niche market usually through the introduction of a novel 
drug or blockbuster.
0. An organisation has not established a niche market
1. An organisation has established a niche market
38. Individual efforts
This is a characteristic usually acquired by organisations during their founding The 
research efforts of an individual have eventually led him or her to the development of a 
product, which has resulted in the foundation of a company
0. An organisation was not founded by an individual
1. An organisation was founded by an individual whose legacy is carried by an 
organisation
Environment
39. World Wars
Both world wars have had an impact on the companies’ future. However, to be 
considered as a characteristic for the construction of the cladogram the impact has to be 
specifically on the drug discovery strategy of the company. For instance, the need for the 
production of penicillin made organisations develop new techniques for its development 
in large quantities. Further implications of the war to drug discovery strategies are 
explained in chapter 8.
0. The wars have not affected the drug discovery process
1. The war has played an important role in the development of both the company and
its drug discovery process
40. Cyclamates
In the 1960’s the popularity of the cyclamates (the chemical that has a sweet taste and 
used as an artificial sweetener) was increased. This was due to the fact that people 
became more health and diet conscious and cyclamates were used as a sugar substitute in 
a wide variety of foods. In 1970 the American food and drug administration banned the 
use of cyclamates when they discovered that they were carcinogenic. The acquisition of 
this characteristic means that the drug discovery process of an organisation has been 
affected by this ban.
0. An organisation was not affected by the ban
1. Both an organisation and its drug discovery process have been affected by the ban
41. Enforced price reductions
Enforced price reductions have forced many organisations to reconsider their approach 
to drug discovery. This characteristic reflects this situation. The government or large 
insurance companies (the latter is more common in the USA) usually enforce these price 
reductions.
0. Price reductions have affected the drug discovery process
1. Price reductions have not affected the drug discovery process directly (although) 
they may have affected an organisation.
42. Intense competition
Intense competition on research activities may force organisations to consider 
alternative strategies in the development of new drugs.
0. Competition has not affected the drug discovery process
1. Competition has affected the drug discovery process
43. Community aid
This characteristic means that an organisation has undertaken community aid motivate 
and satisfy its employees This is turn had a reported impact on the process of discovery 
i.e through the improvement of productivity
0. Community had an impact on drug discovery
Community aid had not been carried out or had no reported impact on the drug
discovery
44. Price reductions through competition
Competition especially after the end of a patent may result in the price reduction 
especially in situations where two drugs may offer similar treatment and results. This 
characteristic is included in this study when these price reductions have affected the drug 
discovery strategy.
0. Competition has not forced an organisation to make any price reductions
1. Competition has forced an organisation to reduce the prices of the drug and this has 
a direct effect on the drug discovery process, for instance, by reducing the number of 
products
45. Government support
The support of government especially through the form of funding of associated 
academic institutions also may affect the way new drugs are being developed
0. Government support did not have direct impact on drug discovery
1. Government support had an impact on the drug discovery process
46. Government legislation
This characteristic denotes the effect that legislation may have on the development of 
new drugs. Before drugs are introduced to the market they have to go through the 
process of approval. Therefore, the formation of the drug discovery strategy also has to 
account for that.
0. The drug discovery process has not significantly affected by government legislation
1. Government legislation has forced an organisation to make changes on the drug 
discovery strategy
47. Patent protection laws
Patent protection laws have been in use since early in the century in most of the western 
countries In countries like Japan these laws where not implemented until much later. 
Consequently the approach of these companies on drug discovery was much different.
Since they could not protect their research findings they were more focused on the 
development of generic drugs. This characteristic intends to show the difference that 
these laws had in drug discovery especially in Japanese companies.
0. Patent laws have been in place for significantly long time to be considered as given 
e g. in western countries
1. Patent laws have made significant contribution to the R&D of an organisation e g. 
Japanese organisations
48. Privatisation/Nationalisation
This characteristic represents a situation where the government has either assumed 
control of a company or sold it to private investors. Nationalisation may have an 
immediate effect on drug discovery as funding methods usually differs. The allocation of 
resources is also different in national companies
0. An organisation has not at any moment in history been nationalised
0. An organisation has been nationalised at least once
Technology
The characteristics that fall under this category include key technologies that have 
influenced the drug discovery process. These technologies are explained in chapter 4
State 0 of each characteristic indicates that the technology denoted by the characteristic 
has not been acquired by an organisation. State 1 means that the technology has been 
acquired.
2. Instrumentation development
The focus of an organisation is in the development of medical instruments including 
surgical equipment.
0. an organisation is developing such instruments
1. an organisation is not developing such instruments
Codified knowledge
The characteristics that fall under this category include the therapeutic areas where 
organisations are undertaking research. It is not within the scope o f  this thesis to provide 
information on the medical aspects of each therapeutic area
State 0 of each characteristic indicates that an organisation does not undertake research 
in that area. State 1 means that an organisation undertakes research in that area.
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